Details of Disease

General Information of Disease (ID: DISQVHKL)

• Disease Name: Parkinson disease
• Synonyms: paralysis agitans; Parkinson disease; Parkinson's disease
• Disease Class: 8A00: Parkinsonism
• Definition: A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.
• Disease Hierarchy:
  DISHGY45: Parkinsonian disorder
  DISD715V: Hereditary neurological disease
  DISQVHKL: Parkinson disease
• ICD Code:
  ICD-11: ICD-11: 8A00.0
  ICD-10: ICD-10: F02.3, G20
  ICD-9: ICD-9: 332
  Expand ICD-9: 332
• Disease Identifiers:
  MONDO ID: MONDO_0005180
  MESH ID: D010300
  UMLS CUI: C0030567
  MedGen ID: 10590
  Orphanet ID: 319705
  SNOMED CT ID: 49049000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 37 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Apomorphine	DMX38HQ	Approved	Small molecular drug	[1]
Benztropine	DMGZOVN	Approved	Small molecular drug	[2]
Biperiden	DME78OA	Approved	Small molecular drug	[3]
Bornaprine	DM2OT3L	Approved	Small molecular drug	[3]
Botulinum Toxin Type B	DM58QS1	Approved	NA	[4]
Bromocriptine	DMVE3TK	Approved	Small molecular drug	[5]
Carbidopa	DMHRG8Q	Approved	Small molecular drug	[6]
Clorgyline	DMCEUJD	Approved	Small molecular drug	[7]
Cycrimine	DM8C43Q	Approved	Small molecular drug	[8]
Dopamine	DMPGUCF	Approved	Small molecular drug	[9]
E-2007	DMJDYNQ	Approved	Small molecular drug	[10]
Entacapone	DMLBVKQ	Approved	Small molecular drug	[11]
Ethopropazine	DM0N3L7	Approved	Small molecular drug	[12]
Ioflupane i-123	DMNARJT	Approved	Small molecular drug	[13]
Istradefylline	DM20VSK	Approved	Small molecular drug	[14]
Levodopa	DMN3E57	Approved	Small molecular drug	[15]
Lisuride	DMCME17	Approved	Small molecular drug	[16]
Melevodopa	DMBF8GU	Approved	Small molecular drug	[3]
Metixene	DM0JE6N	Approved	Small molecular drug	[17]
N-0923	DMSOAJ2	Approved	Small molecular drug	[18]
NADH	DM5NM6E	Approved	Small molecular drug	[19]
Opicapone	DM1BKA6	Approved	NA	[20]
Orphenadrine	DMW542E	Approved	Small molecular drug	[21]
Pergolide	DM14MAE	Approved	Small molecular drug	[22]
Pimavanserin	DMR7IVC	Approved	Small molecular drug	[23]
Pramipexole	DMNMW9R	Approved	Small molecular drug	[24]
Procyclidine	DMHFJDT	Approved	Small molecular drug	[25]
Rasagiline	DM3WKQ4	Approved	Small molecular drug	[26]
Ropinirole	DMA6S1D	Approved	Small molecular drug	[27]
Safinamide	DM0YWJC	Approved	Small molecular drug	[28]
Safinamide mesylate	DM0J2ZT	Approved	NA	[29]
Selegiline Hydrochloride	DM3VR1L	Approved	Small molecular drug	[3]
Tolcapone	DM8MNVO	Approved	Small molecular drug	[30]
Trihexyphenidyl	DMB19L8	Approved	Small molecular drug	[31]
Zuranolone	DMGR98T	Approved	NA	[32]
Neupro	DMHEAB1	Phase 4	Small molecular drug	[33]
PD-01	DMTGFRB	Phase 4	NA	[34]

This Disease is Treated as An Indication in 140 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Mosquirix malaria recombinant vaccine	DMQ0NDI	Preregistration	NA	[35]
123I-iometopane	DMIX6H6	Phase 3	NA	[36]
ABBV-951	DMMWO7V	Phase 3	Small molecular drug	[37]
AP-CDLD	DMZCW0C	Phase 3	NA	[32]
CQA 206-291	DM60TVK	Phase 3	Small molecular drug	[38]
Eltoprazine	DMW6C81	Phase 3	Small molecular drug	[32]
Ganoderma	DM9OQG7	Phase 3	NA	[39]
IGIV3I Grifols	DMWB7KS	Phase 3	NA	[40]
KPS-0373	DMP5G1K	Phase 3	NA	[41]
NE3107	DMEZNJI	Phase 3	Small molecule	[42]
Nebracetam	DMFD249	Phase 3	Small molecular drug	[43]
OS-320	DMNMLDM	Phase 3	NA	[44]
OSE-300	DM4H8W7	Phase 3	NA	[45]
P2B-001	DM9PVHX	Phase 3	NA	[32]
Patrome	DM3H2U4	Phase 3	NA	[46]
Semagacestat	DML83IW	Phase 3	Small molecular drug	[47]
SEP-363856	DMG2QP4	Phase 3	NA	[32]
Sumanirole	DMYHV17	Phase 3	Small molecular drug	[48]
Tozadenant	DMATC14	Phase 3	Small molecular drug	[49]
ADX-48621	DM6GTMD	Phase 2/3	Small molecular drug	[50]
Fosgonimeton	DMXMAJA	Phase 2/3	Small molecule	[51]
HD-0801	DMEK19M	Phase 2/3	NA	[52]
Sarizotan	DMH7IPW	Phase 2/3	Small molecular drug	[53]
AAV-GAD	DMOOY9W	Phase 2	Gene therapy	[54]
AKST4290	DM27ZJG	Phase 2	Small molecule	[55]
AV-201	DMDL9WU	Phase 2	NA	[56]
AZD-3241	DMANC59	Phase 2	NA	[57]
BIA 3-202	DMG3ON2	Phase 2	Small molecular drug	[58]
BIIB014	DMH7RJ1	Phase 2	Small molecular drug	[59]
BIIB054	DMZO2SY	Phase 2	NA	[32]
BN82451	DMUM2KA	Phase 2	Small molecular drug	[60]
Brasofensine	DM3TRF7	Phase 2	Small molecular drug	[61]
CERE-120	DMS01AX	Phase 2	NA	[62]
CP-101,606	DMIU19E	Phase 2	Small molecular drug	[63]
CVN424	DMEPQ76	Phase 2	Small molecule	[64]
CX-8998	DM3GEHC	Phase 2	NA	[32]
Dexefaroxan	DMTY4KN	Phase 2	Small molecular drug	[65]
DopaFuse	DMCFDCO	Phase 2	NA	[32]
DT-1687	DMU2GP4	Phase 2	NA	[32]
E2027	DMK8SY6	Phase 2	Small molecular drug	[66]
Ensaculin hydrochloride	DMLPRZJ	Phase 2	Small molecular drug	[67]
ENT-01	DM086S6	Phase 2	Small molecule	[68]
EPI 589	DMZT7EP	Phase 2	NA	[32]
GM608	DMONQVK	Phase 2	NA	[69]
GPI-1485	DM64ZYM	Phase 2	Small molecular drug	[70]
GTS-21	DMEN5KA	Phase 2	Small molecular drug	[71]
INP103	DMK5DKF	Phase 2	NA	[32]
IPX203	DMUO1T5	Phase 2	NA	[72]
JM-010	DMFYEGD	Phase 2	NA	[73]
KDT-3594	DMFTKSI	Phase 2	NA	[74]
KPAX002	DMDT5WM	Phase 2	NA	[32]
LTI-291	DMIUKVW	Phase 2	NA	[32]
LY3154207	DMVGYQ6	Phase 2	NA	[32]
Mesdopetam	DMZGX27	Phase 2	Small molecule	[75]
ND0612	DMULLFS	Phase 2	NA	[32]
NeuroCell-PD	DMHCN5Z	Phase 2	NA	[76]
NLY01	DMI9OMV	Phase 2	Small molecule	[77]
Nuedexta	DM9DO9B	Phase 2	NA	[32]
NYX-458	DM0BT41	Phase 2	Small molecule	[78]
Paliroden	DMX8ZAQ	Phase 2	Small molecular drug	[79]
Pardoprunox	DMD275X	Phase 2	Small molecular drug	[80]
PRX002	DMKTP8E	Phase 2	Antibody	[81]
PT320	DMZYKXN	Phase 2	Peptide	[82]
PTX-200	DM0ZIT2	Phase 2	NA	[83]
RG7935	DME1YMX	Phase 2	Antibody	[32]
RP5063	DMKUE8O	Phase 2	NA	[84]
SAGE-324	DM5NC39	Phase 2	Small molecular drug	[85]
SAGE-718	DM9RC7D	Phase 2	Small molecular drug	[86]
SCH 420814	DMMWCZS	Phase 2	Small molecular drug	[87]
Spheramine	DMJW59N	Phase 2	NA	[88]
SPI-205	DMHC2AW	Phase 2	NA	[89]
SYN-120	DMPW0UL	Phase 2	NA	[32]
SYN120	DMDF7XB	Phase 2	Small molecular drug	[90]
Talampanel	DMJOM5L	Phase 2	Small molecular drug	[91]
Tocovid Suprabio	DMRD4R4	Phase 2	NA	[92]
Valiloxybate	DMHMUUM	Phase 2	Small molecule	[93]
Venglustat	DMLPEZS	Phase 2	NA	[32]
VY-AADC	DMPSBTL	Phase 2	Gene therapy	[94]
WIN-1001X	DMCXISP	Phase 2	NA	[95]
Xanomeline tartrate	DMXG5WU	Phase 2	Small molecular drug	[96]
XP-21279	DM8N3ZQ	Phase 2	NA	[97]
Avigen Parkinson	DMP619O	Phase 1/2	NA	[98]
CPHPC	DM1ZGUX	Phase 1/2	Small molecular drug	[99]
Cu(II)ATSM	DM5I2CC	Phase 1/2	NA	[32]
Hypoestoxide	DMF0HWX	Phase 1/2	Small molecule	[100]
ISC-hpNSC	DM0OQTX	Phase 1/2	NA	[101]
ITI-214	DM08TH3	Phase 1/2	NA	[102]
Neu-120	DMXKOUC	Phase 1/2	NA	[103]
OXB-102	DMXF9DM	Phase 1/2	Gene therapy	[104]
PR001	DMQWR4N	Phase 1/2	Gene therapy	[105]
ProSavin	DMJ42E6	Phase 1/2	NA	[106]
V81444	DMPWHU6	Phase 1/2	NA	[107]
AAV-hAADC gene therapy	DMG22F0	Phase 1	NA	[108]
AAV2 GDNF	DMH8SE5	Phase 1	NA	[109]
AlloRx	DMNREXZ	Phase 1	Cell therapy	[110]
ANAVEX 2-73	DM67OU4	Phase 1	NA	[32]
Anle138b	DMEC8E2	Phase 1	Small molecule	[111]
Arecoline	DMFJZK3	Phase 1	Small molecular drug	[112]
AVE-8112	DMZNTHJ	Phase 1	NA	[113]
BGC-20-1259	DMED4AJ	Phase 1	Small molecular drug	[114]
BIIB094	DMLUO5K	Phase 1	Antisense oligonucleotide	[115]
DNL151	DMZT89C	Phase 1	NA	[32]
DNL201	DMFEORD	Phase 1	NA	[32]
DSP-6745	DMM86OH	Phase 1	NA	[32]
FB-101	DM3HL5F	Phase 1	Small molecule	[116]
GCC-1290K	DMJ7WRI	Phase 1	NA	[117]
GZ404477	DMNHLZG	Phase 1	NA	[108]
IkT-148009	DMMJ9HY	Phase 1	NA	[118]
ION464	DMZAQS8	Phase 1	Antisense oligonucleotide	[119]
JNJ-0376	DMFSXLQ	Phase 1	NA	[120]
KF-17837	DMQ6DLZ	Phase 1	Small molecular drug	[121]
KM-819	DMRAWGC	Phase 1	NA	[122]
Lu AF28996	DMY572G	Phase 1	Small molecule	[123]
Lu-02-750	DMQ0K95	Phase 1	NA	[124]
Lu-AE04621	DMP9UO0	Phase 1	NA	[125]
LY03003	DMB78EA	Phase 1	NA	[32]
LY03009	DM242BA	Phase 1	NA	[126]
MEDI1341	DMQDBSU	Phase 1	NA	[32]
MSK-DA01	DMHMHOO	Phase 1	Cell therapy	[127]
NPT200-11	DMFDBV5	Phase 1	Small molecular drug	[32]
NuroPro	DM9LG91	Phase 1	NA	[128]
OK99	DMKDVKW	Phase 1	Cell therapy	[129]
PD01A	DMQRD1C	Phase 1	Vaccine	[130]
PF-06649751	DMJ682M	Phase 1	NA	[131]
PF9601N	DMGLEM1	Phase 1	Small molecular drug	[132]
PRIM-DJ2727	DMWW1KN	Phase 1	Fecal Microbiota Transplantation	[133]
SAR446159	DMWAO33	Phase 1	Antibody	[134]
SER-214	DMUKUIC	Phase 1	NA	[32]
SPN-803	DM8O2AQ	Phase 1	Antisense drug	[135]
SUN-K0706	DMIF8RY	Phase 1	NA	[32]
Talineuren	DMV2G7K	Phase 1	NA	[136]
TPU-002	DMTCUII	Phase 1	NA	[32]
UB-312	DMBSAWZ	Phase 1	Vaccine	[137]
UCB0599	DMCNM6F	Phase 1	NA	[32]
UCB7853	DMD7I23	Phase 1	Monoclonal antibody	[138]
VY-AADC01	DM0N71R	Phase 1	Gene therapy	[139]
XC130-A10H	DM2JDLK	Phase 1	NA	[140]
YKP10461	DMUOEM4	Phase 1	NA	[32]
ZT-1	DMO2WYX	Phase 1	Small molecular drug	[141]
AB-4166	DMVJL2W	Clinical Trial	Small molecular drug	[142]

This Disease is Treated as An Indication in 6 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Diazepinone derivative 1	DM9YD0Q	Patented	Small molecular drug	[143]
Diazepinone derivative 2	DMLQ7PG	Patented	Small molecular drug	[143]
Diazepinone derivative 3	DMPTZ69	Patented	Small molecular drug	[143]
Diazepinone derivative 4	DM389YD	Patented	Small molecular drug	[143]
Diazepinone derivative 5	DM2U1QH	Patented	Small molecular drug	[143]
PMID30124346-Compound-60TABLE5	DM3QX0R	Patented	Small molecular drug	[143]

This Disease is Treated as An Indication in 23 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Etilevodopa	DMF93U1	Discontinued in Phase 3	Small molecular drug	[144]
BAM-1110	DMPMKUF	Discontinued in Phase 2	Small molecular drug	[145]
DMP-543	DMCNEOZ	Discontinued in Phase 2	Small molecular drug	[146]
HP-290	DMUMGCY	Discontinued in Phase 2	Small molecular drug	[147]
Naxagolide	DM9K2IO	Discontinued in Phase 2	Small molecular drug	[148]
NLX-P101	DM6NPUJ	Discontinued in Phase 2	NA	[149]
SL65.0155	DMAM9BD	Discontinued in Phase 2	Small molecular drug	[150]
PD-151832	DMO34NQ	Discontinued in Phase 1/2	Small molecular drug	[151]
Besonprodil	DMMAFQP	Discontinued in Phase 1	Small molecular drug	[152]
HT-1067	DMUPOIG	Discontinued in Phase 1	NA	[153]
Lu-AA47070	DML86MJ	Discontinued in Phase 1	NA	[154]
SCH-211803	DM92E0W	Discontinued in Phase 1	Small molecular drug	[155]
Z-321	DMLO2QY	Discontinued in Phase 1	Small molecular drug	[156]
A 77636	DM0NY6K	Terminated	Small molecular drug	[162]
AMR-103	DMW5RNZ	Terminated	NA	[163]
AX-208	DMPNQK1	Terminated	NA	[164]
BL-1825	DMOUOLS	Terminated	NA	[165]
Etrabamine	DMRQOXG	Terminated	Small molecular drug	[166]
Gpi-1046	DMD5WK4	Terminated	Small molecular drug	[167]
SIB-1508Y	DMT43AI	Terminated	Small molecular drug	[168]
SKF-81297	DM4LGPT	Terminated	Small molecular drug	[169]
SLV-307	DMCPDBS	Terminated	NA	[170]
SPD-474	DMT8PHQ	Terminated	NA	[171]

This Disease is Treated as An Indication in 5 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GYKI-47261	DM97RV4	Preclinical	Small molecular drug	[157]
PHENSERINE TARTRATE	DMIGH6W	Preclinical	Small molecular drug	[158]
Rottlerin	DMOQ63E	Preclinical	Small molecular drug	[159]
S32504	DM4V8ZD	Preclinical	Small molecular drug	[160]
TEV-56287	DMX9OIL	Preclinical	NA	[161]

This Disease is Treated as An Indication in 34 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AC-8632	DM09BJ4	Investigative	Small molecular drug	[172]
AMG-889436	DMKP8L9	Investigative	NA	[173]
AT-3375	DM6UNH2	Investigative	NA	[174]
BDD-20617	DMVHKZV	Investigative	NA	[174]
CDNF/MANF	DM2YT92	Investigative	NA	[174]
CM-PK	DMSFAIG	Investigative	NA	[174]
COV08-0064	DM2LWNF	Investigative	Small molecular drug	[175]
CX-1846	DMR2Q3P	Investigative	NA	[174]
Cyprodine	DM7T96M	Investigative	Small molecular drug	[157]
DLO6001	DM5OYBI	Investigative	NA	[174]
Glycolipids	DMKHFZ5	Investigative	NA	[174]
HL-027	DM00PR3	Investigative	NA	[174]
INP-05	DMT0933	Investigative	NA	[174]
KLS-Npk	DMC35XM	Investigative	NA	[174]
LDN-22684	DMD58WR	Investigative	NA	[174]
Modified GDNF	DMD9WS5	Investigative	NA	[174]
MSX-3	DMF9HYI	Investigative	Small molecular drug	[176]
NBI-80649	DMPHNLV	Investigative	NA	[174]
NGN-9076	DMGGE0O	Investigative	NA	[174]
NI-202	DMJ7X7Q	Investigative	NA	[174]
NNI-PD	DM9WLYX	Investigative	NA	[174]
NP-003	DMBA9VE	Investigative	NA	[174]
Paeoniflorin	DMJ5TAU	Investigative	Small molecular drug	[177]
PD-0805	DM731TC	Investigative	NA	[174]
PD-AAV9	DME45PV	Investigative	NA	[174]
PK-236	DMV564I	Investigative	NA	[174]
PNB-03	DM60EOM	Investigative	NA	[174]
PRX-1	DMUWNOC	Investigative	NA	[174]
Rotigitine	DMT0DW4	Investigative	Small molecular drug	[157]
SIG-005	DMWSRXW	Investigative	NA	[174]
ST-4206	DMT57SP	Investigative	NA	[174]
Synuclere	DMBR77G	Investigative	NA	[174]
TC-34	DMB3BS4	Investigative	Small molecular drug	[174]
WS-CoQ10	DMX94B6	Investigative	NA	[174]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 770 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
VPS35	OT9FYHRX	Definitive	Autosomal dominant	[179]
ACAD9	OT4HITJ6	Limited	Altered Expression	[626]
ACO1	OT2VUR7L	Limited	Altered Expression	[627]
ADI1	OT8IOD03	Limited	Genetic Variation	[628]
AFF1	OTT2C78E	Limited	Biomarker	[629]
AFF2	OTMF1PZW	Limited	Genetic Variation	[630]
AGO2	OT4JY32Q	Limited	Genetic Variation	[203]
ANKHD1	OTVYQ7ZL	Limited	Altered Expression	[631]
APBB1	OTZPVSSC	Limited	Biomarker	[632]
APH1B	OTQHPTGC	Limited	Genetic Variation	[186]
ARF3	OTYYQX85	Limited	Biomarker	[633]
ARFGAP1	OTM3KHIE	Limited	Biomarker	[634]
ARIH1	OTO3XDR2	Limited	Biomarker	[635]
ATP2C1	OTQN51T3	Limited	Altered Expression	[636]
AXIN2	OTRMGQNU	Limited	Biomarker	[637]
BIN1	OTK8O0X8	Limited	Genetic Variation	[638]
BIN3	OTMIWWDW	Limited	Genetic Variation	[639]
C4A	OTXMOYXU	Limited	Genetic Variation	[640]
CA8	OT9Y8GA8	Limited	Genetic Variation	[595]
CAST	OTBXZZGF	Limited	Biomarker	[641]
CCN6	OTRFHQ2Z	Limited	Genetic Variation	[203]
CDCP2	OTCA9260	Limited	Biomarker	[642]
CHORDC1	OT3W6F1U	Limited	Altered Expression	[206]
CHP1	OTHTXN1A	Limited	Altered Expression	[206]
CHRNB3	OTE5XENW	Limited	Genetic Variation	[643]
CHST1	OT2GRC5R	Limited	Genetic Variation	[644]
CRISP2	OT8HLTV5	Limited	Biomarker	[645]
CSRP3	OTECBJMV	Limited	Genetic Variation	[646]
CUL9	OTPUCLZT	Limited	Biomarker	[647]
CWC22	OT22MEO6	Limited	Biomarker	[648]
CYC1	OT0962IM	Limited	Altered Expression	[649]
DBNL	OTT2OQOV	Limited	Genetic Variation	[182]
DDX53	OTHK3EGZ	Limited	Biomarker	[650]
DHRS11	OTU3J0ZL	Limited	Altered Expression	[205]
DLD	OT378CU9	Limited	Biomarker	[651]
DLG2	OTQ3BD8U	Limited	Biomarker	[212]
DNAJA2	OTKF1VBT	Limited	Biomarker	[652]
DNAJC14	OT7DPIVN	Limited	Biomarker	[652]
DOCK3	OTF3YS2W	Limited	Biomarker	[653]
DST	OTHZBM4X	Limited	Genetic Variation	[654]
DYNLT3	OT26QKCI	Limited	Altered Expression	[655]
ECD	OT3L3PCU	Limited	Altered Expression	[206]
EEF1A1	OT00THXS	Limited	Altered Expression	[656]
EEF2	OTZ7SZ39	Limited	Altered Expression	[656]
EHHADH	OTBAAHL5	Limited	Biomarker	[600]
EIF1	OTB4GZ0V	Limited	Altered Expression	[656]
EIF2B1	OT4NCVY1	Limited	Biomarker	[657]
EIF2B2	OTQQMHM1	Limited	Biomarker	[657]
EIF2B4	OTTM5SX1	Limited	Biomarker	[657]
EIF2S2	OTXF0B09	Limited	Biomarker	[657]
EIF3A	OTFABY9G	Limited	Altered Expression	[656]
EIF4A2	OT08H03R	Limited	Genetic Variation	[658]
ENDOG	OT5IM7B3	Limited	Biomarker	[659]
FA2H	OT8HA13U	Limited	Genetic Variation	[660]
FADD	OTV7GFHH	Limited	Biomarker	[661]
FAM47E	OTXG216T	Limited	Genetic Variation	[226]
FBXO42	OTHPN53C	Limited	Genetic Variation	[662]
FBXO48	OTVMFNOK	Limited	Genetic Variation	[203]
FBXO9	OTW5P5JF	Limited	Biomarker	[663]
FGF13	OTHNNVSG	Limited	Biomarker	[664]
FLVCR1	OT9XCFOC	Limited	Biomarker	[665]
FUBP1	OT77SC9N	Limited	Biomarker	[647]
GABBR1	OTU5A52J	Limited	Biomarker	[666]
GET3	OTQ8KDFX	Limited	Biomarker	[667]
GIT1	OTHO92S5	Limited	Genetic Variation	[194]
GLUD1	OTXKOCUH	Limited	Genetic Variation	[668]
GNAL	OTESDTEU	Limited	Genetic Variation	[669]
GPR78	OT8TKE6F	Limited	Altered Expression	[670]
GPRC5C	OT45AJT3	Limited	Biomarker	[199]
GSPT1	OT18H1B0	Limited	Genetic Variation	[644]
HAS2	OTTD3PAL	Limited	Genetic Variation	[671]
HEPH	OTZ2F15Z	Limited	Biomarker	[672]
HLA-DRA	OT7KZMP2	Limited	Genetic Variation	[673]
HLA-DRB5	OTUX5TWM	Limited	Genetic Variation	[674]
HLF	OTTRK9XN	Limited	Biomarker	[675]
HOOK2	OTPO4NQV	Limited	Biomarker	[202]
HSPA1L	OTC2V1K6	Limited	Genetic Variation	[676]
INPP5F	OTPKUY50	Limited	Genetic Variation	[677]
INPP5K	OTQFLQKA	Limited	Genetic Variation	[678]
ITPKB	OTSVVPAV	Limited	Genetic Variation	[329]
JTB	OT314JB6	Limited	Biomarker	[679]
KANSL1	OTYNSNNZ	Limited	Genetic Variation	[323]
KIF2A	OT2WQ6QD	Limited	Biomarker	[202]
KLC1	OTSTTTW7	Limited	Genetic Variation	[680]
KREMEN1	OTGJFSAC	Limited	Biomarker	[681]
KRT31	OTB6RCAH	Limited	Biomarker	[682]
LAD1	OT6YGTVX	Limited	Biomarker	[651]
LAMB2	OT71OI2Y	Limited	Biomarker	[683]
LAMP3	OTN0XL3W	Limited	Altered Expression	[684]
LHFPL2	OTDWEEBQ	Limited	Genetic Variation	[685]
LRPAP1	OT6DVD2Q	Limited	Genetic Variation	[686]
MAK16	OTD546E5	Limited	Biomarker	[687]
MAP1LC3A	OTPMGIU4	Limited	Altered Expression	[688]
MAP1S	OT5WUD4C	Limited	Biomarker	[689]
MAP2K6	OTK13JKC	Limited	Altered Expression	[690]
MAP3K12	OT5HODDD	Limited	Genetic Variation	[691]
MBD5	OTFHT4MO	Limited	Genetic Variation	[692]
MCTS1	OT7SAOJP	Limited	Biomarker	[193]
MED1	OTOO24C4	Limited	Biomarker	[653]
MEFV	OTRJ6S6K	Limited	Biomarker	[693]
MEGF8	OT5G38CH	Limited	Biomarker	[694]
MMRN1	OT7ZNYHT	Limited	Genetic Variation	[596]
MS4A6A	OTK4BXQS	Limited	Biomarker	[695]
MT1E	OTXJKU4Y	Limited	Biomarker	[696]
MTHFD1	OTMKHVWC	Limited	Biomarker	[697]
MTX1	OTLSDNZO	Limited	Genetic Variation	[698]
MYO5C	OTKLOCWZ	Limited	Altered Expression	[699]
MYOC	OT6DAHNF	Limited	Genetic Variation	[700]
NANOS3	OTGX9IQU	Limited	Biomarker	[701]
NBL1	OTT37U4O	Limited	Biomarker	[702]
NCSTN	OT5QBTA4	Limited	Genetic Variation	[186]
NEUROD6	OTLFL6K8	Limited	Biomarker	[703]
NFE2L1	OT1QHOS2	Limited	Biomarker	[704]
NPM3	OTIAM1A3	Limited	Altered Expression	[656]
NUB1	OTWA6RTX	Limited	Biomarker	[705]
NXF1	OTEFHXG6	Limited	Biomarker	[706]
OR10A4	OTYYB8SY	Limited	Genetic Variation	[707]
PAK6	OTAHPZTT	Limited	Biomarker	[708]
PANK2	OTFBW889	Limited	Biomarker	[709]
PCNT	OTW4Z65J	Limited	Biomarker	[710]
PDHA1	OTGEU8IK	Limited	Biomarker	[711]
PDIA2	OTC2WMXS	Limited	Biomarker	[712]
PEA15	OTKCKTSX	Limited	Biomarker	[713]
PGLYRP1	OTBTPR2T	Limited	Genetic Variation	[714]
PGLYRP2	OTF8319A	Limited	Genetic Variation	[714]
PGLYRP3	OT5C7PRT	Limited	Genetic Variation	[714]
PGLYRP4	OTI115BR	Limited	Genetic Variation	[714]
PHACTR2	OTWMX2A8	Limited	Biomarker	[715]
PHF1	OTW2PSIR	Limited	Biomarker	[716]
PHYHD1	OTTKHTAC	Limited	Altered Expression	[699]
PKD1	OT5ALRZ5	Limited	Biomarker	[653]
PLEK	OTB73XXA	Limited	Genetic Variation	[717]
PLXNA4	OT5XKB3Q	Limited	Genetic Variation	[718]
PNO1	OT010GIS	Limited	Biomarker	[687]
PPBP	OT1FHGQS	Limited	Biomarker	[653]
PPP1R17	OT19635T	Limited	Altered Expression	[719]
PPP3R1	OTGQNFJQ	Limited	Biomarker	[720]
PQBP1	OTXCBEAH	Limited	Biomarker	[721]
PRDM2	OT8L7CGX	Limited	Genetic Variation	[722]
PRDX3	OTLB2WEU	Limited	Biomarker	[233]
PRKRA	OTUTVZZU	Limited	Biomarker	[723]
PROCR	OTRHED17	Limited	Biomarker	[234]
PROK2	OT70IFEZ	Limited	Biomarker	[724]
PRSS2	OTOMVUWL	Limited	Altered Expression	[248]
PRSS55	OTXXWI5Y	Limited	Biomarker	[645]
PSENEN	OTJ7M7G9	Limited	Genetic Variation	[186]
PSMA2	OTJRT2ZL	Limited	Biomarker	[683]
PSMC1	OTLHD56E	Limited	Biomarker	[725]
PSMD11	OT8KO67V	Limited	Altered Expression	[726]
PTPN5	OT2H1KDK	Limited	Biomarker	[727]
PTPRA	OTZA82J1	Limited	Genetic Variation	[728]
PXDNL	OT52SSS5	Limited	Altered Expression	[636]
QDPR	OTSKOIUX	Limited	Genetic Variation	[607]
QRSL1	OTJDU2UG	Limited	Altered Expression	[729]
RAB1B	OTAFCUAS	Limited	Biomarker	[633]
RAB3B	OTZA4SXL	Limited	Altered Expression	[730]
RAB6A	OTLS86J5	Limited	Biomarker	[731]
RAB6B	OT5N57RK	Limited	Biomarker	[633]
RAI1	OTKLQU00	Limited	Genetic Variation	[732]
RAN	OT2TER5M	Limited	Genetic Variation	[733]
RAP1B	OTHEIIMM	Limited	Biomarker	[633]
RAP2B	OTD2NDQP	Limited	Biomarker	[633]
RBM19	OT3Q6UIM	Limited	Genetic Variation	[692]
RBMS3	OTFSC9MR	Limited	Biomarker	[687]
RGS10	OTQ8N1QH	Limited	Altered Expression	[734]
RHOV	OTW4N3QN	Limited	Genetic Variation	[735]
RIC3	OTDCM6GS	Limited	Autosomal dominant	[736]
RMC1	OT7K8MTJ	Limited	Biomarker	[737]
RMDN3	OTKO7AUM	Limited	Biomarker	[738]
RRAS2	OT83NCEB	Limited	Genetic Variation	[735]
RREB1	OT62460U	Limited	Biomarker	[739]
SAGE1	OT4H6FFA	Limited	Genetic Variation	[740]
SART3	OTC1AM7S	Limited	Biomarker	[741]
SEC16A	OTFNQ1ZU	Limited	Genetic Variation	[742]
SEPTIN14	OTCM6DDO	Limited	Biomarker	[743]
SERPINA5	OTTZXPGD	Limited	Biomarker	[248]
SGTA	OTKOJ3JB	Limited	Altered Expression	[206]
SH3GL2	OTOE443G	Limited	Genetic Variation	[744]
SH3RF1	OT7MYGYO	Limited	Biomarker	[745]
SHC3	OT305NPA	Limited	Altered Expression	[746]
SMG1	OTTS3SXE	Limited	Altered Expression	[747]
SRGAP3	OT9ZS72C	Limited	Biomarker	[231]
ST13	OTNML6UP	Limited	Biomarker	[748]
STUB1	OTSUYI9A	Limited	Biomarker	[749]
TCEANC2	OTSJXAEJ	Limited	Genetic Variation	[750]
TCIM	OTARUXQF	Limited	Biomarker	[751]
TEF	OTY3LAD9	Limited	Genetic Variation	[752]
THAP1	OTIWUSON	Limited	Genetic Variation	[753]
TIGAR	OTR7NMRJ	Limited	Biomarker	[202]
TIMM8A	OTDX9687	Limited	Altered Expression	[754]
TLCD3B	OTM6EPUS	Limited	Altered Expression	[755]
TLE5	OTEH0BFG	Limited	Biomarker	[756]
TLX2	OTPFAUM8	Limited	Biomarker	[757]
TPM1	OTD73X6R	Limited	Genetic Variation	[685]
TRAM1	OT3I0H8E	Limited	Biomarker	[758]
TRAPPC4	OT3THRCA	Limited	Altered Expression	[231]
TRIM9	OTKYG33W	Limited	Biomarker	[759]
AIFM1	OTKPWB7Q	Disputed	Biomarker	[760]
ARFGEF1	OTPAU0L4	Disputed	Biomarker	[761]
ARID2	OTIRJXWM	Disputed	Biomarker	[761]
CD180	OTITK5E6	Disputed	Biomarker	[762]
CSMD1	OTIVDSC4	Disputed	Genetic Variation	[763]
DLGAP3	OT0GR2F6	Disputed	Biomarker	[764]
EPRS1	OTXK0FLB	Disputed	Genetic Variation	[765]
GPR151	OT7EACU6	Disputed	Altered Expression	[256]
HIF3A	OTPWAAMC	Disputed	Altered Expression	[766]
LGR6	OTPZ1PWR	Disputed	Altered Expression	[256]
LYPD5	OTGP7UKA	Disputed	Biomarker	[271]
MARK1	OTP7KL47	Disputed	Biomarker	[767]
MRGPRX3	OTRKCCDS	Disputed	Altered Expression	[256]
MRGPRX4	OTOBHZVA	Disputed	Altered Expression	[256]
NDN	OTYBYJ82	Disputed	Altered Expression	[768]
PDIK1L	OTISF4KG	Disputed	Biomarker	[769]
PHLDA2	OTMV9DPP	Disputed	Biomarker	[770]
PIAS2	OTJLSC3V	Disputed	Altered Expression	[771]
PIK3C2B	OTY2PROB	Disputed	Biomarker	[772]
PPP1R1A	OTGTAGCV	Disputed	Genetic Variation	[773]
PRKACB	OT6RMDCE	Disputed	Biomarker	[261]
RING1	OTCWTAX0	Disputed	Genetic Variation	[774]
SETD1A	OTVVWRIC	Disputed	Biomarker	[775]
TINAGL1	OTZZO56M	Disputed	Altered Expression	[776]
BAG5	OT0J97C6	moderate	Biomarker	[777]
CCDC62	OTTIAOBP	moderate	Genetic Variation	[226]
DGKQ	OT8OEPYT	moderate	Biomarker	[547]
DNM1L	OTXK1Q1G	moderate	Biomarker	[778]
ERCC6L2	OTWFECWG	moderate	Genetic Variation	[779]
FBP1	OTQBANEP	moderate	Biomarker	[780]
GLUD2	OTF3GGYY	moderate	Genetic Variation	[781]
HSPA1A	OTKGIE76	moderate	Therapeutic	[782]
MCCC1	OTLOHEQE	moderate	Genetic Variation	[783]
OPTN	OT2UXWH9	moderate	Biomarker	[398]
RAB1A	OTKPHRD0	moderate	Altered Expression	[784]
RFC1	OT3L5PK3	moderate	Genetic Variation	[605]
RMDN1	OTE1NB6U	moderate	Biomarker	[738]
RMDN2	OTK5WSFI	moderate	Biomarker	[738]
RNASE1	OTKZ7CO9	moderate	Genetic Variation	[785]
STH	OTK8ULTH	moderate	Genetic Variation	[786]
SYBU	OT3FQV7N	moderate	Biomarker	[738]
TCL1B	OT4CSO39	moderate	Biomarker	[265]
TMEM175	OT6DUIYC	moderate	Genetic Variation	[547]
TMEM230	OTAFALFV	Moderate	Semidominant	[736]
A2M	OTFTX90K	Strong	Biomarker	[787]
ACACA	OT5CQPZY	Strong	Biomarker	[788]
ACMSD	OTPSXPSF	Strong	Genetic Variation	[789]
ACOT7	OT7C68YV	Strong	Biomarker	[278]
ACSBG1	OTM040MW	Strong	Biomarker	[790]
ACTBL2	OTD6B81U	Strong	Biomarker	[278]
ACTG2	OTRDWUO0	Strong	Biomarker	[278]
ADAMTSL1	OTBNYF3F	Strong	Genetic Variation	[791]
ADARB2	OTDJKS39	Strong	Biomarker	[265]
AGAP1	OTVX8835	Strong	Genetic Variation	[226]
AGFG1	OTI8ZKC4	Strong	Biomarker	[792]
AHSA1	OTC7AFHT	Strong	Biomarker	[287]
AMFR	OTQRX7LC	Strong	Biomarker	[793]
AMIGO2	OTPAIT1O	Strong	Genetic Variation	[794]
ANK2	OTWB4R1Y	Strong	Biomarker	[795]
ANKK1	OT0OM1O0	Strong	Genetic Variation	[796]
ANO3	OTM34U6Q	Strong	Genetic Variation	[797]
APAF1	OTJWIVY0	Strong	Biomarker	[798]
APOD	OTT77XW8	Strong	Biomarker	[799]
AQP4	OTA9MYD5	Strong	Biomarker	[800]
ARC	OTN2QQPG	Strong	Biomarker	[801]
ARL6IP5	OTYZ6BEQ	Strong	Biomarker	[802]
ARPC3	OTKWVF8P	Strong	Therapeutic	[803]
ASCL1	OTI4X44G	Strong	Genetic Variation	[804]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[805]
ATF2	OTNIZPEA	Strong	Biomarker	[806]
ATG12	OTJRO09Y	Strong	Altered Expression	[807]
ATG13	OTYMHNEJ	Strong	Altered Expression	[531]
ATG5	OT4T5SMS	Strong	Biomarker	[536]
ATOX1	OT05LF59	Strong	Biomarker	[808]
ATP13A4	OTJYVW1I	Strong	Biomarker	[809]
ATP1A3	OTM8EG6H	Strong	Biomarker	[341]
ATP5F1B	OTLFZUQK	Strong	Biomarker	[398]
ATP6AP2	OT0IABVV	Strong	Altered Expression	[810]
ATXN10	OTKRDUNN	Strong	Biomarker	[811]
B3GALT4	OTLKSMQE	Strong	Altered Expression	[812]
BAG1	OTRQNIA4	Strong	Biomarker	[813]
BAG3	OTVXYUDQ	Strong	Biomarker	[814]
BMS1	OTEGQ8ZO	Strong	Biomarker	[788]
BNIP3L	OTJKOMXE	Strong	Biomarker	[815]
BORCS7	OTQUOZC2	Strong	Genetic Variation	[334]
BPIFA2	OTLFSDZD	Strong	Genetic Variation	[431]
BRCC3	OTK0ZN7Y	Strong	Altered Expression	[311]
BRINP1	OTEUVSCP	Strong	Genetic Variation	[816]
C19orf12	OTVSJ1AR	Strong	Biomarker	[817]
CAB39L	OTQEBL0W	Strong	Genetic Variation	[226]
CACYBP	OTJMZD2T	Strong	Biomarker	[614]
CADPS2	OTV1FW0M	Strong	Altered Expression	[818]
CALB1	OTM7IXDG	Strong	Altered Expression	[819]
CALB2	OTSNMCG9	Strong	Biomarker	[315]
CALCOCO2	OTRGX0OV	Strong	Biomarker	[398]
CALD1	OTNJKJ6Q	Strong	Biomarker	[506]
CARD16	OT4NUHWB	Strong	Biomarker	[820]
CASK	OT8EF7ZF	Strong	Altered Expression	[821]
CASS4	OTGPIPUS	Strong	Genetic Variation	[822]
CBLIF	OTNE20WU	Strong	Biomarker	[738]
CBLL2	OTB4AD3V	Strong	Altered Expression	[823]
CCDC154	OTFGNMNP	Strong	Biomarker	[824]
CCDC82	OT16EAZ7	Strong	Genetic Variation	[825]
CD200R1	OT65Q9M6	Strong	Altered Expression	[310]
CD2AP	OTC76KQM	Strong	Genetic Variation	[826]
CDH8	OTS3SRZ6	Strong	Genetic Variation	[827]
CDKL5	OTGL5HRV	Strong	Biomarker	[509]
CDKN2D	OT2TTZPZ	Strong	Biomarker	[828]
CDNF	OT1TP2T8	Strong	Biomarker	[829]
CHCHD10	OTCDHAM6	Strong	Genetic Variation	[830]
CHMP2B	OTZA7RJB	Strong	Genetic Variation	[831]
CISD1	OT0MTVGF	Strong	Biomarker	[832]
CLOCK	OTNEOJY7	Strong	Altered Expression	[833]
CLSTN3	OTPUFK4C	Strong	Biomarker	[440]
CNKSR3	OTXP4QH8	Strong	Genetic Variation	[597]
CNNM2	OTZHO8WU	Strong	Genetic Variation	[334]
CNTNAP2	OT48T2ZP	Strong	Biomarker	[265]
COL13A1	OTM9IM6J	Strong	Genetic Variation	[825]
COL17A1	OTID5AH2	Strong	Biomarker	[834]
COL19A1	OT7W3Q87	Strong	Biomarker	[265]
COL5A2	OT5VOSQE	Strong	Genetic Variation	[835]
COPE	OTBKHBT7	Strong	Genetic Variation	[836]
COX5A	OTP0961M	Strong	Genetic Variation	[837]
CTIF	OT7DU7WN	Strong	Genetic Variation	[791]
CTNNA3	OT9Z0P1E	Strong	Genetic Variation	[791]
CUX1	OTU1LCNJ	Strong	Biomarker	[408]
CYP20A1	OTIUZ6CF	Strong	Genetic Variation	[838]
CYTB	OTAHB98A	Strong	Genetic Variation	[839]
DAPK2	OTWODUQG	Strong	Biomarker	[343]
DBN1	OTZVKG8A	Strong	Therapeutic	[840]
DCDC2	OTSUFH1H	Strong	Biomarker	[841]
DCTN4	OTM7C943	Strong	Biomarker	[411]
DCUN1D1	OT8UJLZU	Strong	Genetic Variation	[842]
DDRGK1	OT3KCK0U	Strong	Genetic Variation	[677]
DECR1	OTCDIR6X	Strong	Biomarker	[843]
DENR	OTXP9HOY	Strong	Biomarker	[343]
DEPDC7	OT62C942	Strong	Genetic Variation	[507]
DLG1	OTCRZYWT	Strong	Biomarker	[844]
DLGAP4	OTNELLIN	Strong	Altered Expression	[326]
DMRT1	OT5PU9U1	Strong	Genetic Variation	[831]
DNAJB6	OTMHIIAN	Strong	Biomarker	[845]
DNAJB9	OT38EQT6	Strong	Biomarker	[440]
DNAJC1	OTCKFOZ0	Strong	Genetic Variation	[791]
DNER	OT2GH2E5	Strong	Biomarker	[846]
DRAXIN	OT3H5C42	Strong	Biomarker	[265]
DTNBP1	OT9UQT2S	Strong	Altered Expression	[847]
DUSP2	OTH54FMR	Strong	Biomarker	[281]
DUSP26	OTI7WIYN	Strong	Biomarker	[848]
EIF2B3	OTG6HE7D	Strong	Biomarker	[642]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[849]
ELAVL4	OT3YH6J6	Strong	Biomarker	[850]
ENO2	OTRODL0T	Strong	Biomarker	[851]
ERG	OTOTX9VU	Strong	Biomarker	[852]
FBRS	OTUVH446	Strong	Biomarker	[317]
FBXO8	OTZNGJGW	Strong	Biomarker	[317]
FEZ1	OTWCXPRE	Strong	Biomarker	[853]
FGB	OT6RKLI9	Strong	Biomarker	[854]
FGF9	OT2SKDGM	Strong	Biomarker	[855]
FHL5	OT6C00Z1	Strong	Biomarker	[278]
FKBP1B	OT8CMPB2	Strong	Biomarker	[354]
FKBP2	OTHBZHX0	Strong	Biomarker	[354]
FKBP3	OT7ETKPE	Strong	Biomarker	[354]
FKBP9	OTGRFVKZ	Strong	Biomarker	[354]
FOXA1	OTEBY0TD	Strong	Biomarker	[856]
FOXA2	OTJOCVOY	Strong	Altered Expression	[857]
FRY	OT74IAG2	Strong	Genetic Variation	[596]
FSIP1	OTYLL6GM	Strong	Altered Expression	[858]
FTMT	OTIUX6XG	Strong	Altered Expression	[859]
FXYD1	OTNKT6GP	Strong	Biomarker	[860]
GABARAPL2	OTS7YVHF	Strong	Biomarker	[861]
GBF1	OTY1KEHY	Strong	Genetic Variation	[226]
GC	OTWS63BY	Strong	Genetic Variation	[862]
GLIS1	OTBDNB26	Strong	Genetic Variation	[863]
GORASP2	OTL3PLD2	Strong	Biomarker	[864]
GPC4	OTUJ14DW	Strong	Biomarker	[865]
GPR143	OTWUA2AV	Strong	Biomarker	[866]
GPR158	OTYOC1RQ	Strong	Biomarker	[372]
GPR37	OTIMDDI3	Strong	Biomarker	[867]
GPR37L1	OTOV08EV	Strong	Biomarker	[867]
GPR65	OTCF5O4G	Strong	Genetic Variation	[226]
GPX4	OTRAFFX2	Strong	Biomarker	[868]
GPX7	OTINT9Z4	Strong	Biomarker	[869]
GRAP2	OTS5NIZ3	Strong	Biomarker	[287]
GRK6	OT4LZTP9	Strong	Biomarker	[870]
GRP	OT8JDFNI	Strong	Biomarker	[871]
GSTM2	OTG4WT05	Strong	Genetic Variation	[872]
GTF2H1	OTCRXC6B	Strong	Biomarker	[411]
GTPBP6	OTY0L6K6	Strong	Biomarker	[873]
H3C1	OTGBGOZW	Strong	Biomarker	[683]
HAPLN2	OT0G3KEQ	Strong	Biomarker	[874]
HBG1	OTVL4NSU	Strong	Biomarker	[265]
HCLS1	OTX7WGYN	Strong	Biomarker	[408]
HCN3	OTMO1ZYQ	Strong	Biomarker	[875]
HERPUD1	OT9EROL6	Strong	Altered Expression	[876]
HIP1R	OTIPKEJC	Strong	Genetic Variation	[877]
HIVEP3	OTM3QT3L	Strong	Biomarker	[850]
HMGXB3	OTTZ1AS6	Strong	Altered Expression	[878]
HOMER1	OTWFD3SI	Strong	Genetic Variation	[879]
HOXD13	OTWSC8TF	Strong	Biomarker	[880]
HSD17B6	OTSB55D2	Strong	Biomarker	[519]
HSPA4	OT5HR0AR	Strong	Altered Expression	[881]
IGFALS	OTTWCZYM	Strong	Genetic Variation	[882]
IP6K2	OTCUMUUP	Strong	Genetic Variation	[226]
IREB2	OT747D24	Strong	Biomarker	[883]
ISYNA1	OT49ONSE	Strong	Altered Expression	[884]
ITIH1	OTSXJGQF	Strong	Genetic Variation	[226]
KCNIP4	OTB1BS0X	Strong	Genetic Variation	[750]
KHSRP	OTDHZARB	Strong	Biomarker	[408]
KLHDC1	OTMX4YTM	Strong	Genetic Variation	[685]
KRT7	OTLT3JFN	Strong	Genetic Variation	[621]
LCLAT1	OTCOP0JN	Strong	Biomarker	[885]
LCN1	OT8BWXTV	Strong	Genetic Variation	[317]
LDOC1	OTWZH4O9	Strong	Altered Expression	[886]
LGALS4	OTKQCG0H	Strong	Biomarker	[887]
LINGO2	OT3N88Q1	Strong	Genetic Variation	[888]
LMX1A	OTEEYD5L	Strong	Posttranslational Modification	[889]
LMX1B	OTM8145D	Strong	Altered Expression	[889]
LRPPRC	OTXSK5LP	Strong	Genetic Variation	[258]
LRRK1	OTCQMOIX	Strong	Genetic Variation	[890]
LSAMP	OTYXVQX2	Strong	Altered Expression	[684]
LSM2	OTHL77NY	Strong	Biomarker	[891]
MACF1	OTVIHD77	Strong	Biomarker	[892]
MAFF	OT9B7MX0	Strong	Biomarker	[893]
MAP1B	OTVXW089	Strong	Altered Expression	[894]
MAP1LC3B	OTUYHB84	Strong	Biomarker	[398]
MAP2	OT6UYT3X	Strong	Biomarker	[895]
MAP3K13	OTS93BTX	Strong	Biomarker	[896]
MAP6	OTPUI00F	Strong	Biomarker	[897]
MATN3	OTH9H74J	Strong	Biomarker	[898]
MCAT	OTH07FIW	Strong	Genetic Variation	[493]
MCIDAS	OTK1JVAH	Strong	Biomarker	[899]
MCPH1	OTYT3TT5	Strong	Genetic Variation	[493]
MCU	OTQZAYWQ	Strong	Biomarker	[900]
MDGA2	OTIJ0T5J	Strong	Genetic Variation	[835]
MEF2C	OTZGF1Y5	Strong	Biomarker	[901]
MEF2D	OT7CEIG0	Strong	Biomarker	[902]
MFAP1	OTZN4FT3	Strong	Biomarker	[903]
MFHAS1	OTS922CJ	Strong	Biomarker	[904]
MFN2	OTPYN8A3	Strong	Altered Expression	[905]
MIDN	OTHE4ZEK	Strong	Biomarker	[906]
MINDY4	OTBZ2SZB	Strong	Altered Expression	[907]
MIP	OTEBLU3E	Strong	Biomarker	[331]
MKRN2	OTDD1V3O	Strong	Biomarker	[908]
MLKL	OTDSLC81	Strong	Biomarker	[479]
MOK	OTQK7M9V	Strong	Biomarker	[285]
MPHOSPH6	OT6E2S48	Strong	Biomarker	[909]
MPRIP	OT5FV5NS	Strong	Biomarker	[479]
MPZ	OTAR2YXH	Strong	Biomarker	[909]
MSC	OTBRPZL5	Strong	Biomarker	[910]
MT3	OTVCZ7HI	Strong	Biomarker	[911]
MTIF3	OTPQ7FPQ	Strong	Biomarker	[912]
MUL1	OT2JC9YR	Strong	Genetic Variation	[913]
MX2	OT05NF37	Strong	Genetic Variation	[750]
MZB1	OT071TET	Strong	Altered Expression	[280]
NCAPD2	OT8VGE2O	Strong	Genetic Variation	[914]
NCAPG2	OTZYENKO	Strong	Biomarker	[265]
NCK2	OTUYPF55	Strong	Altered Expression	[434]
ND1	OTCLGIXV	Strong	Biomarker	[915]
ND2	OTG9OHOX	Strong	Genetic Variation	[916]
ND3	OT1OC3K3	Strong	Biomarker	[917]
ND5	OT45LW1K	Strong	Genetic Variation	[918]
NDE1	OT2N8Q17	Strong	Biomarker	[919]
NDFIP1	OTIORSWF	Strong	Altered Expression	[920]
NDRG2	OT5L6KD7	Strong	Biomarker	[921]
NDUFA1	OTKBUQXP	Strong	Biomarker	[922]
NDUFA2	OTNSTATK	Strong	Altered Expression	[923]
NDUFS4	OTJKUYEE	Strong	Biomarker	[519]
NECTIN2	OTIE0W6O	Strong	Biomarker	[265]
NEFH	OTMSCW5I	Strong	Biomarker	[440]
NEFL	OTQESJV4	Strong	Biomarker	[924]
NEFM	OT8VCBNF	Strong	Biomarker	[925]
NEIL1	OTHBU5DJ	Strong	Biomarker	[926]
NELFE	OTL4E94L	Strong	Biomarker	[341]
NFE2	OTLM94BI	Strong	Biomarker	[927]
NHS	OTKE8QAT	Strong	Biomarker	[928]
NIF3L1	OT4MP90J	Strong	Biomarker	[929]
NKTR	OTIADJNW	Strong	Biomarker	[354]
NLN	OTFRITPU	Strong	Altered Expression	[331]
NMS	OTFYS4LO	Strong	Biomarker	[930]
NOCT	OTVSYP2D	Strong	Biomarker	[210]
NOL3	OT1K0L0D	Strong	Altered Expression	[447]
NOX1	OTZPJQCC	Strong	Altered Expression	[931]
NPAS2	OTMRT2TS	Strong	Biomarker	[932]
NPC2	OTE9UEJC	Strong	Genetic Variation	[933]
NR2C1	OTJEL7WT	Strong	Genetic Variation	[507]
NRF1	OTOXWNV8	Strong	Biomarker	[704]
NTS	OTPGDNQS	Strong	Biomarker	[934]
NUBP1	OTE8RAKZ	Strong	Biomarker	[324]
NUCB2	OTHO6JWN	Strong	Biomarker	[935]
NUCKS1	OTL4VJC5	Strong	Genetic Variation	[783]
NUFIP2	OTZBZ224	Strong	Biomarker	[936]
NUP62	OTMN63DH	Strong	Biomarker	[411]
OBP2A	OTBIJ5TI	Strong	Genetic Variation	[937]
OCM	OTQRML29	Strong	Biomarker	[938]
OGA	OT7ZBWT1	Strong	Altered Expression	[939]
OPN1MW	OTPJ7LX4	Strong	Biomarker	[940]
OPN3	OTON6BFU	Strong	Altered Expression	[941]
OPN4	OT1LZ7TS	Strong	Biomarker	[942]
OXR1	OTPIDMT3	Strong	Biomarker	[943]
P2RX2	OT0LF34A	Strong	Altered Expression	[449]
P2RX5	OTLBR20R	Strong	Altered Expression	[449]
P2RX6	OT1FNTXA	Strong	Altered Expression	[449]
PACRG	OT1NYNNW	Strong	Biomarker	[944]
PAEP	OTQA0NV4	Strong	Biomarker	[945]
PARL	OT7DMHSA	Strong	Genetic Variation	[946]
PCMT1	OTGYVSGU	Strong	Altered Expression	[947]
PCP4	OTM1XXYX	Strong	Altered Expression	[948]
PDC	OT1UUVYY	Strong	Biomarker	[949]
PDE8B	OT4217NK	Strong	Genetic Variation	[950]
PDIA3	OTHPQ0Q3	Strong	Altered Expression	[951]
PDSS2	OTEOQBMX	Strong	Biomarker	[952]
PELI1	OTMLBCLC	Strong	Biomarker	[953]
PENK	OT8P3HMP	Strong	Altered Expression	[954]
PFN3	OTXSGOQE	Strong	Biomarker	[955]
PGK1	OT6V1ICH	Strong	Altered Expression	[956]
PGP	OT6QQ7OR	Strong	Biomarker	[957]
PHOX2B	OT3SFR2O	Strong	Biomarker	[958]
PIEZO1	OTBG1FU4	Strong	Genetic Variation	[959]
PIP4P2	OT8OVB6R	Strong	Genetic Variation	[791]
PLA2G6	OT5FL0WU	Strong	Genetic Variation	[960]
PLB1	OTZ6TTYV	Strong	Biomarker	[457]
PLEKHM1	OT1SLPGD	Strong	Genetic Variation	[596]
PLPPR1	OT4A560N	Strong	Genetic Variation	[961]
PLXNA2	OTNNBJMQ	Strong	Biomarker	[962]
PM20D1	OTXXNQ5K	Strong	Genetic Variation	[596]
PNOC	OTJEAADN	Strong	Altered Expression	[447]
PODXL	OTPNQXF3	Strong	Genetic Variation	[963]
POLDIP2	OT8SZSJ6	Strong	Biomarker	[287]
POLR1D	OTOCZQNA	Strong	Biomarker	[964]
POTEM	OT7L2HGH	Strong	Biomarker	[278]
POU2F1	OTK7ELJ0	Strong	Genetic Variation	[495]
PPIG	OTZ8BTTM	Strong	Genetic Variation	[682]
PPIL1	OTS5S837	Strong	Biomarker	[354]
PPIL2	OTL9Y4IO	Strong	Biomarker	[354]
PPIL3	OT0GPU73	Strong	Biomarker	[354]
PPIL4	OTFTLFJS	Strong	Biomarker	[354]
PPIL6	OTOZQMQE	Strong	Biomarker	[354]
PPM1H	OTKSVU7S	Strong	Altered Expression	[965]
PPP1R15A	OTYG179K	Strong	Biomarker	[966]
PPP1R1B	OTSIJMQ9	Strong	Genetic Variation	[967]
PPP1R9B	OTDCTHTT	Strong	Biomarker	[968]
PPP2R2B	OTSFVC82	Strong	Genetic Variation	[969]
PRDX2	OTLWCY9T	Strong	Altered Expression	[970]
PRKAB1	OT1OG4QZ	Strong	Altered Expression	[971]
PRKAR1B	OT777OHS	Strong	Biomarker	[972]
PRKAR2A	OTZ7P17Z	Strong	Biomarker	[469]
PROP1	OT8GF6N8	Strong	Altered Expression	[973]
PRRX2	OT8UR4AU	Strong	Altered Expression	[970]
PRSS21	OT8ZYC7G	Strong	Biomarker	[974]
PRSS53	OT3HUUI3	Strong	Genetic Variation	[597]
PSAP	OTUOEKY7	Strong	Genetic Variation	[975]
PSMC4	OTS3XN41	Strong	Biomarker	[348]
PSMD6	OTX59EGK	Strong	Altered Expression	[821]
PSMG1	OTZ5I6UM	Strong	Biomarker	[281]
PSPH	OTV1PVAX	Strong	Genetic Variation	[431]
PSPN	OT54LLZJ	Strong	Genetic Variation	[431]
PTGES3	OTPPQWI0	Strong	Biomarker	[312]
PTPA	OTRGFOI7	Strong	Biomarker	[976]
PTPN22	OTDCNTC3	Strong	Biomarker	[713]
PVALB	OTZW1WVQ	Strong	Biomarker	[977]
QSOX1	OT4ZPK4P	Strong	Biomarker	[978]
RAB10	OT8ZN26V	Strong	Biomarker	[979]
RAB32	OTTR4H7S	Strong	Genetic Variation	[980]
RAB35	OTRH1E2T	Strong	Biomarker	[981]
RAB3IP	OT3UPQAA	Strong	Biomarker	[982]
RAB7B	OT60A0E9	Strong	Biomarker	[475]
RABEP2	OTO61X27	Strong	Genetic Variation	[323]
RAPH1	OTMQXW7S	Strong	Biomarker	[790]
RBM3	OTAJ7R31	Strong	Biomarker	[983]
REG1A	OTMHUH1D	Strong	Genetic Variation	[431]
REM1	OTUXL0HC	Strong	Genetic Variation	[984]
RER1	OTTBAUBP	Strong	Biomarker	[985]
REST	OTLL92LQ	Strong	Biomarker	[986]
RGS9	OTRA1LOC	Strong	Genetic Variation	[987]
RHEB	OTFLTSEC	Strong	Genetic Variation	[988]
RHOT1	OTBIRR8Q	Strong	Biomarker	[989]
RIDA	OTW4098I	Strong	Genetic Variation	[431]
RIPK3	OTL1D484	Strong	Biomarker	[479]
RNASE4	OTA5SZLC	Strong	Altered Expression	[784]
RNF11	OTFBJSKQ	Strong	Genetic Variation	[850]
RNF146	OTE4CO7E	Strong	Altered Expression	[823]
RNF19A	OTKWCV80	Strong	Biomarker	[287]
RPL14	OTZZW7TK	Strong	Biomarker	[646]
RPL23A	OTPYLCCX	Strong	Biomarker	[646]
RPL6	OTRU71O4	Strong	Biomarker	[646]
RPS27A	OTIIGGZ2	Strong	Biomarker	[522]
RPS6	OTT4D1LN	Strong	Altered Expression	[990]
RPS8	OTEBS4HZ	Strong	Biomarker	[646]
RRAS	OTBBF28C	Strong	Biomarker	[312]
RTL10	OTHGB81W	Strong	Biomarker	[991]
RTN1	OTCX1SMK	Strong	Biomarker	[992]
SARM1	OTEP4I5O	Strong	Posttranslational Modification	[993]
SATB2	OT2W80XC	Strong	Altered Expression	[847]
SBNO1	OTNX3RL0	Strong	Altered Expression	[994]
SBNO2	OT1C6J3K	Strong	Altered Expression	[994]
SCARB2	OTN929M8	Strong	Genetic Variation	[995]
SCGN	OTGD7SKH	Strong	Genetic Variation	[614]
SEC22A	OTSAGTP6	Strong	Biomarker	[996]
SELENOH	OTZ0QU22	Strong	Genetic Variation	[997]
SELENOP	OT02B8IR	Strong	Altered Expression	[998]
SELENOT	OTKQGMLB	Strong	Biomarker	[997]
SEMA5A	OTUOIOJV	Strong	Genetic Variation	[999]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[495]
SEPTIN4	OTD16B30	Strong	Biomarker	[1000]
SEPTIN5	OT6JTJBO	Strong	Biomarker	[1001]
SERPINA3	OT9BP2S0	Strong	Biomarker	[1002]
SERPINF2	OTZGAF8B	Strong	Biomarker	[1003]
SESN2	OT889IXY	Strong	Biomarker	[1004]
SESN3	OTJRY1Y5	Strong	Biomarker	[1005]
SGSM3	OTIB1P8A	Strong	Biomarker	[1006]
SH3BP5	OTOOEGUJ	Strong	Biomarker	[1007]
SHMT1	OTIINA3J	Strong	Genetic Variation	[1008]
SHMT2	OT5NCAZN	Strong	Genetic Variation	[1008]
SHOC1	OTP51XIP	Strong	Biomarker	[594]
SIGLEC7	OTNDLURR	Strong	Biomarker	[408]
SIPA1L2	OT8NJE5D	Strong	Genetic Variation	[677]
SKIL	OTNBXH32	Strong	Altered Expression	[994]
SKP1	OT5BPAZ4	Strong	Genetic Variation	[1009]
SMARCA1	OT0Y6PTU	Strong	Biomarker	[1010]
SMN2	OT54RLO1	Strong	Altered Expression	[501]
SMPD3	OTHQBETH	Strong	Biomarker	[1011]
SMUG1	OT2YIOCQ	Strong	Biomarker	[1012]
SNAP23	OTY2MYBX	Strong	Altered Expression	[819]
SNCAIP	OTH8VNOK	Strong	Biomarker	[1013]
SNRNP70	OTP52YZ3	Strong	Biomarker	[1014]
SNRPF	OTZE5W6G	Strong	Altered Expression	[878]
SNX3	OTXL5W8F	Strong	Biomarker	[1015]
SNX6	OTLKQYJU	Strong	Biomarker	[980]
SOD3	OTIOZQAB	Strong	Genetic Variation	[274]
SORL1	OTQ8FFNS	Strong	Genetic Variation	[1016]
SOX6	OTT0W0LE	Strong	Biomarker	[959]
SPAG11A	OTNQ9UB0	Strong	Biomarker	[471]
SPPL2C	OTUTY2ED	Strong	Genetic Variation	[323]
SPTSSB	OTITDZW9	Strong	Genetic Variation	[226]
SRA1	OTYOGMTG	Strong	Biomarker	[1017]
SRRM2	OTSIMMC9	Strong	Biomarker	[1018]
SRY	OT516T6D	Strong	Biomarker	[1019]
ST3GAL2	OT8WM21E	Strong	Altered Expression	[812]
STK35	OTLEMU48	Strong	Biomarker	[1020]
STMN2	OT0FUHLH	Strong	Altered Expression	[1021]
STX1B	OTSW59X0	Strong	Genetic Variation	[789]
STXBP1	OTRYA8C3	Strong	Biomarker	[1022]
STXBP3	OTTTYMAQ	Strong	Genetic Variation	[431]
SUCLA2	OTMZD4PW	Strong	Biomarker	[684]
SV2B	OTAO5WIU	Strong	Biomarker	[1023]
SYNM	OTOI8TRJ	Strong	Biomarker	[357]
SYT17	OTTW4MI3	Strong	Genetic Variation	[226]
TAC1	OTM842YW	Strong	Biomarker	[958]
TAL1	OTX4K6QZ	Strong	Genetic Variation	[621]
TALDO1	OTDKV2S2	Strong	Biomarker	[854]
TAOK2	OTNUMOZ1	Strong	Biomarker	[509]
TAS1R2	OT53VYMN	Strong	Genetic Variation	[507]
TAS2R13	OTSTOX5G	Strong	Altered Expression	[1024]
TAS2R38	OTX5MM36	Strong	Genetic Variation	[1025]
TBC1D5	OTNHLLAX	Strong	Genetic Variation	[226]
TCOF1	OT4BOYTM	Strong	Biomarker	[1026]
TFEB	OTJUJJQY	Strong	Altered Expression	[1027]
TFR2	OTMYCCEO	Strong	Biomarker	[1028]
TGS1	OTM79LML	Strong	Altered Expression	[947]
THY1	OTVONVTB	Strong	Biomarker	[1029]
TMC3	OTSXYLTH	Strong	Genetic Variation	[825]
TMED10	OTUXSHH7	Strong	Altered Expression	[1030]
TMED9	OTYGAQS0	Strong	Biomarker	[1031]
TMEM106B	OTUWA6NW	Strong	Genetic Variation	[1032]
TMEM163	OTCT1Y1L	Strong	Genetic Variation	[1033]
TMEM229B	OT50LI46	Strong	Genetic Variation	[226]
TMEM59	OTX4EKES	Strong	Biomarker	[1034]
TMPRSS9	OT7ETD15	Strong	Genetic Variation	[226]
TNMD	OTHLVA9G	Strong	Altered Expression	[210]
TOMM20	OT76TPR2	Strong	Altered Expression	[1035]
TOMM40	OTZDQ29F	Strong	Genetic Variation	[1036]
TOX3	OTC9NR4W	Strong	Genetic Variation	[1037]
TPPP	OTCFMSUF	Strong	Biomarker	[357]
TPTE2	OTR3K733	Strong	Genetic Variation	[827]
TRAF2	OT1MEZZN	Strong	Biomarker	[1038]
TRAP1	OTNG0L8J	Strong	Genetic Variation	[1039]
TRAPPC2L	OT1LN60D	Strong	Genetic Variation	[959]
TRAT1	OTMPUNPD	Strong	Biomarker	[1040]
TRIB3	OTG5OS7X	Strong	Altered Expression	[1024]
TRIM10	OTEO4UCZ	Strong	Altered Expression	[1040]
TRIM3	OT704FQ0	Strong	Biomarker	[824]
TRIM32	OTJOV0PG	Strong	Biomarker	[1041]
ACAD8	OT3JI5GB	Definitive	Biomarker	[1042]
ADGRB1	OTJSEXRC	Definitive	Biomarker	[1043]
AFDN	OTTRU341	Definitive	Biomarker	[1044]
AMBRA1	OTY0YGT9	Definitive	Biomarker	[1045]
ANKRD50	OTTLA4W2	Definitive	Genetic Variation	[555]
ASAH1	OT1DNGXL	Definitive	Altered Expression	[1046]
ASAP1	OT4DLRYY	Definitive	Biomarker	[567]
ASAP2	OTGEXULW	Definitive	Biomarker	[567]
ASPSCR1	OTXTOD10	Definitive	Biomarker	[1047]
AXIN1	OTRGZGZ5	Definitive	Altered Expression	[569]
B3GAT1	OTXFP98E	Definitive	Altered Expression	[1048]
B4GALNT1	OTCY80HS	Definitive	Genetic Variation	[1049]
C1R	OTA0ZNIU	Definitive	Biomarker	[292]
CACNG5	OTN4PGI5	Definitive	Biomarker	[1050]
CACUL1	OT6P1ZVP	Definitive	Genetic Variation	[1009]
CAV2	OT1FGRQX	Definitive	Biomarker	[1051]
CCL26	OT2B7HR9	Definitive	Altered Expression	[533]
CNBP	OTTGM9NK	Definitive	Biomarker	[1052]
CPLX1	OT7UIGTP	Definitive	Biomarker	[1053]
CTNNBL1	OT6KLHPA	Definitive	Genetic Variation	[1054]
CTSZ	OTSCX2LL	Definitive	Altered Expression	[1055]
CUL1	OTXPE1UZ	Definitive	Biomarker	[1056]
DBI	OT884QY9	Definitive	Altered Expression	[1057]
DHDDS	OTVLYBUS	Definitive	Biomarker	[1058]
DVL1	OTD67RF1	Definitive	Biomarker	[1059]
EBF3	OTB0IWLW	Definitive	Biomarker	[1060]
EBPL	OT59J1GY	Definitive	Biomarker	[1061]
ELF4	OT167PR5	Definitive	Biomarker	[404]
ELOVL7	OT89NYVC	Definitive	Genetic Variation	[639]
ENDOU	OTB7OF7Y	Definitive	Altered Expression	[1062]
EXOSC6	OTAC10N6	Definitive	Altered Expression	[1062]
FAIM2	OT6QINVO	Definitive	Biomarker	[1063]
FBXO2	OTF3677S	Definitive	Genetic Variation	[1064]
FBXO41	OT5MC4TZ	Definitive	Genetic Variation	[1064]
FBXW12	OTA7XY4B	Definitive	Genetic Variation	[1064]
FYCO1	OTKZHTZ5	Definitive	Biomarker	[475]
GABARAP	OTAQUX6E	Definitive	Biomarker	[536]
GBA1	OT0XMD63	Definitive	Autosomal dominant	[179]
GBA2	OTOZXG5D	Definitive	Biomarker	[1065]
GDF1	OTZ1VRBH	Definitive	Biomarker	[1066]
GK5	OT65U8L1	Definitive	Biomarker	[1067]
GOLGA6A	OTHU9MRX	Definitive	Biomarker	[1068]
GTF2H4	OTPD1DIU	Definitive	Biomarker	[562]
IMMT	OTBDSLE7	Definitive	Biomarker	[1069]
KLF9	OTBFEJRQ	Definitive	Biomarker	[1070]
KRT10	OTSVRD3Q	Definitive	Biomarker	[1071]
LRP10	OT8490HT	Definitive	Biomarker	[1072]
LRRK2	OTLS7C99	Definitive	Autosomal dominant	[179]
MARCHF5	OTBK6BBM	Definitive	Biomarker	[1073]
MRPS30	OTDXIAGG	Definitive	Biomarker	[567]
MTFMT	OT1OIVJL	Definitive	Altered Expression	[1074]
MTPAP	OT6HQ02S	Definitive	Biomarker	[567]
MYL4	OTURFCSE	Definitive	Biomarker	[1075]
NCEH1	OTZ66CKX	Definitive	Biomarker	[1076]
NEDD4L	OT1B19RU	Definitive	Biomarker	[1077]
NPDC1	OT788NC8	Definitive	Biomarker	[1078]
NRGN	OTVGE10W	Definitive	Biomarker	[1079]
OMP	OT7JH0DY	Definitive	Biomarker	[1080]
PAGR1	OTXR5PQ8	Definitive	Genetic Variation	[548]
PAPOLA	OTPHD65D	Definitive	Biomarker	[567]
PARK7	OT0SKNTG	Definitive	Autosomal recessive	[179]
PDAP1	OTJSWMOD	Definitive	Biomarker	[567]
PEAK1	OTVVM637	Definitive	Biomarker	[1081]
PIGC	OTDFW5KH	Definitive	Biomarker	[639]
PINK1	OT50NR57	Definitive	Autosomal recessive	[179]
PPP1R13L	OTNCPLWE	Definitive	Biomarker	[1066]
PPP4C	OT4B0TNV	Definitive	Biomarker	[1082]
PRDM6	OTKY12D9	Definitive	Biomarker	[949]
PRDX1	OTZ3BEC4	Definitive	Altered Expression	[970]
PRKN	OTJBN41W	Definitive	Autosomal recessive	[179]
PRRX1	OTTZK5G8	Definitive	Altered Expression	[970]
PSG5	OTHTU98X	Definitive	Genetic Variation	[1083]
PTPRU	OTHDO0QG	Definitive	Biomarker	[598]
RAB8A	OTPB54Y3	Definitive	Biomarker	[1084]
RCBTB1	OTAYELI8	Definitive	Biomarker	[1068]
RNH1	OT6EC79B	Definitive	Biomarker	[1066]
RPL32	OTKRQJT4	Definitive	Biomarker	[536]
RSPO2	OT3HHXU0	Definitive	Biomarker	[1085]
SALL1	OTYYZGLH	Definitive	Biomarker	[536]
SEL1L	OTC0FB7T	Definitive	Biomarker	[505]
SNCA	OTPWC1MR	Definitive	Autosomal dominant	[179]
SV2C	OTIH108W	Definitive	Biomarker	[1086]
SYN3	OTSGYNA5	Definitive	Genetic Variation	[1087]
TFDP2	OTKQFX5H	Definitive	Biomarker	[565]
TIAL1	OTV2KFZH	Definitive	Altered Expression	[543]
TIMM23	OTAAS85T	Definitive	Biomarker	[1035]
TNFAIP8L2	OTII0RM0	Definitive	Altered Expression	[1088]
TOR2A	OT1EGCDU	Definitive	Biomarker	[1089]
TPSG1	OTDESHKT	Definitive	Genetic Variation	[1090]
TRIM17	OTUJZUOS	Definitive	Biomarker	[1091]
TRIM41	OTU3ADNG	Definitive	Biomarker	[1091]

This Disease Is Related to 473 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACO2	TTMTF2P	Limited	Biomarker	[180]
ADORA1	TTK25J1	Limited	Biomarker	[181]
AOC1	TTM3B5R	Limited	Genetic Variation	[182]
APLN	TT87D3J	Limited	Biomarker	[183]
APOC3	TTXOZQ1	Limited	Biomarker	[184]
ASIC2	TTVMWLP	Limited	Altered Expression	[185]
BACE2	TT69DB8	Limited	Genetic Variation	[186]
BCKDK	TT7WD2Q	Limited	Genetic Variation	[187]
CAPN1	TT1WBIJ	Limited	Biomarker	[188]
CASP6	TTKW4ML	Limited	Genetic Variation	[189]
CCKBR	TTVFO0U	Limited	Genetic Variation	[190]
CCND3	TT1JXNR	Limited	Altered Expression	[191]
CHRNB4	TTTVAFQ	Limited	Biomarker	[192]
CMA1	TT8VUE0	Limited	Biomarker	[193]
CRAT	TTC8M31	Limited	Genetic Variation	[194]
CRY2	TTAO58M	Limited	Biomarker	[195]
DAPK3	TTERVQN	Limited	Biomarker	[196]
F12	TTRJSMV	Limited	Genetic Variation	[197]
GAL	TTXZAJ5	Limited	Biomarker	[198]
GPRC5D	TTHRAPJ	Limited	Biomarker	[199]
GRIN1	TTLD29N	Limited	Biomarker	[200]
HEXA	TTJI5JW	Limited	Genetic Variation	[201]
HK2	TTK02H8	Limited	Biomarker	[202]
HPD	TT8DSFC	Limited	Genetic Variation	[203]
HPGDS	TTCYE56	Limited	Biomarker	[204]
HSD17B13	TTDJYZR	Limited	Altered Expression	[205]
HSP90AA1	TT78R5H	Limited	Altered Expression	[206]
HTR6	TTJS8PY	Limited	Genetic Variation	[207]
HTRA1	TT8POQR	Limited	Genetic Variation	[208]
IGF2R	TTPNE41	Limited	Biomarker	[209]
INS	TTZOPHG	Limited	Biomarker	[210]
ISG15	TTVOH3T	Limited	Altered Expression	[211]
ITGA8	TT1FW8B	Limited	Biomarker	[212]
JUP	TTREN0G	Limited	Genetic Variation	[213]
KCNA5	TTW0CMT	Limited	Biomarker	[202]
KDM6B	TTDIJUQ	Limited	Biomarker	[214]
KLK2	TTJLNAW	Limited	Biomarker	[202]
LONP1	TTM1VPZ	Limited	Biomarker	[215]
LTF	TTSZDQU	Limited	Altered Expression	[216]
MAG	TT9XFON	Limited	Biomarker	[217]
MAPK8IP1	TTXKZ8Q	Limited	Biomarker	[218]
MBP	TT2RY5P	Limited	Genetic Variation	[219]
MCOLN1	TT9XBVO	Limited	Biomarker	[201]
MOG	TTQAFX5	Limited	Biomarker	[219]
MTNR1B	TT32JK8	Limited	Altered Expression	[220]
NACC1	TT4AQ5F	Limited	Biomarker	[221]
NEDD8	TTNDC4K	Limited	Biomarker	[222]
NPPB	TTY63XT	Limited	Altered Expression	[223]
NPTX2	TTNJ5A6	Limited	Altered Expression	[224]
PAH	TTGSVH2	Limited	Biomarker	[225]
PAM	TTF4ZPC	Limited	Genetic Variation	[226]
PAWR	TT3I4WV	Limited	Biomarker	[227]
PDCD2	TTYOVWN	Limited	Biomarker	[228]
PDE1B	TT3ZS42	Limited	Biomarker	[229]
PDE7B	TTWIEY9	Limited	Biomarker	[230]
PDXK	TTXI3KF	Limited	Genetic Variation	[231]
PNMT	TT0NZIC	Limited	Biomarker	[232]
PRDX5	TTLPJWH	Limited	Biomarker	[233]
PROC	TTZUXYS	Limited	Biomarker	[234]
PSMB8	TTEAD9J	Limited	Altered Expression	[235]
REL	TT1ZCTH	Limited	Biomarker	[236]
RGS2	TTKB7T3	Limited	Biomarker	[237]
SCN8A	TT54ERL	Limited	Biomarker	[238]
SCN9A	TT4G2JS	Limited	Genetic Variation	[239]
SLC1A1	TTG2A6F	Limited	Biomarker	[240]
SLC7A1	TT4S150	Limited	Genetic Variation	[194]
SMPD1	TTJTM88	Limited	Genetic Variation	[241]
SPRY1	TT0PSN6	Limited	Biomarker	[242]
ST8SIA4	TTDP8YM	Limited	Genetic Variation	[243]
SUGT1	TT7Q9WR	Limited	Altered Expression	[206]
TF	TT8WXAV	Limited	Genetic Variation	[244]
TMPRSS6	TTL9KE7	Limited	Altered Expression	[220]
TNKS2	TTFQI4H	Limited	Posttranslational Modification	[245]
TPCN2	TTHQJ2Y	Limited	Biomarker	[246]
TPO	TT52XDZ	Limited	Genetic Variation	[247]
TPSD1	TTNWD8O	Limited	Biomarker	[248]
TRPV6	TTBK14N	Limited	Genetic Variation	[194]
UBE3A	TTUZX6V	Limited	Biomarker	[249]
UCHL3	TT23UD6	Limited	Genetic Variation	[250]
USP30	TTQ9EDI	Limited	Biomarker	[251]
USP37	TTJDELN	Limited	Genetic Variation	[243]
YWHAH	TTADIOY	Limited	Biomarker	[252]
CDA	TTQ12RK	Disputed	Genetic Variation	[253]
ESRRG	TT9ZRHB	Disputed	Biomarker	[254]
FGF18	TT6ICRA	Disputed	Biomarker	[255]
GPRC6A	TTI1PRE	Disputed	Altered Expression	[256]
HCN1	TTNB6UQ	Disputed	Altered Expression	[257]
HNRNPA1	TTPJ9XK	Disputed	Genetic Variation	[258]
ITPR1	TT5HWAT	Disputed	Biomarker	[259]
ITPR3	TTH1769	Disputed	Biomarker	[259]
MRGPRX1	TTIX6PK	Disputed	Altered Expression	[256]
NPPC	TTRK0B9	Disputed	Biomarker	[260]
OXER1	TT7WBSV	Disputed	Altered Expression	[256]
PDPK1	TTYMGWX	Disputed	Biomarker	[261]
SMPD2	TTE5VI6	Disputed	Biomarker	[262]
AIF1	TT12MEP	moderate	Altered Expression	[263]
BCHE	TT3MSAO	moderate	Biomarker	[264]
FCER2	TTCH6MU	moderate	Biomarker	[265]
GFAP	TTI6FFX	moderate	Altered Expression	[266]
GPNMB	TT7315J	moderate	Genetic Variation	[187]
GPX1	TTYAHBP	moderate	Altered Expression	[267]
HGF	TT4V2JM	moderate	Therapeutic	[268]
IL6	TTT1V78	moderate	Altered Expression	[269]
KCNJ4	TTXF0ZW	moderate	Therapeutic	[270]
MTA1	TTO4HUS	moderate	Biomarker	[271]
MTHFR	TTQWOU1	moderate	Altered Expression	[272]
NQO1	TT8XK6L	moderate	Biomarker	[273]
SOD2	TT9O4C5	moderate	Genetic Variation	[274]
STK39	TTYQTIU	moderate	Biomarker	[275]
ABL1	TT6B75U	Strong	Altered Expression	[276]
ACHE	TT1RS9F	Strong	Altered Expression	[277]
ACTG1	TTGAZF9	Strong	Biomarker	[278]
ADCY5	TTN64VU	Strong	Biomarker	[279]
ADCYAP1	TTW4LYC	Strong	Altered Expression	[280]
ADCYAP1R1	TT5OREU	Strong	Biomarker	[281]
ADH7	TT3LE7P	Strong	Genetic Variation	[282]
ADORA2A	TTM2AOE	Strong	Biomarker	[283]
ADRB2	TTG8ZWP	Strong	Biomarker	[284]
AGER	TTMO9HF	Strong	Biomarker	[285]
AGTR1	TT8DBY3	Strong	Biomarker	[286]
AIMP2	TTXWHGF	Strong	Biomarker	[287]
AKR1B1	TTFBNVI	Strong	Biomarker	[288]
ALDH2	TTFLN4T	Strong	Altered Expression	[289]
APEX1	TTHGL48	Strong	Biomarker	[290]
APLNR	TTJ8E43	Strong	Biomarker	[291]
APOA1	TT5S8DR	Strong	Altered Expression	[292]
APOB	TTN1IE2	Strong	Biomarker	[293]
APP	TTE4KHA	Strong	Genetic Variation	[294]
AQP9	TTQEI32	Strong	Biomarker	[295]
ARRB1	TTMVD4A	Strong	Biomarker	[281]
ARSA	TTYQANR	Strong	Biomarker	[296]
ATF4	TTQCKWT	Strong	Biomarker	[297]
ATG7	TTLVB9Z	Strong	Altered Expression	[298]
BACE1	TTJUNZF	Strong	Genetic Variation	[186]
BMX	TTN2I9E	Strong	Altered Expression	[299]
CA12	TTSYM0R	Strong	Genetic Variation	[300]
CACNA1A	TTX4QDJ	Strong	Biomarker	[301]
CALCA	TTVSFJW	Strong	Biomarker	[302]
CASP1	TTCQIBE	Strong	Biomarker	[303]
CASP9	TTB6T7O	Strong	Altered Expression	[304]
CBS	TTVZJ7G	Strong	Biomarker	[305]
CCK	TT90CMU	Strong	Genetic Variation	[306]
CCKAR	TTCG0AL	Strong	Genetic Variation	[307]
CCN2	TTIL516	Strong	Biomarker	[308]
CD19	TTW640A	Strong	Biomarker	[309]
CD200	TT0BE68	Strong	Altered Expression	[310]
CD38	TTPURFN	Strong	Biomarker	[309]
CD55	TT5Z9WY	Strong	Biomarker	[210]
CD69	TTPQE9F	Strong	Biomarker	[309]
CDK5	TTL4Q97	Strong	Altered Expression	[311]
CDK5R1	TTBYM6V	Strong	Biomarker	[312]
CEACAM6	TTIGH2W	Strong	Biomarker	[265]
CEBPB	TTUI35N	Strong	Biomarker	[313]
CFP	TTLA0VS	Strong	Genetic Variation	[314]
CHAT	TTKYFSB	Strong	Biomarker	[315]
CHIT1	TTDYX6T	Strong	Altered Expression	[316]
CHRM3	TTQ13Z5	Strong	Biomarker	[317]
CHRNA4	TT4H1MQ	Strong	Biomarker	[318]
CHRNA5	TTH2QRX	Strong	Genetic Variation	[319]
CIT	TT3BKTU	Strong	Biomarker	[320]
CLK1	TTE6YDG	Strong	Biomarker	[321]
CNR2	TTMSFAW	Strong	Biomarker	[322]
CNTN1	TTPR8FK	Strong	Genetic Variation	[323]
COASY	TT4YO0Z	Strong	Biomarker	[324]
COPS5	TTSTNJR	Strong	Biomarker	[325]
CREB1	TTH4AN3	Strong	Biomarker	[326]
CRHR1	TT7EFHR	Strong	Genetic Variation	[323]
CRK	TTFEUYR	Strong	Biomarker	[287]
CRP	TTWRN6M	Strong	Altered Expression	[327]
CRY1	TT5MLZR	Strong	Genetic Variation	[328]
CRYZ	TTP6UO8	Strong	Biomarker	[273]
CTNS	TT1W2ZS	Strong	Biomarker	[210]
CTSB	TTF2LRI	Strong	Biomarker	[329]
CTSC	TT4H0V2	Strong	Biomarker	[330]
CTSL	TT36ETB	Strong	Altered Expression	[331]
CX3CL1	TT1OFBQ	Strong	Biomarker	[332]
CX3CR1	TT2T98G	Strong	Biomarker	[332]
CYBB	TT5T8MR	Strong	Biomarker	[333]
CYP17A1	TTRA5BZ	Strong	Genetic Variation	[334]
CYP2B6	TTMH124	Strong	Altered Expression	[335]
CYP2C9	TTR40YJ	Strong	Biomarker	[336]
CYP3A4	TTWP7HQ	Strong	Biomarker	[337]
CYP3A5	TTHS0OK	Strong	Biomarker	[336]
DDC	TTN451K	Strong	Biomarker	[338]
DDIT4	TTVEOY6	Strong	Altered Expression	[339]
DNAJB1	TTPXAWS	Strong	Altered Expression	[340]
DPEP1	TTYUENF	Strong	Biomarker	[341]
DPYSL2	TTZCW3T	Strong	Posttranslational Modification	[342]
DRD1	TTZFYLI	Strong	Biomarker	[343]
DYRK1A	TTSBVFO	Strong	Biomarker	[344]
EDN1	TTJR60Z	Strong	Biomarker	[345]
EGLN1	TT9ISBX	Strong	Biomarker	[312]
EHMT1	TTOFXD7	Strong	Biomarker	[346]
ELK3	TT5OJMV	Strong	Biomarker	[347]
EPHB1	TT8MDAC	Strong	Biomarker	[347]
ERN1	TTKIAT3	Strong	Biomarker	[298]
F9	TTFEZ5Q	Strong	Genetic Variation	[348]
FABP3	TT3TGLR	Strong	Biomarker	[349]
FAF1	TTSKL3G	Strong	Biomarker	[350]
FASLG	TTO7014	Strong	Biomarker	[351]
FDXR	TT3W4IX	Strong	Biomarker	[352]
FGF8	TTIUF3J	Strong	Altered Expression	[353]
FKBP10	TT4P8O2	Strong	Biomarker	[354]
FKBP1A	TTMW94E	Strong	Biomarker	[354]
FKBP4	TTHY0FT	Strong	Biomarker	[354]
FKBP5	TT0J5KQ	Strong	Biomarker	[354]
FKBP7	TTO1ENI	Strong	Biomarker	[354]
FOSL2	TT689IR	Strong	Altered Expression	[355]
FPR2	TTOJ1NF	Strong	Biomarker	[210]
FTH1	TT975ZT	Strong	Biomarker	[356]
FYN	TT2B9KF	Strong	Biomarker	[357]
G3BP1	TTG0R8Z	Strong	Biomarker	[358]
GAD1	TTKGEP3	Strong	Biomarker	[359]
GAD2	TT7UY6K	Strong	Biomarker	[360]
GALC	TT5IZRB	Strong	Altered Expression	[361]
GAP43	TTSGLN5	Strong	Biomarker	[362]
GAPDH	TTUGSWA	Strong	Biomarker	[363]
GCG	TT6Y4PN	Strong	Biomarker	[364]
GCH1	TTLSWP6	Strong	Biomarker	[365]
GDF15	TT4MXVG	Strong	Biomarker	[366]
GDF5	TT37XV9	Strong	Biomarker	[367]
GIP	TT40HS5	Strong	Biomarker	[368]
GJC2	TTPOCAL	Strong	Therapeutic	[369]
GLA	TTIS03D	Strong	Biomarker	[370]
GLP1R	TTVIMDE	Strong	Biomarker	[364]
GLRX	TTRJCNG	Strong	Biomarker	[371]
GLUL	TTURQ2G	Strong	Biomarker	[372]
GPER1	TTDSB34	Strong	Biomarker	[373]
GPR139	TTOL9B0	Strong	Biomarker	[374]
GPR17	TTMPART	Strong	Biomarker	[375]
GPR3	TTHZVSK	Strong	Biomarker	[376]
GPR55	TTNET8J	Strong	Biomarker	[377]
GPR6	TTSDWS5	Strong	Biomarker	[376]
GPR88	TTMRQY1	Strong	Biomarker	[378]
GRIA2	TTWM461	Strong	Biomarker	[363]
GRIK3	TTNP6O2	Strong	Biomarker	[379]
GRIN2A	TTKJEMQ	Strong	Biomarker	[380]
GRIN2B	TTN9D8E	Strong	Biomarker	[381]
GRIN2D	TT5POTG	Strong	Biomarker	[382]
GRK2	TTAZ3MN	Strong	Biomarker	[383]
GRK3	TT5A4DX	Strong	Biomarker	[383]
GRK5	TTTCXO0	Strong	Genetic Variation	[384]
GRM2	TTXJ47W	Strong	Biomarker	[385]
GRM4	TTICZ1O	Strong	Biomarker	[386]
GRM5	TTHS256	Strong	Biomarker	[387]
GSK3B	TTRSMW9	Strong	Biomarker	[388]
HCAR2	TTWNV8U	Strong	Biomarker	[389]
HCN2	TT9EUT4	Strong	Biomarker	[390]
HCRT	TTU5HJP	Strong	Biomarker	[391]
HDAC4	TTTQGH8	Strong	Biomarker	[392]
HDAC6	TT5ZKDI	Strong	Genetic Variation	[393]
HLA-DRB1	TTUXSTW	Strong	Genetic Variation	[394]
HMOX2	TTWZRL4	Strong	Genetic Variation	[395]
HRH3	TT9JNIC	Strong	Biomarker	[396]
HSF1	TTN6STZ	Strong	Biomarker	[397]
HSPA5	TTW26OG	Strong	Biomarker	[297]
HSPD1	TT9HL5R	Strong	Biomarker	[398]
HTR1A	TTSQIFT	Strong	Biomarker	[399]
HTR1B	TTK8CXU	Strong	Altered Expression	[400]
HTR2A	TTJQOD7	Strong	Altered Expression	[401]
HTT	TTIWZ0O	Strong	Biomarker	[402]
IAPP	TTHN8EM	Strong	Biomarker	[403]
IDE	TT2EDHU	Strong	Biomarker	[404]
IGF1R	TTQFBMY	Strong	Biomarker	[405]
IGF2	TTE8WGO	Strong	Biomarker	[406]
IL13RA1	TTNEAMG	Strong	Biomarker	[407]
IL2RB	TT9721Y	Strong	Biomarker	[408]
INSR	TTCBFJO	Strong	Biomarker	[345]
KCNJ6	TTTIBVP	Strong	Biomarker	[409]
KEAP1	TT3Z6Y9	Strong	Biomarker	[410]
KHDRBS1	TTAT6C7	Strong	Biomarker	[411]
KLK6	TTLPF4X	Strong	Biomarker	[188]
KLK7	TTE6GTB	Strong	Biomarker	[412]
LAG3	TTNVXAW	Strong	Biomarker	[413]
LAMP1	TTC214J	Strong	Biomarker	[398]
LBP	TTVQJLY	Strong	Biomarker	[414]
LEP	TTBJEZ5	Strong	Biomarker	[415]
LIFR	TTID542	Strong	Biomarker	[416]
LILRB1	TTC0QRJ	Strong	Biomarker	[417]
LIN28A	TTO50LN	Strong	Biomarker	[418]
MANF	TT56RYE	Strong	Biomarker	[419]
MAP2K2	TT8H9GB	Strong	Biomarker	[420]
MAP3K11	TTETX6Q	Strong	Biomarker	[421]
MAP3K3	TTJZNIG	Strong	Altered Expression	[422]
MAP4K4	TT6NI13	Strong	Genetic Variation	[226]
MAPK10	TT056SO	Strong	Altered Expression	[423]
MAPK14	TTQBR95	Strong	Biomarker	[287]
MAPK8	TT0K6EO	Strong	Genetic Variation	[424]
MARK2	TTAJ45Y	Strong	Genetic Variation	[425]
MAS1	TTOISYB	Strong	Altered Expression	[426]
MFGE8	TT1GLAJ	Strong	Biomarker	[427]
MGAM	TTXWASR	Strong	Biomarker	[428]
MGLL	TTZ963I	Strong	Altered Expression	[429]
MPO	TTVCZPI	Strong	Biomarker	[430]
MSMB	TTYH1ZK	Strong	Genetic Variation	[431]
MTR	TTUTO39	Strong	Genetic Variation	[432]
NAGLU	TTDM6HZ	Strong	Biomarker	[433]
NCL	TTK1V5Q	Strong	Biomarker	[434]
NDUFAF2	TTCHGVF	Strong	Genetic Variation	[226]
NEDD4	TT1QU6G	Strong	Altered Expression	[435]
NEDD9	TT1UREA	Strong	Biomarker	[436]
NES	TTHZ752	Strong	Biomarker	[437]
NGF	TTDN3LF	Strong	Biomarker	[438]
NGFR	TTEDJN4	Strong	Genetic Variation	[408]
NLRP1	TTQX29T	Strong	Biomarker	[404]
NLRP3	TT4EN8X	Strong	Biomarker	[439]
NOTCH4	TTXDIK2	Strong	Biomarker	[440]
NPEPPS	TT371QC	Strong	Biomarker	[441]
NQO2	TTJLP0R	Strong	Altered Expression	[442]
NR4A1	TTMXE2Q	Strong	Biomarker	[443]
NT5E	TTK0O6Y	Strong	Biomarker	[283]
NTF3	TTZHKV9	Strong	Biomarker	[444]
NTF4	TTIM2WO	Strong	Biomarker	[445]
OGDH	TTH8T6I	Strong	Altered Expression	[446]
OPRL1	TTNT7K8	Strong	Altered Expression	[447]
OSMR	TTAH0KM	Strong	Biomarker	[448]
P2RX1	TTJW7B3	Strong	Altered Expression	[449]
P2RX3	TT2THBD	Strong	Altered Expression	[449]
P2RX4	TT1NLOA	Strong	Altered Expression	[449]
P2RY1	TTA93TL	Strong	Altered Expression	[449]
P2RY2	TTOZHQC	Strong	Altered Expression	[449]
P2RY6	TTNVSKA	Strong	Biomarker	[450]
PDE10A	TTJW4LU	Strong	Altered Expression	[451]
PDE4A	TTZ97H5	Strong	Biomarker	[452]
PDE7A	TT1BC3A	Strong	Altered Expression	[453]
PEBP1	TT1BGU8	Strong	Biomarker	[454]
PIK3CB	TT9H4P3	Strong	Biomarker	[455]
PIN1	TTJNTSI	Strong	Altered Expression	[456]
PLA2G1B	TT9V5JH	Strong	Biomarker	[457]
PLD1	TT3T17P	Strong	Altered Expression	[458]
PLD2	TTRLMKF	Strong	Altered Expression	[459]
PLK2	TT976FS	Strong	Genetic Variation	[460]
POLB	TTA0XPV	Strong	Biomarker	[461]
PPARD	TT2JWF6	Strong	Biomarker	[462]
PPID	TTNAFOU	Strong	Biomarker	[463]
PPIF	TTRFQTB	Strong	Biomarker	[463]
PREP	TTNGKET	Strong	Biomarker	[464]
PRKACA	TT5U49F	Strong	Biomarker	[465]
PRKCG	TTRFOXJ	Strong	Biomarker	[466]
PRKD1	TTSLUMT	Strong	Biomarker	[467]
PRNP	TTY5F9C	Strong	Biomarker	[468]
PROKR2	TTM67AX	Strong	Biomarker	[469]
PSEN1	TTZ3S8C	Strong	Genetic Variation	[186]
PSEN2	TTWN3F4	Strong	Genetic Variation	[186]
PSIP1	TTH9LDP	Strong	Biomarker	[408]
PTBP1	TTWMX0U	Strong	Biomarker	[470]
PTGER2	TT1ZAVI	Strong	Biomarker	[471]
PTGES	TTYLQ8V	Strong	Biomarker	[472]
PTK2B	TTTEFBV	Strong	Biomarker	[455]
PTN	TTA9EJK	Strong	Altered Expression	[473]
PTPRC	TTUS45N	Strong	Altered Expression	[474]
RAB7A	TTF6WAQ	Strong	Biomarker	[475]
RENBP	TTZCG0Q	Strong	Biomarker	[476]
RET	TT4DXQT	Strong	Biomarker	[477]
RGS4	TTGTKX9	Strong	Biomarker	[478]
RIPK1	TTVJHX8	Strong	Altered Expression	[479]
ROCK2	TTGWKQJ	Strong	Biomarker	[480]
ROS1	TTSZ6Y3	Strong	Biomarker	[481]
RPH3A	TT9L4J8	Strong	Biomarker	[482]
RTN4R	TTVRZUO	Strong	Biomarker	[483]
SCD	TT6RIOV	Strong	Biomarker	[484]
SCG3	TTY5R9H	Strong	Biomarker	[485]
SCN2A	TTLJTUF	Strong	Genetic Variation	[226]
SGCA	TTS9Q5V	Strong	Biomarker	[486]
SIGMAR1	TT5TPI6	Strong	Biomarker	[487]
SIRPA	TTBRJS9	Strong	Altered Expression	[488]
SIRT2	TTLKF5M	Strong	Biomarker	[489]
SIRT3	TTVZLIJ	Strong	Altered Expression	[490]
SIRT5	TTH0IOD	Strong	Altered Expression	[491]
SLC11A2	TT2IS7P	Strong	Biomarker	[492]
SLC16A1	TTN1J82	Strong	Genetic Variation	[493]
SLC18A3	TTV8KWS	Strong	Biomarker	[494]
SLC22A1	TTM5Q4V	Strong	Genetic Variation	[495]
SLC2A4	TTP6MT5	Strong	Genetic Variation	[496]
SLC52A2	TT6TKEN	Strong	Genetic Variation	[425]
SLC6A2	TTAWNKZ	Strong	Biomarker	[497]
SLC7A11	TTBZMIO	Strong	Genetic Variation	[498]
SLC8A1	TTCF82X	Strong	Biomarker	[499]
SLC8B1	TTJN46R	Strong	Biomarker	[500]
SMN1	TT8QL6X	Strong	Altered Expression	[501]
SNAP25	TTYQWA0	Strong	Biomarker	[502]
SP1	TTZEP6S	Strong	Altered Expression	[503]
SPTBN1	TTS9BDA	Strong	Biomarker	[504]
SQSTM1	TTOT2RY	Strong	Biomarker	[411]
SYVN1	TT8XKYM	Strong	Biomarker	[505]
TCF3	TTULOD8	Strong	Biomarker	[408]
TLN1	TTQSMFG	Strong	Biomarker	[506]
TNFRSF14	TTWGTC1	Strong	Genetic Variation	[507]
TNFRSF4	TTL31H0	Strong	Altered Expression	[508]
TNIK	TTPB1W3	Strong	Biomarker	[509]
TOR1A	TTF85KW	Strong	Genetic Variation	[510]
TPH2	TT3KLDP	Strong	Altered Expression	[400]
TPT1	TT3PTB6	Strong	Biomarker	[312]
TREM1	TTHZQP0	Strong	Biomarker	[511]
TRH	TT2Z39D	Strong	Biomarker	[512]
TRIM27	TTTO3QN	Strong	Biomarker	[210]
TRPC1	TTA76X0	Strong	Biomarker	[513]
TRPM2	TTEBMN7	Strong	Biomarker	[514]
TRPM7	TTFPVZO	Strong	Biomarker	[515]
TRPV1	TTMI6F5	Strong	Altered Expression	[516]
TST	TT51OTS	Strong	Biomarker	[517]
TXNIP	TTTLDZK	Strong	Biomarker	[518]
TXNRD1	TTR7UJ3	Strong	Biomarker	[519]
TXNRD3	TTDYFVB	Strong	Genetic Variation	[520]
TYR	TTULVH8	Strong	Altered Expression	[521]
UBC	TTBP3XA	Strong	Biomarker	[522]
UCP2	TTSC2YM	Strong	Altered Expression	[523]
ULK1	TT4D7MJ	Strong	Biomarker	[524]
USP1	TTG9MT5	Strong	Biomarker	[525]
USP10	TT5IH09	Strong	Biomarker	[358]
USP13	TTVJIO2	Strong	Altered Expression	[526]
UTRN	TTNO1VA	Strong	Biomarker	[343]
VCP	TTHNLSB	Strong	Genetic Variation	[527]
VDAC1	TTAMKGB	Strong	Biomarker	[528]
VIPR2	TT4O5P0	Strong	Altered Expression	[529]
YOD1	TTFSH0K	Strong	Altered Expression	[530]
ZUP1	TTZC0KV	Strong	Biomarker	[531]
CASP7	TTM7Y45	Definitive	Biomarker	[532]
CCR3	TTD3XFU	Definitive	Biomarker	[533]
CEL	TTTRNQW	Definitive	Genetic Variation	[534]
CLN3	TTORF9W	Definitive	Biomarker	[535]
CNGA1	TTHIQMC	Definitive	Biomarker	[536]
CNTF	TTGEM5Q	Definitive	Biomarker	[537]
CNTN2	TT2Z1WB	Definitive	Biomarker	[538]
CSNK1D	TTH30UI	Definitive	Biomarker	[539]
DMPK	TTZQTY2	Definitive	Biomarker	[540]
DPP7	TTOYT5L	Definitive	Biomarker	[541]
EEF2K	TT1QFLA	Definitive	Biomarker	[542]
ELAVL1	TTPC9D0	Definitive	Altered Expression	[543]
FCGR2B	TT5RWKQ	Definitive	Biomarker	[544]
FFAR1	TTB8FUC	Definitive	Biomarker	[545]
FGG	TTR31L7	Definitive	Biomarker	[292]
FST	TTDNM9W	Definitive	Genetic Variation	[546]
GAK	TT0AGBL	Definitive	Biomarker	[547]
GALNS	TTT9YPO	Definitive	Genetic Variation	[548]
GBA1	TTCYHJ4	Definitive	Autosomal dominant	[179]
GJB6	TTAU8SJ	Definitive	Biomarker	[549]
GNAQ	TTL1SRG	Definitive	Biomarker	[416]
GRIN2C	TT1M8OW	Definitive	Biomarker	[550]
GRM8	TT0IFKL	Definitive	Biomarker	[551]
HCRTR1	TT60Q8D	Definitive	Biomarker	[552]
HIPK2	TTOB49C	Definitive	Biomarker	[553]
IFNAR1	TTSYFMA	Definitive	Biomarker	[554]
KCNMA1	TTE87WJ	Definitive	Genetic Variation	[555]
LGMN	TTPTWV5	Definitive	Biomarker	[556]
LGR5	TTTSGRH	Definitive	Biomarker	[557]
LRP6	TTSXOWE	Definitive	Biomarker	[558]
LRRK2	TTK0FEA	Definitive	Autosomal dominant	[179]
MCHR1	TTX4RTB	Definitive	Biomarker	[559]
MMP8	TTGA1IV	Definitive	Genetic Variation	[560]
NEK1	TTO5QT2	Definitive	Genetic Variation	[561]
NFKB2	TTKLNRV	Definitive	Biomarker	[562]
NUCB1	TT6A5ZL	Definitive	Genetic Variation	[563]
PNPLA6	TTWAQU2	Definitive	Biomarker	[416]
PPY	TTIB95A	Definitive	Biomarker	[564]
PTGDR2	TTQDMX5	Definitive	Biomarker	[565]
PTGER4	TT79WV3	Definitive	Biomarker	[566]
REG3A	TTL4H8N	Definitive	Biomarker	[567]
RGMA	TTURJV4	Definitive	Biomarker	[568]
SLC1A6	TT6KMPN	Definitive	Altered Expression	[569]
SLC33A1	TTL69WB	Definitive	Biomarker	[570]
SLC40A1	TT6Y1PG	Definitive	Altered Expression	[571]
SLC6A11	TT8RXO5	Definitive	Altered Expression	[572]
SNCA	TT08OSU	Definitive	Autosomal dominant	[179]
SPN	TTOZAX0	Definitive	Biomarker	[573]
TBK1	TTMP03S	Definitive	Posttranslational Modification	[574]
TKT	TT04R7I	Definitive	Biomarker	[575]
TMBIM6	TT7QSMG	Definitive	Biomarker	[576]
TUSC2	TTJ8O14	Definitive	Biomarker	[567]
UCP1	TTI12YJ	Definitive	Altered Expression	[577]
UTS2R	TTW5UDX	Definitive	Genetic Variation	[578]
VIPR1	TTCL30I	Definitive	Altered Expression	[579]
WAS	TTE8T73	Definitive	Biomarker	[580]

This Disease Is Related to 23 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCA5	DT195NK	Limited	Altered Expression	[581]
SLC16A7	DTLT3UG	Limited	Biomarker	[193]
SLC20A2	DTFD4VB	Limited	Genetic Variation	[582]
SLC25A28	DT4NW1F	Limited	Biomarker	[583]
SLC41A1	DTB37ZE	Limited	Genetic Variation	[584]
SLC11A1	DT650XW	Disputed	Biomarker	[585]
ABCA7	DTDVSJA	moderate	Genetic Variation	[586]
ATP7A	DT0LT17	Strong	Genetic Variation	[587]
SLC17A6	DT5LHCR	Strong	Biomarker	[588]
SLC22A5	DT3HUVD	Strong	Genetic Variation	[589]
SLC25A27	DT0HW5C	Strong	Altered Expression	[590]
SLC2A13	DT0NSKB	Strong	Genetic Variation	[591]
SLC2A14	DT18YD9	Strong	Biomarker	[265]
SLC2A6	DTS4MKQ	Strong	Biomarker	[592]
SLC30A10	DTYBI73	Strong	Biomarker	[593]
SLC39A2	DTL8VXO	Strong	Biomarker	[594]
SLC39A8	DTLPQGT	Strong	Genetic Variation	[595]
SLC45A3	DTGEFXH	Strong	Genetic Variation	[596]
SLC50A1	DTI9CQU	Strong	Genetic Variation	[597]
SLC14A2	DT8QC7K	Definitive	Genetic Variation	[578]
SLC25A3	DTCRIWV	Definitive	Biomarker	[598]
SLC6A13	DTX8KP0	Definitive	Altered Expression	[572]
SLC8A3	DTYFRQT	Definitive	Genetic Variation	[599]

This Disease Is Related to 34 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HK1	DEDMAGE	Limited	Biomarker	[202]
HSD17B10	DEGSPC9	Limited	Biomarker	[600]
HSD17B7	DEDMWFX	Limited	Altered Expression	[205]
LPO	DEHX1DZ	Limited	Biomarker	[601]
MAT2B	DEKF1OH	Limited	Genetic Variation	[520]
MT2A	DEFKGT7	Limited	Altered Expression	[220]
PER1	DE9HF0I	Limited	Genetic Variation	[602]
SAT1	DEMWO83	Limited	Altered Expression	[603]
THOP1	DE95LJC	Limited	Biomarker	[604]
MTRR	DE6NIY9	moderate	Genetic Variation	[605]
NNMT	DECVGJ3	moderate	Biomarker	[606]
SPR	DEJVDAT	moderate	Genetic Variation	[607]
ACP3	DEDW5H6	Strong	Biomarker	[608]
ADH1C	DEM1HNL	Strong	Genetic Variation	[282]
ADH4	DEOCWU3	Strong	Genetic Variation	[609]
ALDH1A1	DE2JP1Y	Strong	Altered Expression	[610]
CRMP1	DE0EUXB	Strong	Biomarker	[343]
CYP4F3	DEFCMPI	Strong	Genetic Variation	[611]
FAAH	DEUM1EX	Strong	Biomarker	[612]
FXN	DEXVHDB	Strong	Biomarker	[613]
GNPDA2	DEPJGQB	Strong	Altered Expression	[614]
GPX6	DEOS3FD	Strong	Biomarker	[615]
GSTA4	DEH7XYP	Strong	Biomarker	[616]
MSRA	DEU2ZBY	Strong	Biomarker	[617]
NAT2	DER7TA0	Strong	Genetic Variation	[618]
NDUFS3	DE741FI	Strong	Biomarker	[619]
PON2	DEHJU7E	Strong	Altered Expression	[620]
SCLY	DEH4TD6	Strong	Genetic Variation	[621]
SI	DE5EO4Y	Strong	Biomarker	[428]
UGT1A9	DE85D2P	Strong	Genetic Variation	[622]
CHDH	DEAHED0	Definitive	Biomarker	[623]
MT1A	DE5ME8A	Definitive	Biomarker	[624]
NDUFS7	DEIW03B	Definitive	Genetic Variation	[625]
PARK7	DEPOVCH	Definitive	Autosomal recessive	[179]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 33).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7601).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 35).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5159).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6636).
• [8] Drug information of Cycrimine, 2008. eduDrugs.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7050).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6647).
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7181).
• [13] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 43).
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7232).
• [18] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4487).
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7251).
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 48).
• [23] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 953).
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7280).
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6641).
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7295).
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [29] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6646).
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7315).
• [32] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [33] ClinicalTrials.gov (NCT01723904) A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease. U.S. National Institutes of Health.
• [34] ClinicalTrials.gov (NCT00776191) Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism. U.S. National Institutes of Health.
• [35] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011712)
• [36] List of drugs in development for neurodegenerative diseases. Neurodegener Dis. 2004;1(1):50-70.
• [37] ClinicalTrials.gov (NCT04750226) Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease. U.S. National Institutes of Health.
• [38] CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. Clin Neuropharmacol. 1990 Aug;13(4):303-11.
• [39] ClinicalTrials.gov (NCT03594656) Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. U.S.National Institutes of Health.
• [40] ClinicalTrials.gov (NCT00511147) IGIV Study for Chronic ITP Patients Ages 3-70. U.S. National Institutes of Health.
• [41] ClinicalTrials.gov (NCT01970111) An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD). U.S. National Institutes of Health.
• [42] ClinicalTrials.gov (NCT05083260) A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107. U.S.National Institutes of Health.
• [43] Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit. Med Sci Monit. 2002 Apr;8(4):BR105-12.
• [44] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041414)
• [45] Clinical pipeline report, company report or official report of Osmotica Pharmaceutical Corp.
• [46] Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80.
• [47] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6978).
• [48] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3949).
• [49] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5611).
• [50] ClinicalTrials.gov (NCT04857359) Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy. U.S. National Institutes of Health.
• [51] ClinicalTrials.gov (NCT04831281) A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies. U.S.National Institutes of Health.
• [52] ClinicalTrials.gov (NCT00784537) High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients. U.S. National Institutes of Health.
• [53] Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
• [54] ClinicalTrials.gov (NCT00643890) Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease. U.S.National Institutes of Health.
• [55] ClinicalTrials.gov (NCT04369430) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment. U.S.National Institutes of Health.
• [56] Clinical pipeline report, company report or official report of Genzyme.
• [57] ClinicalTrials.gov (NCT02388295) AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients. U.S. National Institutes of Health.
• [58] Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18.
• [59] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5612).
• [60] ClinicalTrials.gov (NCT02231580) Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients. U.S. National Institutes of Health.
• [61] Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000 Dec;1(4):504-7.
• [62] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5032).
• [63] ClinicalTrials.gov (NCT00073476) A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke. U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT04191577) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations. U.S.National Institutes of Health.
• [65] Effects of the alpha 2-adrenoreceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death. Neuroscience. 2003;117(2):281-91.
• [66] ClinicalTrials.gov (NCT04764669) A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology. U.S. National Institutes of Health.
• [67] Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58.
• [68] ClinicalTrials.gov (NCT04483479) A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period. U.S.National Institutes of Health.
• [69] ClinicalTrials.gov (NCT01850381) Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease. U.S. National Institutes of Health.
• [70] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [71] ClinicalTrials.gov (NCT02432066) Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT02271503) A Study to Assess the PK and Pharmacodynamics (PD) of IPX203 in Patients With Advanced Parkinsons Disease. U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT04377945) A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components. U.S.National Institutes of Health.
• [74] ClinicalTrials.gov (NCT04867551) A Phase II Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease. U.S.National Institutes of Health.
• [75] ClinicalTrials.gov (NCT04435431) A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease. U.S.National Institutes of Health.
• [76] ClinicalTrials.gov (NCT00226460) Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.. U.S. National Institutes of Health.
• [77] ClinicalTrials.gov (NCT04154072) Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease. U.S.National Institutes of Health.
• [78] ClinicalTrials.gov (NCT04148391) A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia. U.S.National Institutes of Health.
• [79] ClinicalTrials.gov (NCT00285025) Study of the Effect of SR57667B in Patients With Alzheimer's Disease. U.S. National Institutes of Health.
• [80] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [81] ClinicalTrials.gov (NCT03100149) A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA). U.S. National Institutes of Health.
• [82] ClinicalTrials.gov (NCT04269642) Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease. U.S.National Institutes of Health.
• [83] PTX-200 Phase 1b/2 clinical trial update. Prescient Therapeutics. 26 August 2015.
• [84] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [85] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [86] ClinicalTrials.gov (NCT04476017) A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI). U.S. National Institutes of Health.
• [87] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5614).
• [88] ClinicalTrials.gov (NCT00206687) STEPS Trial - Spheramine Safety and Efficacy Study. U.S. National Institutes of Health.
• [89] ClinicalTrials.gov (NCT00041795) Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT02258152) SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (SYNAPSE). U.S. National Institutes of Health.
• [91] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8279).
• [92] ClinicalTrials.gov (NCT04491383) Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial. U.S.National Institutes of Health.
• [93] ClinicalTrials.gov (NCT05056194) A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of XW10172 MR for the Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease. U.S.National Institutes of Health.
• [94] ClinicalTrials.gov (NCT03562494) VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1). U.S. National Institutes of Health.
• [95] ClinicalTrials.gov (NCT04220762) A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study. U.S.National Institutes of Health.
• [96] The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action. Pain. 2011 Dec;152(12):2852-60.
• [97] ClinicalTrials.gov (NCT01171313) A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet in Parkinson's Disease Subjects. U.S. National Institutes of Health.
• [98] The Future of Gene Therapy. Biotechnol Healthc. 2005 June; 2(3): 52-54, 56-60.
• [99] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8256).
• [100] ClinicalTrials.gov (NCT04858074) A Proof of Concept (POC) Study to Investigate the Effect of 100% Hypoestes Rosea Powder in Parkinson's Disease Using ActiGraph Wearable as a Quantitative Assessment Tool.. U.S.National Institutes of Health.
• [101] Clinical pipeline report, company report or official report of International Stem Cell.
• [102] ClinicalTrials.gov (NCT03257046) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease. U.S. National Institutes of Health.
• [103] ClinicalTrials.gov (NCT00607451) Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia. U.S. National Institutes of Health.
• [104] ClinicalTrials.gov (NCT03720418) Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD). U.S. National Institutes of Health.
• [105] ClinicalTrials.gov (NCT04127578) A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL). U.S.National Institutes of Health.
• [106] ClinicalTrials.gov (NCT01856439) Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease. U.S. National Institutes of Health.
• [107] ClinicalTrials.gov (NCT02253745) Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
• [108] ClinicalTrials.gov (NCT00229736) A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease. U.S. National Institutes of Health.
• [109] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038467)
• [110] ClinicalTrials.gov (NCT05152394) Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Parkinson's Disease. U.S.National Institutes of Health.
• [111] ClinicalTrials.gov (NCT04685265) A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease. U.S.National Institutes of Health.
• [112] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 296).
• [113] ClinicalTrials.gov (NCT01803945) A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease. U.S. National Institutes of Health.
• [114] Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J Pharmacol Sci.2003 Sep;93(1):95-105.
• [115] ClinicalTrials.gov (NCT03976349) A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease. U.S.National Institutes of Health.
• [116] ClinicalTrials.gov (NCT04165837) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects. U.S.National Institutes of Health.
• [117] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [118] ClinicalTrials.gov (NCT04350177) A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients. U.S.National Institutes of Health.
• [119] ClinicalTrials.gov (NCT04165486) A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy. U.S.National Institutes of Health.
• [120] Clinical pipeline report, company report or official report of JOHNSON & JOHNSON
• [121] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005980)
• [122] ClinicalTrials.gov (NCT03022799) Phase I, KM-819 in Healthy Subjects for Parkinson's Disease. U.S. National Institutes of Health.
• [123] ClinicalTrials.gov (NCT04291859) Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease. U.S.National Institutes of Health.
• [124] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031195)
• [125] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031909)
• [126] ClinicalTrials.gov (NCT04593511) An Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 After a Single Intramuscular Injection. U.S.National Institutes of Health.
• [127] ClinicalTrials.gov (NCT04802733) Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy (MSK-DA01) For Advanced Parkinson's Disease. U.S.National Institutes of Health.
• [128] Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinson's Blood Test Joint Venture
• [129] ClinicalTrials.gov (NCT02780895) Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease. U.S.National Institutes of Health.
• [130] ClinicalTrials.gov (NCT02216188) Follow-up Study to Assess One Boost Immunization With AFFITOPE PD01A With Regard to Safety and Clinical Activity (AFF008A). U.S. National Institutes of Health.
• [131] ClinicalTrials.gov (NCT01981694) A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751. U.S. National Institutes of Health.
• [132] CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes. J Pharm Pharm Sci. 2007;10(4):473-85.
• [133] ClinicalTrials.gov (NCT03671785) A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease. U.S.National Institutes of Health.
• [134] Clinical pipeline report, company report or official report of Sanofi
• [135] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029757)
• [136] ClinicalTrials.gov (NCT04976127) Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients. U.S.National Institutes of Health.
• [137] ClinicalTrials.gov (NCT04075318) A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh? PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease. U.S.National Institutes of Health.
• [138] ClinicalTrials.gov (NCT04651153) A Multicenter, Participant-Blind, Investigator-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of UCB7853 in Healthy Male Study Participants and Multiple Ascending Doses in Patients With Parkinson's Disease. U.S.National Institutes of Health.
• [139] ClinicalTrials.gov (NCT03065192) An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa. U.S.National Institutes of Health.
• [140] ClinicalTrials.gov (NCT04043338) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects. U.S.National Institutes of Health.
• [141] Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. Acta Pharmacol Sin. 2013 Jul;34(7):976-82.
• [142] Microbiome therapeutics go small molecule. Nat Rev Drug Discov. 2019 Jul;18(8):569-572.
• [143] mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.
• [144] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010329)
• [145] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005232)
• [146] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009278)
• [147] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006532)
• [148] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002657)
• [149] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017938)
• [150] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 29).
• [151] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006926)
• [152] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013599)
• [153] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034020)
• [154] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027391)
• [155] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015639)
• [156] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003089)
• [157] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [158] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012344)
• [159] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2611).
• [160] S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity ... J Pharmacol Exp Ther. 2004 Jun;309(3):921-35.
• [161] Clinical pipeline report, company report or official report of Teva Pharmaceutical
• [162] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002413)
• [163] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025731)
• [164] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022461)
• [165] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014899)
• [166] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003368)
• [167] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008349)
• [168] Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist. Brain Res. 2008 Oct 9;1234:16-24.
• [169] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 938).
• [170] Pharmacokinetics, Pharmacodynamics and Tolerance of SLV 307 After Single Oral Administration in Healthy Male Volunteers. Clinical Pharmacology &#38 Therapeutics. 02/1999; 65(2).
• [171] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017359)
• [172] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264).
• [173] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
• [174] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [175] The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. Biochem Pharmacol. 2016 Jul 15;112:90-101.
• [176] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5610).
• [177] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18).
• [178] Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat. 2008 February; 4(1): 39-47.
• [179] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [180] Characterization of the human mitochondrial aconitase gene (ACO2).Gene. 1998 Jun 15;213(1-2):205-18. doi: 10.1016/s0378-1119(98)00188-7.
• [181] Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.Mov Disord. 2016 Jul;31(7):1004-11. doi: 10.1002/mds.26627. Epub 2016 May 2.
• [182] Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease.Neuromolecular Med. 2008;10(1):10-6. doi: 10.1007/s12017-007-8017-7. Epub 2007 Nov 6.
• [183] Apelin/APJ system: A novel promising target for neurodegenerative diseases.J Cell Physiol. 2020 Feb;235(2):638-657. doi: 10.1002/jcp.29001. Epub 2019 Jun 28.
• [184] Microheterogeneity of some serum glycoproteins in neurodegenerative diseases.J Neurol Sci. 2012 Mar 15;314(1-2):20-5. doi: 10.1016/j.jns.2011.11.006. Epub 2011 Nov 26.
• [185] Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels.Mol Biol Cell. 2007 Aug;18(8):3105-18. doi: 10.1091/mbc.e05-11-1027. Epub 2007 Jun 6.
• [186] Cerebrospinal fluid A42 levels and APP processing pathway genes in Parkinson's disease.Mov Disord. 2015 Jun;30(7):936-44. doi: 10.1002/mds.26172. Epub 2015 Mar 24.
• [187] Association of three candidate genetic variants in ACMSD/TMEM163, GPNMB and BCKDK /STX1B with sporadic Parkinson's disease in Han Chinese.Neurosci Lett. 2019 Jun 11;703:45-48. doi: 10.1016/j.neulet.2019.03.019. Epub 2019 Mar 14.
• [188] Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of -synuclein in multiple system atrophy.Neuropathol Appl Neurobiol. 2019 Jun;45(4):347-360. doi: 10.1111/nan.12512. Epub 2018 Aug 29.
• [189] Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6.Cell Death Differ. 2010 Jan;17(1):158-69. doi: 10.1038/cdd.2009.116.
• [190] Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease.Pharmacogenetics. 2003 Jun;13(6):365-9. doi: 10.1097/00008571-200306000-00008.
• [191] G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients.Mol Neurobiol. 2015 Aug;52(1):386-98. doi: 10.1007/s12035-014-8870-y. Epub 2014 Sep 3.
• [192] An exploratory study on the CHRNA3-CHRNA5-CHRNB4 cluster, smoking, and Parkinson's disease.Neurodegener Dis. 2011;8(5):296-9. doi: 10.1159/000323190. Epub 2011 Jan 13.
• [193] Unaltered lactate and glucose transporter levels in the MPTP mouse model of Parkinson's disease.J Parkinsons Dis. 2013 Jan 1;3(3):371-85. doi: 10.3233/JPD-130190.
• [194] Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.J Mol Neurosci. 2010 May;41(1):210-8. doi: 10.1007/s12031-009-9325-1. Epub 2010 Jan 21.
• [195] Association of Tef polymorphism with depression in Parkinson disease.Mov Disord. 2012 Nov;27(13):1694-7. doi: 10.1002/mds.25195. Epub 2012 Nov 8.
• [196] Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease.Brain Res. 2004 Jun 25;1012(1-2):42-51. doi: 10.1016/j.brainres.2004.03.029.
• [197] Association of Parkinson's disease with six single nucleotide polymorphisms located in four PARK genes in the northern Han Chinese population.J Clin Neurosci. 2012 Jul;19(7):1011-5. doi: 10.1016/j.jocn.2011.09.028. Epub 2012 May 8.
• [198] Cholinergic deficits and galaninergic hyperinnervation of the nucleus basalis of Meynert in Alzheimer's disease and Lewy body disorders.Neuropathol Appl Neurobiol. 2020 Apr;46(3):264-278. doi: 10.1111/nan.12577. Epub 2019 Oct 1.
• [199] Induction of macroautophagy by overexpression of the Parkinson's disease-associated GPR37 receptor.FASEB J. 2009 Jun;23(6):1978-87. doi: 10.1096/fj.08-121210. Epub 2009 Feb 13.
• [200] Association analysis of GRIN1 and GRIN2B polymorphisms and Parkinson's disease in a hospital-based case-control study.Neurosci Lett. 2010 Jul 5;478(2):61-5. doi: 10.1016/j.neulet.2010.04.063. Epub 2010 May 10.
• [201] The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.Neurology. 2013 Apr 23;80(17):1606-10. doi: 10.1212/WNL.0b013e31828f180e. Epub 2013 Mar 27.
• [202] TIGAR inclusion pathology is specific for Lewy body diseases.Brain Res. 2019 Mar 1;1706:218-223. doi: 10.1016/j.brainres.2018.09.032. Epub 2018 Sep 26.
• [203] Genetic analysis of the FBXO48 gene in Chinese Han patients with Parkinson disease.Neurosci Lett. 2013 Apr 29;541:224-6. doi: 10.1016/j.neulet.2013.02.031. Epub 2013 Feb 26.
• [204] Inhibition of glutathione S-transferase-pi triggers c-jun N-terminal kinase-dependent neuronal death in Zn-induced Parkinsonism.Mol Cell Biochem. 2019 Feb;452(1-2):95-104. doi: 10.1007/s11010-018-3415-8. Epub 2018 Aug 3.
• [205] Parkin maintains mitochondrial levels of the protective Parkinson's disease-related enzyme 17- hydroxysteroid dehydrogenase type 10.Cell Death Differ. 2015 Oct;22(10):1563-76. doi: 10.1038/cdd.2014.224. Epub 2015 Jan 16.
• [206] HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies.J Parkinsons Dis. 2019;9(1):97-107. doi: 10.3233/JPD-181443.
• [207] Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson's disease.Neurology. 2002 Mar 12;58(5):828-9. doi: 10.1212/wnl.58.5.828.
• [208] Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease.Neurobiol Aging. 2005 Aug-Sep;26(8):1161-5. doi: 10.1016/j.neurobiolaging.2004.11.001. Epub 2004 Dec 18.
• [209] Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.PLoS One. 2016 Aug 10;11(8):e0160501. doi: 10.1371/journal.pone.0160501. eCollection 2016.
• [210] Reducing INS-IGF1 signaling protects against non-cell autonomous vesicle rupture caused by SNCA spreading.Autophagy. 2020 May;16(5):878-899. doi: 10.1080/15548627.2019.1643657. Epub 2019 Jul 29.
• [211] Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin.Open Biol. 2016 Aug;6(8):160193. doi: 10.1098/rsob.160193.
• [212] DLG2, but not TMEM229B, GPNMB, and ITGA8 polymorphism, is associated with Parkinson's disease in a Taiwanese population.Neurobiol Aging. 2018 Apr;64:158.e1-158.e6. doi: 10.1016/j.neurobiolaging.2017.11.016. Epub 2017 Dec 8.
• [213] Identification of regulatory relationships in Parkinson's disease.J Mol Neurosci. 2013 Sep;51(1):9-12. doi: 10.1007/s12031-012-9937-8. Epub 2013 Feb 21.
• [214] Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease.Cell Death Differ. 2014 Mar;21(3):369-80. doi: 10.1038/cdd.2013.159. Epub 2013 Nov 8.
• [215] Alternative cleavage and polyadenylation of genes associated with protein turnover and mitochondrial function are deregulated in Parkinson's, Alzheimer's and ALS disease.BMC Med Genomics. 2019 May 9;12(1):60. doi: 10.1186/s12920-019-0509-4.
• [216] Iron transport in Parkinson's disease.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S209-11. doi: 10.1016/S1353-8020(09)70816-8.
• [217] Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonism.J Neural Transm (Vienna). 2017 Feb;124(2):209-216. doi: 10.1007/s00702-016-1632-4. Epub 2016 Oct 20.
• [218] Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease.Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10433-8. doi: 10.1073/pnas.181182298. Epub 2001 Aug 14.
• [219] Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls.PLoS One. 2014 Feb 21;9(2):e88604. doi: 10.1371/journal.pone.0088604. eCollection 2014.
• [220] Melatonin MT1 and MT2 receptor expression in Parkinson's disease.Med Sci Monit. 2010 Feb;16(2):BR61-7.
• [221] NAC1, A POZ/BTB protein interacts with Parkin and may contribute to Parkinson's disease.Neuroscience. 2014 Jan 17;257:86-95. doi: 10.1016/j.neuroscience.2013.11.001. Epub 2013 Nov 11.
• [222] Regulation of parkin and PINK1 by neddylation.Hum Mol Genet. 2012 Jun 1;21(11):2514-23. doi: 10.1093/hmg/dds070. Epub 2012 Mar 2.
• [223] B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist.Neurology. 2009 Feb 17;72(7):621-6. doi: 10.1212/01.wnl.0000342467.47860.f2.
• [224] Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies.Acta Neuropathol. 2008 Apr;115(4):471-8. doi: 10.1007/s00401-007-0309-3. Epub 2007 Nov 7.
• [225] Phenylalanine hydroxylase: A biomarker of disease susceptibility in Parkinson's disease and Amyotrophic lateral sclerosis.Med Hypotheses. 2018 Sep;118:29-33. doi: 10.1016/j.mehy.2018.06.018. Epub 2018 Jun 20.
• [226] A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci.Nat Genet. 2017 Oct;49(10):1511-1516. doi: 10.1038/ng.3955. Epub 2017 Sep 11.
• [227] Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson's disease autopsies.Acta Neuropathol. 2004 Jan;107(1):23-6. doi: 10.1007/s00401-003-0769-z. Epub 2003 Sep 17.
• [228] Programmed cell death-2 isoform1 is ubiquitinated by parkin and increased in the substantia nigra of patients with autosomal recessive Parkinson's disease.FEBS Lett. 2009 Feb 4;583(3):521-5. doi: 10.1016/j.febslet.2008.12.055. Epub 2009 Jan 13.
• [229] Phosphodiesterases in neurodegenerative disorders.IUBMB Life. 2012 Dec;64(12):965-70. doi: 10.1002/iub.1104. Epub 2012 Nov 5.
• [230] Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice.Neurobiol Aging. 2015 Feb;36(2):1160-73. doi: 10.1016/j.neurobiolaging.2014.10.008. Epub 2014 Oct 13.
• [231] Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene.Ann Neurol. 2009 Dec;66(6):792-8. doi: 10.1002/ana.21780.
• [232] Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.J Neural Transm (Vienna). 2016 Nov;123(11):1255-1278. doi: 10.1007/s00702-016-1596-4. Epub 2016 Aug 4.
• [233] Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+.Neurosci Lett. 2008 Mar 15;433(3):219-24. doi: 10.1016/j.neulet.2007.12.068. Epub 2008 Jan 17.
• [234] MPTP/MPP+ suppresses activation of protein C in Parkinson's disease.J Alzheimers Dis. 2015;43(1):133-42. doi: 10.3233/JAD-140126.
• [235] Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in -Synuclein Aggregation Disorders.EBioMedicine. 2018 May;31:307-319. doi: 10.1016/j.ebiom.2018.05.007.
• [236] Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction.Biochem Pharmacol. 1999 Jan 1;57(1):1-7. doi: 10.1016/s0006-2952(98)00214-7.
• [237] A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.Hum Mol Genet. 2014 Sep 15;23(18):4887-905. doi: 10.1093/hmg/ddu202. Epub 2014 May 2.
• [238] Resurgent current and voltage sensor trapping enhanced activation by a beta-scorpion toxin solely in Nav1.6 channel. Significance in mice Purkinje neurons.J Biol Chem. 2006 Jul 21;281(29):20326-37. doi: 10.1074/jbc.M600565200. Epub 2006 May 15.
• [239] Contribution of genetic variants to pain susceptibility in Parkinson disease.Eur J Pain. 2012 Oct;16(9):1243-50. doi: 10.1002/j.1532-2149.2012.00134.x. Epub 2012 Apr 4.
• [240] N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse.Ann Neurol. 2011 Mar;69(3):509-20. doi: 10.1002/ana.22162. Epub 2010 Nov 23.
• [241] SMPD1 mutations, activity, and -synuclein accumulation in Parkinson's disease.Mov Disord. 2019 Apr;34(4):526-535. doi: 10.1002/mds.27642. Epub 2019 Feb 20.
• [242] Targeted methylation sequencing reveals dysregulated Wnt signaling in Parkinson disease.J Genet Genomics. 2016 Oct 20;43(10):587-592. doi: 10.1016/j.jgg.2016.05.002. Epub 2016 May 13.
• [243] Convergence of miRNA expression profiling, -synuclein interacton and GWAS in Parkinson's disease.PLoS One. 2011;6(10):e25443. doi: 10.1371/journal.pone.0025443. Epub 2011 Oct 7.
• [244] Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population.J Neurol. 2005 Oct;252(10):1269-70. doi: 10.1007/s00415-005-0695-1. Epub 2005 Aug 1.
• [245] Epigenome-wide association study for Parkinson's disease.Neuromolecular Med. 2014 Dec;16(4):845-55. doi: 10.1007/s12017-014-8332-8. Epub 2014 Oct 11.
• [246] Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition.J Cell Sci. 2015 Jan 15;128(2):232-8. doi: 10.1242/jcs.164152. Epub 2014 Nov 21.
• [247] PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.Front Aging Neurosci. 2019 Sep 11;11:249. doi: 10.3389/fnagi.2019.00249. eCollection 2019.
• [248] Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's Disease.J Mol Neurosci. 2015 Sep;57(1):48-62. doi: 10.1007/s12031-015-0576-8. Epub 2015 May 17.
• [249] The ubiquitin ligase E6-AP promotes degradation of alpha-synuclein.J Neurochem. 2009 Sep;110(6):1955-64. doi: 10.1111/j.1471-4159.2009.06293.x. Epub 2009 Jul 23.
• [250] Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson's diseas... Clin Chim Acta. 2010 Jul 4;411(13-14):955-8.
• [251] The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.Nature. 2014 Jun 19;510(7505):370-5. doi: 10.1038/nature13418. Epub 2014 Jun 4.
• [252] 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta.Brain Res Mol Brain Res. 2002 Dec;108(1-2):33-9. doi: 10.1016/s0169-328x(02)00510-7.
• [253] Colonic diverticular disease: A new risk factor for Parkinson's disease?.Parkinsonism Relat Disord. 2017 Sep;42:61-65. doi: 10.1016/j.parkreldis.2017.06.011. Epub 2017 Jun 20.
• [254] ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease.EBioMedicine. 2017 Aug;22:225-241. doi: 10.1016/j.ebiom.2017.07.024. Epub 2017 Jul 25.
• [255] FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.Neuroscience. 2017 Jul 25;356:229-241. doi: 10.1016/j.neuroscience.2017.05.007. Epub 2017 May 11.
• [256] Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand.Sci Rep. 2017 Jul 10;7(1):4944. doi: 10.1038/s41598-017-05095-5.
• [257] SUMOylation of the Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 2 Increases Surface Expression and the Maximal Conductance of the Hyperpolarization-Activated Current.Front Mol Neurosci. 2017 Jan 12;9:168. doi: 10.3389/fnmol.2016.00168. eCollection 2016.
• [258] Parkinson's disease-related gene variants influence pre-mRNA splicing processes.Neurobiol Aging. 2016 Nov;47:127-138. doi: 10.1016/j.neurobiolaging.2016.07.014. Epub 2016 Jul 28.
• [259] Determining the Roles of Inositol Trisphosphate Receptors in Neurodegeneration: Interdisciplinary Perspectives on a Complex Topic.Mol Neurobiol. 2017 Nov;54(9):6870-6884. doi: 10.1007/s12035-016-0205-8. Epub 2016 Oct 22.
• [260] Central and systemic C-type Natriuretic Peptide are both reduced in Parkinson's Disease.Parkinsonism Relat Disord. 2017 Oct;43:15-19. doi: 10.1016/j.parkreldis.2017.06.019. Epub 2017 Jun 27.
• [261] Identification of key genes and pathways in Parkinson's disease through integrated analysis.Mol Med Rep. 2017 Oct;16(4):3769-3776. doi: 10.3892/mmr.2017.7112. Epub 2017 Jul 31.
• [262] Neutral Sphingomyelinase Behaviour in Hippocampus Neuroinflammation of MPTP-Induced Mouse Model of Parkinson's Disease and in Embryonic Hippocampal Cells.Mediators Inflamm. 2017;2017:2470950. doi: 10.1155/2017/2470950. Epub 2017 Nov 16.
• [263] Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease.Neuroscience. 2019 Aug 21;414:8-27. doi: 10.1016/j.neuroscience.2019.06.006. Epub 2019 Jun 18.
• [264] Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.Exp Ther Med. 2019 Mar;17(3):1611-1624. doi: 10.3892/etm.2018.7129. Epub 2018 Dec 24.
• [265] Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.Neurobiol Aging. 2015 Feb;36(2):1105-9. doi: 10.1016/j.neurobiolaging.2014.10.039. Epub 2014 Nov 5.
• [266] Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.Mov Disord. 2020 Mar;35(3):468-477. doi: 10.1002/mds.27935. Epub 2019 Dec 4.
• [267] Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies.Acta Neuropathol. 2009 Jan;117(1):63-73. doi: 10.1007/s00401-008-0438-3. Epub 2008 Oct 14.
• [268] Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.Gene Ther. 2006 Dec;13(23):1639-44. doi: 10.1038/sj.gt.3302810. Epub 2006 Jun 22.
• [269] Tremor-Dominant in Parkinson Disease: The Relevance to Iron Metabolism and Inflammation.Front Neurosci. 2019 Mar 27;13:255. doi: 10.3389/fnins.2019.00255. eCollection 2019.
• [270] Overexpression of Kir2.3 in PC12 cells resists rotenone-induced neurotoxicity associated with PKC signaling pathway.Biochem Biophys Res Commun. 2008 Sep 19;374(2):204-9. doi: 10.1016/j.bbrc.2008.07.003. Epub 2008 Jul 11.
• [271] Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor.J Biol Chem. 2016 Jun 3;291(23):12310-21. doi: 10.1074/jbc.M115.707224. Epub 2016 Apr 4.
• [272] Paraquat Exposure Increases Oxidative Stress Within the Dorsal Striatum of Male Mice With a Genetic Deficiency in One-carbon Metabolism.Toxicol Sci. 2019 May 1;169(1):25-33. doi: 10.1093/toxsci/kfz034.
• [273] Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson's Disease.J Neurosci. 2019 Sep 11;39(37):7291-7305. doi: 10.1523/JNEUROSCI.0625-19.2019. Epub 2019 Jul 29.
• [274] Superoxide dismutase coding of gene polymorphisms associated with susceptibility to Parkinson's disease.J Integr Neurosci. 2019 Sep 30;18(3):299-303. doi: 10.31083/j.jin.2019.03.127.
• [275] STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation.Oncol Lett. 2017 Oct;14(4):4599-4604. doi: 10.3892/ol.2017.6728. Epub 2017 Aug 7.
• [276] The c-Abl inhibitor in Parkinson disease.Neurol Sci. 2017 Apr;38(4):547-552. doi: 10.1007/s10072-016-2808-2. Epub 2017 Jan 11.
• [277] 7-chloro-4-(phenylselanyl) quinoline prevents dopamine depletion in a Drosophila melanogaster model of Parkinson's-like disease.J Trace Elem Med Biol. 2019 Jul;54:232-243. doi: 10.1016/j.jtemb.2018.10.015. Epub 2018 Oct 15.
• [278] Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease.Am J Med Genet. 2002 May 8;114(4):446-9. doi: 10.1002/ajmg.10249.
• [279] Motor dysfunction in type 5 adenylyl cyclase-null mice.J Biol Chem. 2003 May 9;278(19):16936-40. doi: 10.1074/jbc.C300075200. Epub 2003 Mar 28.
• [280] Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.Neurotox Res. 2018 May;33(4):702-715. doi: 10.1007/s12640-017-9841-7. Epub 2017 Dec 11.
• [281] New insights about the peculiar role of the 28-38 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection.Biochem Pharmacol. 2018 Aug;154:193-202. doi: 10.1016/j.bcp.2018.04.024. Epub 2018 Apr 25.
• [282] No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease.Neurobiol Aging. 2020 Mar;87:140.e19-140.e22. doi: 10.1016/j.neurobiolaging.2019.11.006. Epub 2019 Nov 14.
• [283] CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling.Brain. 2019 Mar 1;142(3):700-718. doi: 10.1093/brain/awy351.
• [284] Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?.Neurobiol Dis. 2020 Feb;134:104671. doi: 10.1016/j.nbd.2019.104671. Epub 2019 Nov 6.
• [285] RAGE and its emerging role in the pathogenesis of Parkinson's disease.Neurosci Lett. 2018 Apr 13;672:65-69. doi: 10.1016/j.neulet.2018.02.049. Epub 2018 Mar 21.
• [286] Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.Neurotox Res. 2018 Oct;34(3):597-612. doi: 10.1007/s12640-018-9921-3. Epub 2018 Jul 13.
• [287] MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson's disease.FASEB J. 2019 Jul;33(7):8648-8665. doi: 10.1096/fj.201900363R. Epub 2019 Apr 17.
• [288] Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson's disease.Neurobiol Aging. 2017 Feb;50:119-133. doi: 10.1016/j.neurobiolaging.2016.11.008. Epub 2016 Nov 23.
• [289] Oxadiazon affects the expression and activity of aldehyde dehydrogenase and acylphosphatase in human striatal precursor cells: A possible role in neurotoxicity. Toxicology. 2019 Jan 1;411:110-121.
• [290] Ape1 protects against MPP+-induced neurotoxicity through ERK1/2 signaling in PC12 cells.Neuroreport. 2017 Jan 1;28(1):10-16. doi: 10.1097/WNR.0000000000000712.
• [291] The effect of docosahexaenoic acid on apelin distribution of nervous system in the experimental mouse model of Parkinson's disease.Tissue Cell. 2019 Feb;56:41-51. doi: 10.1016/j.tice.2018.12.002. Epub 2018 Dec 6.
• [292] Proteomic Profiling of Exosomal Proteins for Blood-based Biomarkers in Parkinson's Disease.Neuroscience. 2018 Nov 10;392:121-128. doi: 10.1016/j.neuroscience.2018.09.017. Epub 2018 Sep 26.
• [293] Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease.Psychogeriatrics. 2020 Mar;20(2):180-188. doi: 10.1111/psyg.12483. Epub 2019 Dec 11.
• [294] Serotonin, -amyloid, and cognition in Parkinson disease.Ann Neurol. 2018 May;83(5):994-1002. doi: 10.1002/ana.25236. Epub 2018 May 11.
• [295] Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease.PLoS One. 2018 Mar 22;13(3):e0194896. doi: 10.1371/journal.pone.0194896. eCollection 2018.
• [296] Association of Parkinson's disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records.BMJ Open. 2019 Jun 19;9(6):e025574. doi: 10.1136/bmjopen-2018-025574.
• [297] Oxyresveratrol exerts ATF4- and Grp78-mediated neuroprotection against endoplasmic reticulum stress in experimental Parkinson's disease.Nutr Neurosci. 2021 Mar;24(3):181-196. doi: 10.1080/1028415X.2019.1613764. Epub 2019 May 17.
• [298] IRE1 promotes neurodegeneration through autophagy-dependent neuron death in the Drosophila model of Parkinson's disease.Cell Death Dis. 2019 Oct 22;10(11):800. doi: 10.1038/s41419-019-2039-6.
• [299] Voluntary Physical Exercise Improves Subsequent Motor and Cognitive Impairments in a Rat Model of Parkinson's Disease.Int J Mol Sci. 2018 Feb 8;19(2):508. doi: 10.3390/ijms19020508.
• [300] Association between common genetic risk variants and depression in Parkinson's disease: A dPD study in Chinese.Parkinsonism Relat Disord. 2016 Dec;33:122-126. doi: 10.1016/j.parkreldis.2016.09.029. Epub 2016 Sep 29.
• [301] Parkinsonism in spinocerebellar ataxia.Biomed Res Int. 2015;2015:125273. doi: 10.1155/2015/125273. Epub 2015 Mar 19.
• [302] Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder.Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102. eCollection 2017.
• [303] C-terminal truncation exacerbates the aggregation and cytotoxicity of -Synuclein: A vicious cycle in Parkinson's disease.Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3714-3725. doi: 10.1016/j.bbadis.2018.10.003. Epub 2018 Oct 2.
• [304] Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson's disease.Toxicol Mech Methods. 2018 Nov;28(9):699-708. doi: 10.1080/15376516.2018.1502386. Epub 2018 Oct 2.
• [305] Impaired CBS-H(2)S signaling axis contributes to MPTP-induced neurodegeneration in a mouse model of Parkinson's disease.Brain Behav Immun. 2018 Jan;67:77-90. doi: 10.1016/j.bbi.2017.07.159. Epub 2017 Aug 1.
• [306] Psychosis in Parkinson's disease: From the soft signs to the hard science.J Neurol Sci. 2017 Aug 15;379:169-176. doi: 10.1016/j.jns.2017.06.011. Epub 2017 Jun 12.
• [307] Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.Arch Neurol. 2004 Aug;61(8):1280-4. doi: 10.1001/archneur.61.8.1280.
• [308] Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration.Neurosci Lett. 2009 Aug 21;460(1):27-31. doi: 10.1016/j.neulet.2009.05.044. Epub 2009 May 20.
• [309] Peripheral blood lymphocyte phenotypes in Alzheimer and Parkinson's diseases.Neurologia (Engl Ed). 2022 Mar;37(2):110-121. doi: 10.1016/j.nrl.2018.10.004. Epub 2019 Mar 11.
• [310] Analysis of the Impact of CD200 on Phagocytosis.Mol Neurobiol. 2017 Sep;54(7):5730-5739. doi: 10.1007/s12035-016-0223-6. Epub 2016 Nov 9.
• [311] The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson's disease models.Biochem Biophys Res Commun. 2020 Feb 12;522(3):647-654. doi: 10.1016/j.bbrc.2019.11.141. Epub 2019 Nov 29.
• [312] Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinson's disease.Neurotoxicology. 2018 Mar;65:166-173. doi: 10.1016/j.neuro.2018.02.012. Epub 2018 Feb 20.
• [313] CCAAT/Enhancer binding protein silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease.Sci Rep. 2017 Oct 19;7(1):13526. doi: 10.1038/s41598-017-13269-4.
• [314] Parkinson's disease and multiple system atrophy have distinct -synuclein seed characteristics.J Biol Chem. 2019 Jan 18;294(3):1045-1058. doi: 10.1074/jbc.RA118.004471. Epub 2018 Nov 26.
• [315] Thecalretinin interneurons of the striatum: comparisons between rodents and primates under normal and pathological conditions.J Neural Transm (Vienna). 2018 Mar;125(3):279-290. doi: 10.1007/s00702-017-1687-x. Epub 2017 Feb 6.
• [316] Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):239-247. doi: 10.1136/jnnp-2017-317138. Epub 2017 Nov 15.
• [317] Bioassay-guided Isolation of Neuroprotective Fatty Acids from Nigella sativa against 1-methyl-4-phenylpyridinium-induced Neurotoxicity.Pharmacogn Mag. 2017 Oct-Dec;13(52):627-633. doi: 10.4103/pm.pm_470_16. Epub 2017 Nov 13.
• [318] Activation of 7-nAChRs protects SH-SY5Y cells from 1-methyl-4-phenylpyridinium-induced apoptotic cell death via ERK/p53 signaling pathway.J Cell Physiol. 2019 Aug;234(10):18480-18491. doi: 10.1002/jcp.28484. Epub 2019 Mar 25.
• [319] Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: gene and smoking status interaction.Parkinsonism Relat Disord. 2013 Jan;19(1):72-6. doi: 10.1016/j.parkreldis.2012.07.007. Epub 2012 Aug 9.
• [320] Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal (123)I-FP-CIT SPECT study.Parkinsonism Relat Disord. 2020 Aug;77:170-175. doi: 10.1016/j.parkreldis.2019.03.025. Epub 2019 Apr 5.
• [321] Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming.Brain Behav Immun. 2017 Feb;60:206-219. doi: 10.1016/j.bbi.2016.10.018. Epub 2016 Oct 18.
• [322] The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109745. doi: 10.1016/j.pnpbp.2019.109745. Epub 2019 Aug 20.
• [323] Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.Hum Mol Genet. 2014 Sep 1;23(17):4693-702. doi: 10.1093/hmg/ddu158. Epub 2014 May 19.
• [324] L-3-n-butylphthalide soft capsules in the treatment of Parkinson disease dementia: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore). 2019 Jun;98(24):e16082. doi: 10.1097/MD.0000000000016082.
• [325] The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases.Neurosci Lett. 2005 Jul 1-8;382(1-2):175-8. doi: 10.1016/j.neulet.2005.03.008. Epub 2005 Apr 2.
• [326] Circular RNA circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway in Parkinson's disease.Biochem Biophys Res Commun. 2020 Feb 5;522(2):388-394. doi: 10.1016/j.bbrc.2019.11.102. Epub 2019 Nov 21.
• [327] Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.Mov Disord. 2020 Feb;35(2):279-287. doi: 10.1002/mds.27888. Epub 2019 Nov 6.
• [328] Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease.Acta Neuropsychiatr. 2020 Feb;32(1):10-22. doi: 10.1017/neu.2019.28. Epub 2019 Aug 27.
• [329] ITPKB and ZNF184 are associated with Parkinson's disease risk in East Asians.Neurobiol Aging. 2020 Feb;86:201.e15-201.e17. doi: 10.1016/j.neurobiolaging.2019.01.026. Epub 2019 Feb 2.
• [330] Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study.Parkinsonism Relat Disord. 2018 Oct;55:50-54. doi: 10.1016/j.parkreldis.2018.05.010. Epub 2018 May 17.
• [331] Respiratory muscle strength and lung function in the stages of Parkinson's disease.J Bras Pneumol. 2019 Sep 30;45(6):e20180148. doi: 10.1590/1806-3713/e20180148. eCollection 2019.
• [332] Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.Glia. 2018 Aug;66(8):1752-1762. doi: 10.1002/glia.23338. Epub 2018 Apr 6.
• [333] The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration.J Neuroinflammation. 2019 Dec 5;16(1):255. doi: 10.1186/s12974-019-1659-1.
• [334] Genome-wide association study reveals genetic risk underlying Parkinson's disease.Nat Genet. 2009 Dec;41(12):1308-12. doi: 10.1038/ng.487. Epub 2009 Nov 15.
• [335] P450 enzymes and Parkinson's disease: the story so far.Mov Disord. 1998 Mar;13(2):212-20. doi: 10.1002/mds.870130204.
• [336] Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson's Disease.Planta Med. 2019 Nov;85(17):1351-1362. doi: 10.1055/a-1013-7686. Epub 2019 Sep 26.
• [337] Anti-Parkinson's disease drugs and pharmacogenetic considerations.Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):859-74. doi: 10.1517/17425255.2013.789018. Epub 2013 Apr 9.
• [338] Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.Ann Neurol. 2019 May;85(5):704-714. doi: 10.1002/ana.25450. Epub 2019 Mar 26.
• [339] RTP801 is a critical factor in the neurodegeneration process of A53T -synuclein in a mouse model of Parkinson's disease under chronic restraint stress.Br J Pharmacol. 2018 Feb;175(4):590-605. doi: 10.1111/bph.14091. Epub 2018 Jan 17.
• [340] Astrocyte-specific DJ-1 overexpression protects against rotenone-induced neurotoxicity in a rat model of Parkinson's disease.Neurobiol Dis. 2018 Jul;115:101-114. doi: 10.1016/j.nbd.2018.04.008. Epub 2018 Apr 9.
• [341] A novel peptide delivers plasmids across blood-brain barrier into neuronal cells as a single-component transfer vector.PLoS One. 2013;8(3):e59642. doi: 10.1371/journal.pone.0059642. Epub 2013 Mar 29.
• [342] Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's model mice.Genes Cells. 2019 Jan;24(1):31-40. doi: 10.1111/gtc.12651. Epub 2018 Nov 18.
• [343] Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.Behav Brain Res. 2020 Jan 27;378:112304. doi: 10.1016/j.bbr.2019.112304. Epub 2019 Oct 15.
• [344] Poloxamer 188 rescues MPTP-induced lysosomal membrane integrity impairment in cellular and mouse models of Parkinson's disease.Neurochem Int. 2019 Jun;126:178-186. doi: 10.1016/j.neuint.2019.03.013. Epub 2019 Mar 20.
• [345] Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity.J Alzheimers Dis. 2009;16(3):585-99. doi: 10.3233/JAD-2009-0995.
• [346] Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.Neuropharmacology. 2018 May 1;133:385-394. doi: 10.1016/j.neuropharm.2018.02.012. Epub 2018 Feb 17.
• [347] Polymorphisms of COMT (c.649G>A), MAO-A (c.1460C>T), NET (c.1287G>A) Genes and the Level of Catecholamines, Serotonin in Patients with Parkinson's Disease.DNA Cell Biol. 2017 Jun;36(6):501-512. doi: 10.1089/dna.2016.3569. Epub 2017 Apr 18.
• [348] Psychotropics regulate Skp1a, Aldh1a1, and Hspa8 transcription--potential to delay Parkinson's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:236-9. doi: 10.1016/j.pnpbp.2012.08.021. Epub 2012 Oct 7.
• [349] Inhibition of MPTP-induced -synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice.Neuropharmacology. 2019 May 15;150:164-174. doi: 10.1016/j.neuropharm.2019.03.029. Epub 2019 Mar 28.
• [350] A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers. Drug Des Devel Ther. 2019 Mar 29;13:1011-1022.
• [351] Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease.Neurosci Lett. 2007 Nov 27;428(2-3):82-7. doi: 10.1016/j.neulet.2007.09.032. Epub 2007 Sep 25.
• [352] Metabolic response to Parkinson's disease recapitulated by the haploinsufficient diploid yeast cells hemizygous for the adrenodoxin reductase gene.Mol Omics. 2019 Oct 7;15(5):340-347. doi: 10.1039/c9mo00090a.
• [353] Extensive neuronal localization and neurotrophic function of fibroblast growth factor 8 in the nervous system.Brain Res. 2001 Sep 7;912(2):105-15. doi: 10.1016/s0006-8993(01)02726-3.
• [354] The Molecular Basis of the Interaction of CyclophilinA with -Synuclein.Angew Chem Int Ed Engl. 2020 Mar 27;59(14):5643-5646. doi: 10.1002/anie.201914878. Epub 2020 Jan 29.
• [355] Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.Sci Rep. 2017 May 24;7(1):2348. doi: 10.1038/s41598-017-02572-9.
• [356] Charcot spinal arthropathy presenting as adjacent segment disease after lumbar spinal fusion surgery in Parkinson's disease: A case report.J Clin Neurosci. 2019 Mar;61:281-284. doi: 10.1016/j.jocn.2018.11.013. Epub 2018 Nov 13.
• [357] Pharmacological targeting of -synuclein and TPPP/p25 in Parkinson's disease: challenges and opportunities in a Nutshell.FEBS Lett. 2019 Jul;593(13):1641-1653. doi: 10.1002/1873-3468.13464. Epub 2019 Jun 11.
• [358] G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10.Sci Rep. 2019 Sep 9;9(1):12896. doi: 10.1038/s41598-019-46237-1.
• [359] A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Br J Clin Pharmacol. 2013 Aug;76(2):217-32. doi: 10.1111/bcp.12065.
• [360] Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models.Gene Ther. 2005 Aug;12(15):1215-22. doi: 10.1038/sj.gt.3302520.
• [361] Analysis of age-related changes in psychosine metabolism in the human brain.PLoS One. 2018 Feb 26;13(2):e0193438. doi: 10.1371/journal.pone.0193438. eCollection 2018.
• [362] Small Fibre Neuropathy in Parkinson's Disease: Comparison of Skin Biopsies from the More Affected and Less Affected Sides.J Parkinsons Dis. 2019;9(4):761-765. doi: 10.3233/JPD-191697.
• [363] Nuclear accumulation of GAPDH, GluA2 and p53 in post-mortem substantia nigral region of patients with Parkinson's disease.Neurosci Lett. 2020 Jan 18;716:134641. doi: 10.1016/j.neulet.2019.134641. Epub 2019 Nov 20.
• [364] Semaglutide is Neuroprotective and Reduces -Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.J Parkinsons Dis. 2019;9(1):157-171. doi: 10.3233/JPD-181503.
• [365] Human tyrosine hydroxylase in Parkinson's disease and in related disorders.J Neural Transm (Vienna). 2019 Apr;126(4):397-409. doi: 10.1007/s00702-018-1903-3. Epub 2018 Jul 11.
• [366] GDF-15promotesmitochondrialfunction and proliferation in neuronal HT22 cells.J Cell Biochem. 2019 Jun;120(6):10530-10547. doi: 10.1002/jcb.28339. Epub 2019 Jan 11.
• [367] Signaling by growth/differentiation factor 5 through the bone morphogenetic protein receptor type IB protects neurons against kainic acid-induced neurodegeneration.Neurosci Lett. 2017 Jun 9;651:36-42. doi: 10.1016/j.neulet.2017.04.055. Epub 2017 Apr 27.
• [368] GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.Peptides. 2020 Mar;125:170184. doi: 10.1016/j.peptides.2019.170184. Epub 2019 Nov 6.
• [369] Nigrostriatal proteomics of cypermethrin-induced dopaminergic neurodegeneration: microglial activation-dependent and -independent regulations.Toxicol Sci. 2011 Aug;122(2):526-38. doi: 10.1093/toxsci/kfr115. Epub 2011 May 10.
• [370] The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein.Neurobiol Dis. 2018 Feb;110:68-81. doi: 10.1016/j.nbd.2017.11.006. Epub 2017 Dec 2.
• [371] Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.Antioxid Redox Signal. 2019 Apr 1;30(10):1352-1368. doi: 10.1089/ars.2017.7411. Epub 2018 Jan 5.
• [372] Mapping Spatiotemporal Microproteomics Landscape in Experimental Model of Traumatic Brain Injury Unveils a link to Parkinson's Disease.Mol Cell Proteomics. 2019 Aug;18(8):1669-1682. doi: 10.1074/mcp.RA119.001604. Epub 2019 Jun 16.
• [373] GPR30 Activation Contributes to the Puerarin-Mediated Neuroprotection in MPP(+)-Induced SH-SY5Y Cell Death. J Mol Neurosci. 2017 Feb;61(2):227-234. doi: 10.1007/s12031-016-0856-y. Epub 2016 Oct 30.
• [374] The GPR139 reference agonists 1a and 7c, and tryptophan and phenylalanine share a common binding site.Sci Rep. 2017 Apr 25;7(1):1128. doi: 10.1038/s41598-017-01049-z.
• [375] Identification of novel GPR17-agonists by structural bioinformatics and signaling activation.Int J Biol Macromol. 2018 Jan;106:901-907. doi: 10.1016/j.ijbiomac.2017.08.088. Epub 2017 Aug 18.
• [376] GPR3 and GPR6, novel molecular targets for cannabidiol.Biochem Biophys Res Commun. 2017 Aug 12;490(1):17-21. doi: 10.1016/j.bbrc.2017.05.165. Epub 2017 May 29.
• [377] Targeting CB(1) and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease.Mol Neurobiol. 2019 Aug;56(8):5900-5910. doi: 10.1007/s12035-019-1495-4. Epub 2019 Jan 28.
• [378] Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.Neuropharmacology. 2020 Jan 1;162:107829. doi: 10.1016/j.neuropharm.2019.107829. Epub 2019 Oct 24.
• [379] The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain.Exp Neurol. 2020 Jan;323:113062. doi: 10.1016/j.expneurol.2019.113062. Epub 2019 Sep 9.
• [380] Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.Brain. 2019 May 1;142(5):1365-1385. doi: 10.1093/brain/awz065.
• [381] Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.Medchemcomm. 2019 Jan 10;10(2):315-325. doi: 10.1039/c8md00545a. eCollection 2019 Feb 1.
• [382] NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.Neurobiol Dis. 2019 Jan;121:338-349. doi: 10.1016/j.nbd.2018.09.021. Epub 2018 Sep 24.
• [383] Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.J Neurochem. 2008 Mar;104(6):1622-36. doi: 10.1111/j.1471-4159.2007.05104.x. Epub 2007 Nov 7.
• [384] Role of G-protein coupled receptor kinase 5 gene in cognitive impairment in Parkinson's disease.Psychiatry Res. 2015 Dec 30;230(3):975-7. doi: 10.1016/j.psychres.2015.11.026. Epub 2015 Nov 17.
• [385] Activation of calcium-impermeable GluR2-containing AMPA receptors in the lateral habenula produces antidepressant-like effects in a rodent model of Parkinson's disease.Exp Neurol. 2019 Dec;322:113058. doi: 10.1016/j.expneurol.2019.113058. Epub 2019 Sep 6.
• [386] Characterization of [(11)C]PXT012253 as a PET Radioligand for mGlu(4) Allosteric Modulators in Nonhuman Primates.Mol Imaging Biol. 2019 Jun;21(3):500-508. doi: 10.1007/s11307-018-1257-0.
• [387] mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.Mol Neurobiol. 2020 Mar;57(3):1418-1431. doi: 10.1007/s12035-019-01818-z. Epub 2019 Nov 21.
• [388] A Triazolotriazine-Based Dual GSK-3/CK-1 Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition.ChemMedChem. 2019 Feb 5;14(3):310-314. doi: 10.1002/cmdc.201800778. Epub 2019 Jan 15.
• [389] Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A.Int J Mol Sci. 2019 Sep 14;20(18):4559. doi: 10.3390/ijms20184559.
• [390] Regularizing firing patterns of rat subthalamic neurons ameliorates parkinsonian motor deficits.J Clin Invest. 2018 Dec 3;128(12):5413-5427. doi: 10.1172/JCI99986. Epub 2018 Oct 29.
• [391] Depletion of hypothalamic hypocretin/orexin neurons correlates with impaired memory in a Parkinson's disease animal model.Exp Neurol. 2020 Jan;323:113110. doi: 10.1016/j.expneurol.2019.113110. Epub 2019 Nov 8.
• [392] Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes.Cell Stem Cell. 2019 Jan 3;24(1):93-106.e6. doi: 10.1016/j.stem.2018.10.023. Epub 2018 Nov 29.
• [393] Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology.Biochim Biophys Acta Mol Basis Dis. 2019 Aug 1;1865(8):2008-2023. doi: 10.1016/j.bbadis.2018.11.014. Epub 2018 Dec 17.
• [394] A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson's disease.Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7419-7424. doi: 10.1073/pnas.1821778116. Epub 2019 Mar 25.
• [395] Association between a heme oxygenase-2 genetic variant and risk of Parkinson's disease in Han Chinese.Neurosci Lett. 2017 Mar 6;642:119-122. doi: 10.1016/j.neulet.2017.02.008. Epub 2017 Feb 6.
• [396] The histamine H3 receptor antagonist thioperamide rescues circadian rhythm and memory function in experimental parkinsonism.Transl Psychiatry. 2017 Apr 11;7(4):e1088. doi: 10.1038/tp.2017.58.
• [397] New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease.Exp Neurol. 2018 Aug;306:199-208. doi: 10.1016/j.expneurol.2018.04.012. Epub 2018 Apr 26.
• [398] LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10.Autophagy. 2020 Feb;16(2):203-222. doi: 10.1080/15548627.2019.1603548. Epub 2019 Apr 19.
• [399] Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes.Neurochem Int. 2020 Jan;132:104608. doi: 10.1016/j.neuint.2019.104608. Epub 2019 Nov 22.
• [400] Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged A53T -synuclein-expressing mice.Neurobiol Aging. 2019 Aug;80:29-37. doi: 10.1016/j.neurobiolaging.2019.03.014. Epub 2019 Apr 1.
• [401] Advances in Management of Psychosis in Neurodegenerative Diseases.Curr Treat Options Neurol. 2019 Jan 23;21(1):3. doi: 10.1007/s11940-019-0545-6.
• [402] Dynamin-related protein 1: A critical protein in the pathogenesis of neural system dysfunctions and neurodegenerative diseases.J Cell Physiol. 2019 Jul;234(7):10032-10046. doi: 10.1002/jcp.27866. Epub 2018 Dec 4.
• [403] Serum albumin impedes the amyloid aggregation and hemolysis of human islet amyloid polypeptide and alpha synuclein.Biochim Biophys Acta Biomembr. 2018 Sep;1860(9):1803-1809. doi: 10.1016/j.bbamem.2018.01.015. Epub 2018 Jan 31.
• [404] 6-Hydroxydopamine induces secretion of PARK7/DJ-1 via autophagy-based unconventional secretory pathway.Autophagy. 2018;14(11):1943-1958. doi: 10.1080/15548627.2018.1493043. Epub 2018 Aug 16.
• [405] The novel protective effects of loganin against 1-methyl-4-phenylpyridinium-induced neurotoxicity: Enhancement of neurotrophic signaling, activation of IGF-1R/GLP-1R, and inhibition of RhoA/ROCK pathway.Phytother Res. 2019 Mar;33(3):690-701. doi: 10.1002/ptr.6259. Epub 2018 Dec 16.
• [406] DNA methylation of imprinted loci of autosomal chromosomes and IGF2 is not affected in Parkinson's disease patients' peripheral blood mononuclear cells.Neurol Res. 2017 Mar;39(3):281-284. doi: 10.1080/01616412.2017.1279424. Epub 2017 Jan 12.
• [407] Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death.Cytokine. 2018 Mar;103:114-120. doi: 10.1016/j.cyto.2017.09.018. Epub 2017 Sep 30.
• [408] Genetic Association Between NGFR, ADAM17 Gene Polymorphism, and Parkinson's Disease in the Chinese Han Population.Neurotox Res. 2019 Oct;36(3):463-471. doi: 10.1007/s12640-019-00031-z. Epub 2019 Apr 2.
• [409] Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons.PLoS Biol. 2010 Apr 6;8(4):e1000349. doi: 10.1371/journal.pbio.1000349.
• [410] Neuroprotective Effects of a Traditional Multi-Herbal Medicine Kyung-Ok-Ko in an Animal Model of Parkinson's Disease: Inhibition of MAPKs and NF-B Pathways and Activation of Keap1-Nrf2 Pathway.Front Pharmacol. 2018 Dec 13;9:1444. doi: 10.3389/fphar.2018.01444. eCollection 2018.
• [411] The central regulator p62 between ubiquitin proteasome system and autophagy and its role in the mitophagy and Parkinson's disease.BMB Rep. 2020 Jan;53(1):56-63. doi: 10.5483/BMBRep.2020.53.1.283.
• [412] MicroRNA-326 Inhibits Apoptosis and Promotes Proliferation of Dopaminergic Neurons in Parkinson's Disease Through Suppression of KLK7-Mediated MAPK Signaling Pathway.J Mol Neurosci. 2019 Oct;69(2):197-214. doi: 10.1007/s12031-019-01349-1. Epub 2019 Jul 3.
• [413] Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study.Mov Disord. 2019 Jan;34(1):138-141. doi: 10.1002/mds.27569. Epub 2018 Nov 28.
• [414] Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.PLoS One. 2018 Mar 1;13(3):e0192121. doi: 10.1371/journal.pone.0192121. eCollection 2018.
• [415] Role of Leptin in Mood Disorder and Neurodegenerative Disease.Front Neurosci. 2019 May 3;13:378. doi: 10.3389/fnins.2019.00378. eCollection 2019.
• [416] Subjective and objective halitosis among patients with Parkinson's disease.Gerodontology. 2017 Dec;34(4):460-468. doi: 10.1111/ger.12293. Epub 2017 Aug 31.
• [417] miR-let-7a suppresses -Synuclein-induced microglia inflammation through targeting STAT3 in Parkinson's disease.Biochem Biophys Res Commun. 2019 Nov 19;519(4):740-746. doi: 10.1016/j.bbrc.2019.08.140. Epub 2019 Sep 20.
• [418] LIN28A loss of function is associated with Parkinson's disease pathogenesis.EMBO J. 2019 Dec 16;38(24):e101196. doi: 10.15252/embj.2018101196. Epub 2019 Nov 21.
• [419] Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects against A toxicity via attenuating A-induced endoplasmic reticulum stress.J Neuroinflammation. 2019 Feb 13;16(1):35. doi: 10.1186/s12974-019-1429-0.
• [420] Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy.Autophagy. 2017;13(11):1969-1980. doi: 10.1080/15548627.2017.1371393. Epub 2017 Oct 4.
• [421] The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss.Exp Neurol. 2019 Aug;318:157-164. doi: 10.1016/j.expneurol.2019.05.002. Epub 2019 May 8.
• [422] MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease.J Neuroinflammation. 2018 Jan 12;15(1):13. doi: 10.1186/s12974-018-1053-4.
• [423] Effect of PI3K/Akt/mTOR signaling pathway on JNK3 in Parkinsonian rats.Exp Ther Med. 2019 Mar;17(3):1771-1775. doi: 10.3892/etm.2018.7120. Epub 2018 Dec 20.
• [424] Ethanol extract from Gynostemma pentaphyllum ameliorates dopaminergic neuronal cell death in transgenic mice expressing mutant A53T human alpha-synuclein.Neural Regen Res. 2020 Feb;15(2):361-368. doi: 10.4103/1673-5374.265557.
• [425] Altered ER-mitochondria contact impacts mitochondria calcium homeostasis and contributes to neurodegeneration in vivo in disease models.Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8844-E8853. doi: 10.1073/pnas.1721136115. Epub 2018 Sep 5.
• [426] Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF-B axis.Biochem Pharmacol. 2018 May;151:126-134. doi: 10.1016/j.bcp.2018.01.047. Epub 2018 Feb 8.
• [427] Neurogenesis in Neurodegenerative Diseases: Role of MFG-E8.Front Neurosci. 2019 Jun 4;13:569. doi: 10.3389/fnins.2019.00569. eCollection 2019.
• [428] Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.Food Res Int. 2018 Apr;106:558-567. doi: 10.1016/j.foodres.2018.01.026. Epub 2018 Jan 31.
• [429] Cannabinoid CB1 and CB2Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.Neurotherapeutics. 2018 Apr;15(2):459-469. doi: 10.1007/s13311-018-0603-x.
• [430] Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO--synuclein-A53T mouse model, correlating with increased nitration and aggregation of -synuclein and exacerbation of motor impairment.Free Radic Biol Med. 2019 Sep;141:115-140. doi: 10.1016/j.freeradbiomed.2019.05.033. Epub 2019 Jun 6.
• [431] The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy.Mov Disord. 2019 Sep;34(9):1307-1314. doi: 10.1002/mds.27786. Epub 2019 Jul 12.
• [432] Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan.Clin Chim Acta. 2011 Jan 30;412(3-4):332-8. doi: 10.1016/j.cca.2010.11.004. Epub 2010 Nov 8.
• [433] Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome.Mov Disord. 2012 Feb;27(2):312-5. doi: 10.1002/mds.24029. Epub 2011 Nov 18.
• [434] Identification of crucial genes associated with Parkinson's disease using microarray data.Mol Med Rep. 2018 Mar;17(3):3775-3782. doi: 10.3892/mmr.2017.8305. Epub 2017 Dec 18.
• [435] Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.Oncotarget. 2016 Sep 13;7(37):58813-58831. doi: 10.18632/oncotarget.11020.
• [436] Different implication of NEDD9 genetic variant in early and late-onset Alzheimer's disease.Neurosci Lett. 2010 Jun 25;477(3):121-3. doi: 10.1016/j.neulet.2010.04.046. Epub 2010 Apr 27.
• [437] Testing alternatives: the use of adipose-derived mesenchymal stem cells to slow neurodegeneration in a rat model of Parkinson's disease.Mol Biol Rep. 2019 Dec;46(6):5841-5858. doi: 10.1007/s11033-019-05018-9. Epub 2019 Aug 8.
• [438] Aminochrome decreases NGF, GDNF and induces neuroinflammation in organotypic midbrain slice cultures.Neurotoxicology. 2018 May;66:98-106. doi: 10.1016/j.neuro.2018.03.009. Epub 2018 Mar 26.
• [439] Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.Mov Disord. 2020 Jan;35(1):20-33. doi: 10.1002/mds.27874. Epub 2019 Nov 4.
• [440] Integrated Analysis of Whole Exome Sequencing and Copy Number Evaluation in Parkinson's Disease.Sci Rep. 2019 Mar 4;9(1):3344. doi: 10.1038/s41598-019-40102-x.
• [441] Retrospective Diagnosis of Parkinsonian Syndromes Using Whole-Brain Atrophy Rates.Front Aging Neurosci. 2017 Apr 19;9:99. doi: 10.3389/fnagi.2017.00099. eCollection 2017.
• [442] Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease.J Gerontol A Biol Sci Med Sci. 2008 Feb;63(2):127-34. doi: 10.1093/gerona/63.2.127.
• [443] Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease.Nutrition. 2020 Jan;69:110494. doi: 10.1016/j.nut.2019.04.006. Epub 2019 Apr 25.
• [444] Circulating levels of neurotrophic factors are unchanged in patients with Parkinson's disease.Arq Neuropsiquiatr. 2018 May;76(5):310-315. doi: 10.1590/0004-282X20180035.
• [445] A Combination of NT-4/5 and GDNF Is Favorable for Cultured Human Nigral Neural Progenitor Cells.Cell Transplant. 2018 Apr;27(4):648-653. doi: 10.1177/0963689717753188. Epub 2018 Apr 27.
• [446] Computational prediction of changes in brain metabolic fluxes during Parkinson's disease from mRNA expression.PLoS One. 2018 Sep 12;13(9):e0203687. doi: 10.1371/journal.pone.0203687. eCollection 2018.
• [447] Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.Br J Pharmacol. 2018 Mar;175(5):782-796. doi: 10.1111/bph.14123. Epub 2018 Jan 31.
• [448] Overexpression of microRNA-183 promotes apoptosis of substantia nigra neurons via the inhibition of OSMR in a mouse model of Parkinson's disease.Int J Mol Med. 2019 Jan;43(1):209-220. doi: 10.3892/ijmm.2018.3982. Epub 2018 Nov 7.
• [449] Purinergic Signalling in Parkinson's Disease: A Multi-target System to Combat Neurodegeneration.Neurochem Res. 2019 Oct;44(10):2413-2422. doi: 10.1007/s11064-019-02798-1. Epub 2019 May 4.
• [450] Microglia P2Y6 receptor is related to Parkinson's disease through neuroinflammatory process.J Neuroinflammation. 2017 Feb 20;14(1):38. doi: 10.1186/s12974-017-0795-8.
• [451] Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.Mov Disord. 2019 Oct;34(10):1505-1515. doi: 10.1002/mds.27733. Epub 2019 Jun 3.
• [452] Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.Eur J Med Chem. 2019 Apr 15;168:221-231. doi: 10.1016/j.ejmech.2019.02.026. Epub 2019 Feb 11.
• [453] Phosphodiesterase 7 Regulation in Cellular and Rodent Models of Parkinson's Disease.Mol Neurobiol. 2020 Feb;57(2):806-822. doi: 10.1007/s12035-019-01745-z. Epub 2019 Aug 31.
• [454] Raf kinase inhibitor protein protects microglial cells against 1-methyl-4-phenylpyridinium-induced neuroinflammation in vitro.Exp Cell Res. 2018 Nov 15;372(2):108-117. doi: 10.1016/j.yexcr.2018.09.016. Epub 2018 Sep 20.
• [455] Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221.Neuropharmacology. 2020 Mar 1;164:107900. doi: 10.1016/j.neuropharm.2019.107900. Epub 2019 Dec 5.
• [456] Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases.Prion. 2018 Mar 4;12(2):127-137. doi: 10.1080/19336896.2018.1464367. Epub 2018 May 18.
• [457] Comparison of Administration Routes on the Protective Effects of Bee Venom Phospholipase A2 in a Mouse Model of Parkinson's Disease.Front Aging Neurosci. 2018 Jun 11;10:179. doi: 10.3389/fnagi.2018.00179. eCollection 2018.
• [458] Phospholipase D1 downregulation by -synuclein: Implications for neurodegeneration in Parkinson's disease.Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jun;1863(6):639-650. doi: 10.1016/j.bbalip.2018.03.006. Epub 2018 Mar 21.
• [459] The Lipase Activity of Phospholipase D2 is Responsible for Nigral Neurodegeneration in a Rat Model of Parkinson's Disease.Neuroscience. 2018 May 1;377:174-183. doi: 10.1016/j.neuroscience.2018.02.047. Epub 2018 Mar 9.
• [460] Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated -Synuclein-selective Autophagic Degradation.J Biol Chem. 2017 Mar 3;292(9):3919-3928. doi: 10.1074/jbc.M116.759373. Epub 2017 Jan 30.
• [461] 2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease.Neurochem Res. 2017 Oct;42(10):2996-3004. doi: 10.1007/s11064-017-2330-9. Epub 2017 Jun 19.
• [462] PPAR/ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease.Behav Brain Res. 2019 Jan 1;356:483-489. doi: 10.1016/j.bbr.2018.06.005. Epub 2018 Jun 8.
• [463] Cyclophilin 1 (Cyp1) mutation ameliorates oxidative stress-induced defects in a Drosophila DJ-1 null mutant.Biochem Biophys Res Commun. 2018 Nov 2;505(3):823-829. doi: 10.1016/j.bbrc.2018.10.014. Epub 2018 Oct 6.
• [464] Discovery of covalent prolyl oligopeptidase boronic ester inhibitors.Eur J Med Chem. 2020 Jan 1;185:111783. doi: 10.1016/j.ejmech.2019.111783. Epub 2019 Oct 18.
• [465] Identification of Differentially Expressed Genes and Long Noncoding RNAs Associated with Parkinson's Disease.Parkinsons Dis. 2019 Feb 5;2019:6078251. doi: 10.1155/2019/6078251. eCollection 2019.
• [466] The Role of Cysteine String Protein Phosphorylation at Serine 10 and 34 by Protein Kinase C for Presynaptic Maintenance.J Neurosci. 2018 Jan 10;38(2):278-290. doi: 10.1523/JNEUROSCI.1649-17.2017. Epub 2017 Nov 22.
• [467] Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.J Neurochem. 2017 Jun;141(5):766-782. doi: 10.1111/jnc.14033. Epub 2017 May 9.
• [468] Could it be that neurodegenerative diseases are infectious?.Rev Neurol (Paris). 2019 Sep-Oct;175(7-8):427-430. doi: 10.1016/j.neurol.2019.07.003. Epub 2019 Jul 26.
• [469] Effects of Silibinin Against Prothrombin Kringle-2-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System In Vivo.J Med Food. 2019 Mar;22(3):277-285. doi: 10.1089/jmf.2018.4266. Epub 2019 Jan 11.
• [470] Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2257-62. doi: 10.1073/pnas.1423573112. Epub 2015 Feb 2.
• [471] Prostaglandin EP2 Receptors Mediate Mesenchymal Stromal Cell-Neuroprotective Effects on Dopaminergic Neurons.Mol Neurobiol. 2018 Jun;55(6):4763-4776. doi: 10.1007/s12035-017-0681-5. Epub 2017 Jul 17.
• [472] Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.Neurobiol Dis. 2019 Apr;124:81-92. doi: 10.1016/j.nbd.2018.11.004. Epub 2018 Nov 10.
• [473] Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.Neurosci Lett. 2018 Feb 14;666:5-10. doi: 10.1016/j.neulet.2017.12.024. Epub 2017 Dec 11.
• [474] PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.J Parkinsons Dis. 2018;8(4):529-537. doi: 10.3233/JPD-181391.
• [475] FYCO1 mediates clearance of -synuclein aggregates through a Rab7-dependent mechanism.J Neurochem. 2018 Aug;146(4):474-492. doi: 10.1111/jnc.14461. Epub 2018 Jul 23.
• [476] PARK2 gene mutations in early onset Parkinson's disease patients of South India.Neurosci Lett. 2012 Aug 15;523(2):145-7. doi: 10.1016/j.neulet.2012.06.062. Epub 2012 Jul 3.
• [477] Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.Mov Disord. 2020 Feb;35(2):245-255. doi: 10.1002/mds.27943. Epub 2019 Dec 16.
• [478] Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease.Neurobiol Aging. 2017 Oct;58:30-33. doi: 10.1016/j.neurobiolaging.2017.06.008. Epub 2017 Jun 19.
• [479] RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease.Lab Invest. 2020 Mar;100(3):503-511. doi: 10.1038/s41374-019-0319-5. Epub 2019 Sep 10.
• [480] miR-135b Plays a Neuroprotective Role by Targeting GSK3 in MPP(+)-Intoxicated SH-SY5Y Cells.Dis Markers. 2017;2017:5806146. doi: 10.1155/2017/5806146. Epub 2017 Apr 17.
• [481] Neuroprotective effects of Bacopa monnieri in Parkinson's disease model.Metab Brain Dis. 2020 Mar;35(3):517-525. doi: 10.1007/s11011-019-00526-w. Epub 2019 Dec 13.
• [482] Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiol Dis. 2017 Dec;108:54-64.
• [483] Antagonization of the Nogo-Receptor 1 Enhances Dopaminergic Fiber Outgrowth of Transplants in a Rat Model of Parkinson's Disease.Front Cell Neurosci. 2017 May 26;11:151. doi: 10.3389/fncel.2017.00151. eCollection 2017.
• [484] Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study.J Neurol. 2019 Mar;266(3):745-754. doi: 10.1007/s00415-019-09197-0. Epub 2019 Jan 11.
• [485] Dysregulated expression of secretogranin III is involved in neurotoxin-induced dopaminergic neuron apoptosis. J Neurosci Res. 2012 Dec;90(12):2237-46. doi: 10.1002/jnr.23121. Epub 2012 Sep 18.
• [486] Factors associated with life satisfaction in Parkinson's disease.Acta Neurol Scand. 2017 Jul;136(1):64-71. doi: 10.1111/ane.12695. Epub 2016 Oct 10.
• [487] Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.Neurotherapeutics. 2019 Apr;16(2):465-479. doi: 10.1007/s13311-018-00699-9.
• [488] SIRP deficiency accelerates the pathologic process in models of Parkinson disease.Glia. 2019 Dec;67(12):2343-2359. doi: 10.1002/glia.23689. Epub 2019 Jul 19.
• [489] Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases.Eur J Pharmacol. 2020 Jan 15;867:172847. doi: 10.1016/j.ejphar.2019.172847. Epub 2019 Dec 5.
• [490] Microglia activation induces oxidative injury and decreases SIRT3 expression in dopaminergic neuronal cells.J Neural Transm (Vienna). 2019 May;126(5):559-568. doi: 10.1007/s00702-019-02005-z. Epub 2019 Apr 19.
• [491] Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors. Sci China Life Sci. 2017 Mar;60(3):249-256.
• [492] S-Nitrosylation of Divalent Metal Transporter 1 Enhances Iron Uptake to Mediate Loss of Dopaminergic Neurons and Motoric Deficit.J Neurosci. 2018 Sep 26;38(39):8364-8377. doi: 10.1523/JNEUROSCI.3262-17.2018. Epub 2018 Aug 13.
• [493] Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010?016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers.Cells. 2019 Feb 11;8(2):151. doi: 10.3390/cells8020151.
• [494] Cholinergic system changes of falls and freezing of gait in Parkinson's disease.Ann Neurol. 2019 Apr;85(4):538-549. doi: 10.1002/ana.25430. Epub 2019 Mar 13.
• [495] Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.Lancet Neurol. 2019 Dec;18(12):1091-1102. doi: 10.1016/S1474-4422(19)30320-5.
• [496] The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4.Sci Rep. 2019 Mar 14;9(1):4515. doi: 10.1038/s41598-019-40808-y.
• [497] Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.Neuroscience. 2020 Jan 1;424:58-71. doi: 10.1016/j.neuroscience.2019.08.046. Epub 2019 Nov 1.
• [498] Modulation of Autophagy by a Small Molecule Inverse Agonist of ERR Is Neuroprotective.Front Mol Neurosci. 2018 Apr 9;11:109. doi: 10.3389/fnmol.2018.00109. eCollection 2018.
• [499] Selective inhibition of mitochondrial sodium-calcium exchanger protects striatal neurons from -synuclein plus rotenone induced toxicity.Cell Death Dis. 2019 Jan 28;10(2):80. doi: 10.1038/s41419-018-1290-6.
• [500] Mitochondrial calcium imbalance in Parkinson's disease.Neurosci Lett. 2018 Jan 10;663:86-90. doi: 10.1016/j.neulet.2017.08.044. Epub 2017 Aug 26.
• [501] Functional MRI to Study Gait Impairment in Parkinson's Disease: a Systematic Review and Exploratory ALE Meta-Analysis.Curr Neurol Neurosci Rep. 2019 Jun 18;19(8):49. doi: 10.1007/s11910-019-0967-2.
• [502] SNAP25 Gene Polymorphisms Protect Against Parkinson's Disease and Modulate Disease Severity in Patients.Mol Neurobiol. 2019 Jun;56(6):4455-4463. doi: 10.1007/s12035-018-1386-0. Epub 2018 Oct 17.
• [503] Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP(+) Parkinson's disease models.J Neurosci Res. 2018 Oct;96(10):1663-1676. doi: 10.1002/jnr.24266. Epub 2018 Jul 13.
• [504] 50-Hz MF does not affect global DNA methylation of SH-SY5Y cells treated with the neurotoxin MPP().Bioelectromagnetics. 2019 Jan;40(1):33-41. doi: 10.1002/bem.22158. Epub 2018 Dec 7.
• [505] Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.Biochem Biophys Res Commun. 2018 Nov 30;506(3):516-521. doi: 10.1016/j.bbrc.2018.10.094. Epub 2018 Oct 22.
• [506] Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.PLoS One. 2019 Aug 12;14(8):e0221051. doi: 10.1371/journal.pone.0221051. eCollection 2019.
• [507] Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain.J Neurochem. 2006 Jul;98(1):34-44. doi: 10.1111/j.1471-4159.2006.03801.x.
• [508] OX40 Gene and Serum Protein Expression Profiles in Patients with Parkinson's Disease.Cell J. 2018 Jul;20(2):177-182. doi: 10.22074/cellj.2018.5038. Epub 2018 Mar 18.
• [509] Kinases in synaptic development and neurological diseases.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt B):343-352. doi: 10.1016/j.pnpbp.2017.12.006. Epub 2017 Dec 11.
• [510] DYT1 mutations in early onset primary torsion dystonia and Parkinson disease patients in Chinese populations.Neurosci Lett. 2009 Jan 30;450(2):117-21. doi: 10.1016/j.neulet.2008.10.111. Epub 2008 Nov 20.
• [511] Therapeutic Effect of Modulating TREM-1 via Anti-inflammation and Autophagy in Parkinson's Disease.Front Neurosci. 2019 Aug 2;13:769. doi: 10.3389/fnins.2019.00769. eCollection 2019.
• [512] TRH Analog, Taltirelin Improves Motor Function of Hemi-PD Rats Without Inducing Dyskinesia via Sustained Dopamine Stimulating Effect.Front Cell Neurosci. 2018 Nov 13;12:417. doi: 10.3389/fncel.2018.00417. eCollection 2018.
• [513] The role of Ca(2+) in cell death caused by oxidative glutamate toxicity and ferroptosis.Cell Calcium. 2018 Mar;70:47-55. doi: 10.1016/j.ceca.2017.05.007. Epub 2017 May 12.
• [514] Long non-coding RNA-p21 regulates MPP(+)-induced neuronal injury by targeting miR-625 and derepressing TRPM2 in SH-SY5Y cells.Chem Biol Interact. 2019 Jul 1;307:73-81. doi: 10.1016/j.cbi.2019.04.017. Epub 2019 Apr 18.
• [515] Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7.J Mol Neurosci. 2016 Dec;60(4):445-452. doi: 10.1007/s12031-016-0828-2. Epub 2016 Sep 8.
• [516] Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease.Biochem Biophys Res Commun. 2020 Jan 22;521(4):868-873. doi: 10.1016/j.bbrc.2019.10.204. Epub 2019 Nov 7.
• [517] Discovery of Potent and Selective A(2A) Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression.ACS Med Chem Lett. 2017 Jul 5;8(8):835-840. doi: 10.1021/acsmedchemlett.7b00175. eCollection 2017 Aug 10.
• [518] Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.Stem Cell Reports. 2019 Mar 5;12(3):518-531. doi: 10.1016/j.stemcr.2019.01.020. Epub 2019 Feb 21.
• [519] Age-dependent accumulation of oligomeric SNCA/-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).Autophagy. 2020 Feb;16(2):347-370. doi: 10.1080/15548627.2019.1603545. Epub 2019 Apr 14.
• [520] Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain.Neurobiol Learn Mem. 2007 Jan;87(1):42-56. doi: 10.1016/j.nlm.2006.05.004. Epub 2006 Jul 7.
• [521] Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.Nat Commun. 2019 Mar 7;10(1):973. doi: 10.1038/s41467-019-08858-y.
• [522] Drosophila Ubiquitin C-Terminal Hydrolase Knockdown Model of Parkinson's Disease.Sci Rep. 2018 Mar 13;8(1):4468. doi: 10.1038/s41598-018-22804-w.
• [523] Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?.Antioxid Redox Signal. 2014 May 1;20(13):1955-60. doi: 10.1089/ars.2013.5737. Epub 2014 Mar 7.
• [524] AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson's Disease.Mol Neurobiol. 2020 Feb;57(2):685-697. doi: 10.1007/s12035-019-01744-0. Epub 2019 Aug 24.
• [525] Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease.Acta Neurol Scand. 2017 Apr;135(4):407-411. doi: 10.1111/ane.12614. Epub 2016 May 31.
• [526] Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies.Hum Mol Genet. 2019 Feb 15;28(4):548-560. doi: 10.1093/hmg/ddy365.
• [527] Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy.Clin Genet. 2018 Jan;93(1):119-125. doi: 10.1111/cge.13095.
• [528] MicroRNA Expression Profiling Screen miR-3557/324-Targeted CaMK/mTOR in the Rat Striatum of Parkinson's Disease in Regular Aerobic Exercise.Biomed Res Int. 2019 Jun 12;2019:7654798. doi: 10.1155/2019/7654798. eCollection 2019.
• [529] A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease.Front Cell Neurosci. 2019 Sep 18;13:421. doi: 10.3389/fncel.2019.00421. eCollection 2019.
• [530] YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity.Neurobiol Dis. 2018 Apr;112:14-23. doi: 10.1016/j.nbd.2018.01.006. Epub 2018 Jan 10.
• [531] The PARK10 gene USP24 is a negative regulator of autophagy and ULK1 protein stability.Autophagy. 2020 Jan;16(1):140-153. doi: 10.1080/15548627.2019.1598754. Epub 2019 Apr 7.
• [532] Caspase-1 Deficiency Alleviates Dopaminergic Neuronal Death via Inhibiting Caspase-7/AIF Pathway in MPTP/p Mouse Model of Parkinson's Disease.Mol Neurobiol. 2017 Aug;54(6):4292-4302. doi: 10.1007/s12035-016-9980-5. Epub 2016 Jun 23.
• [533] Eotaxins and C-C chemokine receptor type 3 in Parkinson's disease.Acta Neurol Belg. 2020 Jun;120(3):589-594. doi: 10.1007/s13760-018-01061-8. Epub 2018 Dec 13.
• [534] Genetics of early-onset Parkinson's disease in Finland: exome sequencing and genome-wide association study.Neurobiol Aging. 2017 May;53:195.e7-195.e10. doi: 10.1016/j.neurobiolaging.2017.01.019. Epub 2017 Feb 2.
• [535] What About the Role of Virtual Reality in Parkinson Disease's Cognitive Rehabilitation? Preliminary Findings From a Randomized Clinical Trial.J Geriatr Psychiatry Neurol. 2018 Nov;31(6):312-318. doi: 10.1177/0891988718807973. Epub 2018 Oct 25.
• [536] The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the Drosophila brain.Autophagy. 2018;14(11):1898-1910. doi: 10.1080/15548627.2018.1491489. Epub 2018 Aug 10.
• [537] Inhibition of Microglia-Derived Oxidative Stress by Ciliary Neurotrophic Factor Protects Dopamine Neurons In Vivo from MPP?Neurotoxicity.Int J Mol Sci. 2018 Nov 10;19(11):3543. doi: 10.3390/ijms19113543.
• [538] Discovery of Novel Cell Surface Markers for Purification of Embryonic Dopamine Progenitors for Transplantation in Parkinson's Disease Animal Models.Mol Cell Proteomics. 2018 Sep;17(9):1670-1684. doi: 10.1074/mcp.RA118.000809. Epub 2018 May 29.
• [539] Biological and Pharmacological Characterization of Benzothiazole-Based CK-1 Inhibitors in Models of Parkinson's Disease.ACS Omega. 2017 Aug 31;2(8):5215-5220. doi: 10.1021/acsomega.7b00869. Epub 2017 Aug 30.
• [540] Optimization of M(4) positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.Bioorg Med Chem Lett. 2017 Jun 1;27(11):2296-2301. doi: 10.1016/j.bmcl.2017.04.043. Epub 2017 Apr 13.
• [541] Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.J Neural Transm (Vienna). 2017 Jun;124(6):739-744. doi: 10.1007/s00702-016-1604-8. Epub 2016 Aug 8.
• [542] Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity.Acta Neuropathol Commun. 2018 Jul 2;6(1):54. doi: 10.1186/s40478-018-0554-9.
• [543] Discovering the 3' UTR-mediated regulation of alpha-synuclein.Nucleic Acids Res. 2017 Dec 15;45(22):12888-12903. doi: 10.1093/nar/gkx1048.
• [544] Prion-like Propagation of -Synuclein Is Regulated by the FcRIIB-SHP-1/2 Signaling Pathway in Neurons.Cell Rep. 2018 Jan 2;22(1):136-148. doi: 10.1016/j.celrep.2017.12.009.
• [545] The role of polyunsaturated fatty acids and GPR40 receptor in brain.Neuropharmacology. 2017 Feb;113(Pt B):639-651. doi: 10.1016/j.neuropharm.2015.05.013. Epub 2015 May 22.
• [546] Changes in self-perception in patients treated with neurostimulating devices.Epilepsy Behav. 2019 Jan;90:25-30. doi: 10.1016/j.yebeh.2018.10.012. Epub 2018 Nov 27.
• [547] Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies.Ann Neurol. 2020 Jan;87(1):139-153. doi: 10.1002/ana.25629. Epub 2019 Nov 18.
• [548] Measuring Anxiety in Older Adults: Development, Diagnostic Accuracy, and Preliminary Validation of a Short-Form of the German Geriatric Anxiety Scale (GAS-G-SF).J Pers Assess. 2020 Mar-Apr;102(2):196-204. doi: 10.1080/00223891.2019.1677679. Epub 2019 Oct 18.
• [549] Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.J Neuroinflammation. 2018 Aug 13;15(1):227. doi: 10.1186/s12974-018-1251-0.
• [550] CIQ, a positive allosteric modulator of GluN2C/D-containing N-methyl-d-aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease.CNS Neurosci Ther. 2018 Feb;24(2):144-153. doi: 10.1111/cns.12784. Epub 2017 Dec 11.
• [551] Effects of Sub-Chronic MPTP Exposure on Behavioral and Cognitive Performance and the Microbiome of Wild-Type and mGlu8 Knockout Female and Male Mice.Front Behav Neurosci. 2018 Jul 18;12:140. doi: 10.3389/fnbeh.2018.00140. eCollection 2018.
• [552] Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease.Front Neurosci. 2018 Nov 15;12:835. doi: 10.3389/fnins.2018.00835. eCollection 2018.
• [553] A natural product from Cannabis sativa subsp. sativa inhibits homeodomain-interacting protein kinase 2 (HIPK2), attenuating MPP(+)-induced apoptosis in human neuroblastoma SH-SY5Y cells.Bioorg Chem. 2017 Jun;72:64-73. doi: 10.1016/j.bioorg.2017.03.011. Epub 2017 Mar 30.
• [554] Type-I interferons mediate the neuroinflammatory response and neurotoxicity induced by rotenone.J Neurochem. 2017 Apr;141(1):75-85. doi: 10.1111/jnc.13940.
• [555] Retromer- and WASH-dependent sorting of nutrient transporters requires a multivalent interaction network with ANKRD50.J Cell Sci. 2017 Jan 15;130(2):382-395. doi: 10.1242/jcs.196758. Epub 2016 Dec 1.
• [556] -Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.EMBO J. 2018 Jun 15;37(12):e98878. doi: 10.15252/embj.201798878. Epub 2018 May 16.
• [557] RNA Sequencing Reveals Small and Variable Contributions of Infectious Agents to Transcriptomes of Postmortem Nervous Tissues From Amyotrophic Lateral Sclerosis, Alzheimer's Disease and Parkinson's Disease Subjects, and Increased Expression of Genes From Disease-Activated Microglia.Front Neurosci. 2019 Mar 28;13:235. doi: 10.3389/fnins.2019.00235. eCollection 2019.
• [558] Parkinson's disease-associated receptor GPR37 is an ER chaperone for LRP6.EMBO Rep. 2017 May;18(5):712-725. doi: 10.15252/embr.201643585. Epub 2017 Mar 24.
• [559] Novel Neuroprotective Effects of Melanin-Concentrating Hormone in Parkinson's Disease.Mol Neurobiol. 2017 Dec;54(10):7706-7721. doi: 10.1007/s12035-016-0258-8. Epub 2016 Nov 14.
• [560] Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide.Biochem Biophys Res Commun. 2017 Nov 18;493(2):879-886. doi: 10.1016/j.bbrc.2017.09.129. Epub 2017 Sep 25.
• [561] Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNF-mediated apoptosis.Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5944-E5953. doi: 10.1073/pnas.1806973115. Epub 2018 Jun 11.
• [562] Neuroprotective Effects of Echinacoside on Regulating the Stress-Active p38MAPK and NF-B p52 Signals in the Mice Model of Parkinson's Disease.Neurochem Res. 2017 Apr;42(4):975-985. doi: 10.1007/s11064-016-2130-7. Epub 2016 Dec 15.
• [563] Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.Sci Rep. 2017 Feb 21;7:42880. doi: 10.1038/srep42880.
• [564] Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation.J Parkinsons Dis. 2017;7(4):645-652. doi: 10.3233/JPD-171189.
• [565] Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.J Neuroinflammation. 2018 Sep 20;15(1):272. doi: 10.1186/s12974-018-1305-3.
• [566] Anti-Inflammatory and Neuroprotective Effects of PGE(2) EP4 Signaling in Models of Parkinson's Disease.J Neuroimmune Pharmacol. 2017 Jun;12(2):292-304. doi: 10.1007/s11481-016-9713-6. Epub 2016 Oct 12.
• [567] Treating sleep apnea in Parkinson's disease with C-PAP: feasibility concerns and effects on cognition and alertness.Sleep Med. 2017 May;33:114-118. doi: 10.1016/j.sleep.2017.01.009. Epub 2017 Jan 27.
• [568] Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.J Neurosci. 2017 Sep 27;37(39):9361-9379. doi: 10.1523/JNEUROSCI.0084-17.2017. Epub 2017 Aug 21.
• [569] MicroRNA-128 Protects Dopamine Neurons from Apoptosis and Upregulates the Expression of Excitatory Amino Acid Transporter 4 in Parkinson's Disease by Binding to AXIN1.Cell Physiol Biochem. 2018;51(5):2275-2289. doi: 10.1159/000495872. Epub 2018 Dec 7.
• [570] Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.Expert Opin Investig Drugs. 2017 Oct;26(10):1163-1173. doi: 10.1080/13543784.2017.1371133. Epub 2017 Aug 29.
• [571] Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK/STAT3 pathway in interleukin 6-treated PC-12 cells.Neurosci Lett. 2018 Jan 1;662:1-5. doi: 10.1016/j.neulet.2017.10.001. Epub 2017 Oct 4.
• [572] GAT-3 Dysfunction Generates Tonic Inhibition in External Globus Pallidus Neurons in Parkinsonian Rodents.Cell Rep. 2018 May 8;23(6):1678-1690. doi: 10.1016/j.celrep.2018.04.014.
• [573] Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.J Clin Invest. 2017 Feb 1;127(2):720-734. doi: 10.1172/JCI90132. Epub 2017 Jan 23.
• [574] Expanding the ubiquitin code through post-translational modification.EMBO Rep. 2015 Sep;16(9):1071-83. doi: 10.15252/embr.201540891. Epub 2015 Aug 12.
• [575] Identification of transketolase as a target of PARIS in substantia nigra.Biochem Biophys Res Commun. 2017 Nov 18;493(2):1050-1056. doi: 10.1016/j.bbrc.2017.09.090. Epub 2017 Sep 20.
• [576] Bax-inhibitor-1 knockdown phenotypes are suppressed by Buffy and exacerbate degeneration in a Drosophila model of Parkinson disease.PeerJ. 2017 Feb 21;5:e2974. doi: 10.7717/peerj.2974. eCollection 2017.
• [577] Brown adipose tissue activation in a rat model of Parkinson's disease.Am J Physiol Endocrinol Metab. 2017 Dec 1;313(6):E731-E736. doi: 10.1152/ajpendo.00049.2017. Epub 2017 Aug 29.
• [578] SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder.Neurol Sci. 2017 Jul;38(7):1233-1240. doi: 10.1007/s10072-017-2945-2. Epub 2017 Apr 13.
• [579] Downregulation of neuronal vasoactive intestinal polypeptide in Parkinson's disease and chronic constipation.Neurogastroenterol Motil. 2017 May;29(5):10.1111/nmo.12995. doi: 10.1111/nmo.12995. Epub 2016 Nov 27.
• [580] Long-term exposure to air pollution and the incidence of Parkinson's disease: A nested case-control study.PLoS One. 2017 Aug 15;12(8):e0182834. doi: 10.1371/journal.pone.0182834. eCollection 2017.
• [581] Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression.J Parkinsons Dis. 2012;2(1):41-6. doi: 10.3233/JPD-2012-11059.
• [582] Genetics of Parkinson disease and other movement disorders.Curr Opin Neurol. 2012 Aug;25(4):466-74. doi: 10.1097/WCO.0b013e3283547627.
• [583] Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease.Neurochem Int. 2011 Aug;59(1):73-80. doi: 10.1016/j.neuint.2011.05.006. Epub 2011 Jun 6.
• [584] Associations of rs823128, rs1572931, and rs823156 polymorphisms with reduced Parkinson's disease risks.Neuroreport. 2017 Sep 27;28(14):936-941. doi: 10.1097/WNR.0000000000000846.
• [585] The critical role of Nramp1 in degrading -synuclein oligomers in microglia under iron overload condition.Neurobiol Dis. 2017 Aug;104:61-72. doi: 10.1016/j.nbd.2017.05.001. Epub 2017 May 2.
• [586] Mutation analysis of patients with neurodegenerative disorders using NeuroX array.Neurobiol Aging. 2015 Jan;36(1):545.e9-14. doi: 10.1016/j.neurobiolaging.2014.07.038. Epub 2014 Aug 1.
• [587] Wilson's disease and other neurological copper disorders.Lancet Neurol. 2015 Jan;14(1):103-13. doi: 10.1016/S1474-4422(14)70190-5.
• [588] Genetic deletion of vesicular glutamate transporter in dopamine neurons increases vulnerability to MPTP-induced neurotoxicity in mice.Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):E11532-E11541. doi: 10.1073/pnas.1800886115. Epub 2018 Nov 15.
• [589] Carnitine levels and mutations in the SLC22A5 gene in Faroes patients with Parkinson's disease.Neurosci Lett. 2018 May 14;675:116-119. doi: 10.1016/j.neulet.2018.03.064. Epub 2018 Mar 31.
• [590] Parkinson's disease-related DJ-1 modulates the expression of uncoupling protein 4 against oxidative stress.J Neurochem. 2018 May;145(4):312-322. doi: 10.1111/jnc.14297. Epub 2018 Apr 15.
• [591] Genome-wide association study of Parkinson's disease in East Asians.Hum Mol Genet. 2017 Jan 1;26(1):226-232. doi: 10.1093/hmg/ddw379.
• [592] Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models.Front Mol Neurosci. 2018 Jan 26;11:21. doi: 10.3389/fnmol.2018.00021. eCollection 2018.
• [593] Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese.Neurotoxicology. 2014 Sep;44:314-25. doi: 10.1016/j.neuro.2014.08.006. Epub 2014 Aug 19.
• [594] Functional Characterization of Novel Circular RNA Molecule, circzip-2 and Its Synthesizing Gene zip-2 in C. elegans Model of Parkinson's Disease.Mol Neurobiol. 2018 Aug;55(8):6914-6926. doi: 10.1007/s12035-018-0903-5. Epub 2018 Jan 23.
• [595] Detection and interpretation of shared genetic influences on 42 human traits.Nat Genet. 2016 Jul;48(7):709-17. doi: 10.1038/ng.3570. Epub 2016 May 16.
• [596] Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.
• [597] Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.Ann Neurol. 2012 Mar;71(3):370-84. doi: 10.1002/ana.22687.
• [598] Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease.Protoplasma. 2017 Jan;254(1):33-42. doi: 10.1007/s00709-015-0930-2. Epub 2016 Jan 29.
• [599] NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.Cell Death Dis. 2018 Jun 25;9(7):725. doi: 10.1038/s41419-018-0775-7.
• [600] L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease.Ann Neurol. 2004 Jul;56(1):51-60. doi: 10.1002/ana.20133.
• [601] The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds.Free Radic Biol Med. 2004 Sep 15;37(6):839-49. doi: 10.1016/j.freeradbiomed.2004.06.017.
• [602] Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese.Sci Rep. 2015 Oct 28;5:15891. doi: 10.1038/srep15891.
• [603] Polyamine pathway contributes to the pathogenesis of Parkinson disease.Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16970-5. doi: 10.1073/pnas.1011751107. Epub 2010 Sep 13.
• [604] Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.Mol Neurodegener. 2016 Apr 19;11:29. doi: 10.1186/s13024-016-0097-0.
• [605] Multifactor dimensionality reduction analysis to elucidate the cross-talk between one-carbon and xenobiotic metabolic pathways in multi-disease models.Mol Biol Rep. 2015 Jul;42(7):1211-24. doi: 10.1007/s11033-015-3856-z. Epub 2015 Feb 4.
• [606] Citrullination Inactivates Nicotinamide- N-methyltransferase.ACS Chem Biol. 2018 Sep 21;13(9):2663-2672. doi: 10.1021/acschembio.8b00578. Epub 2018 Aug 8.
• [607] Genetic causes of Parkinson's disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPR.BMC Med Genet. 2016 Sep 9;17(1):65. doi: 10.1186/s12881-016-0327-x.
• [608] Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A(2A) receptor over-activation in a rat model of Parkinson's disease.Br J Pharmacol. 2019 Sep;176(18):3666-3680. doi: 10.1111/bph.14771. Epub 2019 Aug 1.
• [609] High and complementary expression patterns of alcohol and aldehyde dehydrogenases in the gastrointestinal tract: implications for Parkinson's disease.FEBS J. 2007 Mar;274(5):1212-23. doi: 10.1111/j.1742-4658.2007.05665.x. Epub 2007 Jan 25.
• [610] ALDH1A1 regulates postsynaptic -opioid receptor expression in dorsal striatal projection neurons and mitigates dyskinesia through transsynaptic retinoic acid signaling.Sci Rep. 2019 Mar 5;9(1):3602. doi: 10.1038/s41598-019-40326-x.
• [611] Parkinson's disease risk factors: genetic, environmental, or both?.Neurol Res. 2005 Mar;27(2):206-8. doi: 10.1179/016164105X22057.
• [612] Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease.Neurochem Int. 2017 Nov;110:14-24. doi: 10.1016/j.neuint.2017.08.003. Epub 2017 Aug 5.
• [613] Tat-Frataxin protects dopaminergic neuronal cells against MPTP-induced toxicity in a mouse model of Parkinson's disease.Biochimie. 2012 Nov;94(11):2448-56. doi: 10.1016/j.biochi.2012.07.005. Epub 2012 Jul 15.
• [614] Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling.Neurobiol Aging. 2019 Jan;73:123-134. doi: 10.1016/j.neurobiolaging.2018.09.018. Epub 2018 Sep 25.
• [615] An Enriched Environment Ameliorates Oxidative Stress and Olfactory Dysfunction in Parkinson's Disease with -Synucleinopathy.Cell Transplant. 2018 May;27(5):831-839. doi: 10.1177/0963689717742662. Epub 2018 Apr 30.
• [616] Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson's Disease.Front Neurol. 2018 Apr 6;9:222. doi: 10.3389/fneur.2018.00222. eCollection 2018.
• [617] Methionine sulfoxide reductase (Msr) dysfunction in human brain disease.Free Radic Res. 2019 Dec;53(11-12):1144-1154. doi: 10.1080/10715762.2019.1662899. Epub 2019 Nov 27.
• [618] NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis.Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):937-46. doi: 10.1080/17425255.2016.1192127. Epub 2016 Jun 3.
• [619] MISTERMINATE Mechanistically Links Mitochondrial Dysfunction with Proteostasis Failure.Mol Cell. 2019 Aug 22;75(4):835-848.e8. doi: 10.1016/j.molcel.2019.06.031. Epub 2019 Aug 1.
• [620] Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
• [621] The prevalence of psychological distress in Parkinson's disease patients: The brief symptom inventory (BSI-18) versus the Hopkins symptom checklist (SCL-90-R).Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:96-101. doi: 10.1016/j.pnpbp.2018.07.012. Epub 2018 Jul 12.
• [622] Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.Eur J Clin Pharmacol. 2012 Nov;68(11):1493-9. doi: 10.1007/s00228-012-1281-y. Epub 2012 Apr 15.
• [623] Depressive symptoms predict incident chronic disease burden 10years later: Findings from the English Longitudinal Study of Ageing (ELSA).J Psychosom Res. 2018 Oct;113:30-36. doi: 10.1016/j.jpsychores.2018.07.009. Epub 2018 Jul 21.
• [624] Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models.Exp Mol Med. 2018 Aug 17;50(8):1-13. doi: 10.1038/s12276-018-0124-z.
• [625] Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson's disease: A meta-analysis.Parkinsonism Relat Disord. 2017 Sep;42:1-11. doi: 10.1016/j.parkreldis.2017.06.006. Epub 2017 Jun 15.
• [626] Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex.J Parkinsons Dis. 2012;2(1):67-76. doi: 10.3233/JPD-2012-11074.
• [627] Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.J Neurochem. 2002 Oct;83(2):320-30. doi: 10.1046/j.1471-4159.2002.01118.x.
• [628] Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia.Hum Genet. 2004 Jun;115(1):29-35. doi: 10.1007/s00439-004-1123-9. Epub 2004 Apr 24.
• [629] Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4. Epub 2014 Feb 14.
• [630] Intermediate alleles at the FRAXA and FRAXE loci in Parkinson's disease.Parkinsonism Relat Disord. 2011 May;17(4):281-4. doi: 10.1016/j.parkreldis.2010.12.013. Epub 2011 Jan 22.
• [631] Mask loss-of-function rescues mitochondrial impairment and muscle degeneration of Drosophila pink1 and parkin mutants.Hum Mol Genet. 2015 Jun 1;24(11):3272-85. doi: 10.1093/hmg/ddv081. Epub 2015 Mar 5.
• [632] Association of amyloid precursor protein-binding protein, family B, member 1 with nicotine dependence in African and European American smokers.Hum Genet. 2008 Nov;124(4):393-8. doi: 10.1007/s00439-008-0558-9. Epub 2008 Sep 7.
• [633] GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.Biochemistry. 2007 Feb 6;46(5):1380-8. doi: 10.1021/bi061960m.
• [634] GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.
• [635] Ariadne-1: a vital Drosophila gene is required in development and defines a new conserved family of ring-finger proteins.Genetics. 2000 Jul;155(3):1231-44. doi: 10.1093/genetics/155.3.1231.
• [636] The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to -synuclein toxicity in Parkinson's disease models.Cell Death Differ. 2013 Mar;20(3):465-77. doi: 10.1038/cdd.2012.142. Epub 2012 Nov 16.
• [637] Dopamine D1 receptor activation improves adult hippocampal neurogenesis and exerts anxiolytic and antidepressant-like effect via activation of Wnt/-catenin pathways in rat model of Parkinson's disease.Neurochem Int. 2019 Jan;122:170-186. doi: 10.1016/j.neuint.2018.11.020. Epub 2018 Nov 28.
• [638] The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease.J Neurol. 2015 Nov;262(11):2443-7. doi: 10.1007/s00415-015-7868-3. Epub 2015 Aug 2.
• [639] Elucidating Conserved Transcriptional Networks Underlying Pesticide Exposure and Parkinson's Disease: A Focus on Chemicals of Epidemiological Relevance.Front Genet. 2019 Jan 25;9:701. doi: 10.3389/fgene.2018.00701. eCollection 2018.
• [640] HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type.Neurology. 1984 Mar;34(3):310-4. doi: 10.1212/wnl.34.3.310.
• [641] SNPs in CAST are associated with Parkinson disease: a confirmation study.Am J Med Genet B Neuropsychiatr Genet. 2010 Jun 5;153B(4):973-9. doi: 10.1002/ajmg.b.31061.
• [642] Investigation of the PARK10 gene in Parkinson disease.Ann Hum Genet. 2007 Sep;71(Pt 5):639-47. doi: 10.1111/j.1469-1809.2007.00353.x. Epub 2007 Mar 27.
• [643] CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking.Neurobiol Aging. 2014 Sep;35(9):2179.e1-6. doi: 10.1016/j.neurobiolaging.2014.03.014. Epub 2014 Mar 20.
• [644] Glutathione-S-transferase-1 and interleukin-1beta gene polymorphisms in Japanese patients with Parkinson's disease.Mov Disord. 2005 Jul;20(7):901-2. doi: 10.1002/mds.20477.
• [645] Plasma-based circulating MicroRNA biomarkers for Parkinson's disease.J Parkinsons Dis. 2012;2(4):321-31. doi: 10.3233/JPD-012144.
• [646] Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease.Mol Cell Proteomics. 2008 Jul;7(7):1191-203. doi: 10.1074/mcp.M700467-MCP200. Epub 2008 Mar 18.
• [647] Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.J Biol Chem. 2006 Jun 16;281(24):16193-6. doi: 10.1074/jbc.C600041200. Epub 2006 May 3.
• [648] A high-efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats.Cell Transplant. 2015;24(11):2251-62. doi: 10.3727/096368914X685078. Epub 2014 Oct 6.
• [649] Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism.Genet Med. 2011 May;13(5):392-9. doi: 10.1097/GIM.0b013e3182064362.
• [650] Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study.Parkinsonism Relat Disord. 2009 Jul;15(6):430-4. doi: 10.1016/j.parkreldis.2008.11.011. Epub 2009 Feb 4.
• [651] CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients.Neurobiol Aging. 2017 Nov;59:1-9. doi: 10.1016/j.neurobiolaging.2017.06.028. Epub 2017 Jul 11.
• [652] Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease.Neurogenetics. 2006 Mar;7(1):1-11. doi: 10.1007/s10048-005-0020-2. Epub 2006 Jan 12.
• [653] Peripheral assessment of the genes AQP4, PBP and TH in patients with Parkinson's disease.Neurochem Res. 2012 Mar;37(3):512-5. doi: 10.1007/s11064-011-0637-5. Epub 2011 Nov 15.
• [654] Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.Mov Disord. 2012 Jul;27(8):1004-11. doi: 10.1002/mds.25005. Epub 2012 Apr 23.
• [655] Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease.Brain. 2012 Jul;135(Pt 7):2058-73. doi: 10.1093/brain/aws133. Epub 2012 Jun 19.
• [656] Altered machinery of protein synthesis is region- and stage-dependent and is associated with -synuclein oligomers in Parkinson's disease.Acta Neuropathol Commun. 2015 Dec 1;3:76. doi: 10.1186/s40478-015-0257-4.
• [657] Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease.Am J Hum Genet. 2005 Aug;77(2):252-64. doi: 10.1086/432588. Epub 2005 Jun 28.
• [658] EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?.Neurobiol Aging. 2012 Sep;33(9):2233.e1-2233.e5. doi: 10.1016/j.neurobiolaging.2012.05.006. Epub 2012 Jun 1.
• [659] Endonuclease G mediates -synuclein cytotoxicity during Parkinson's disease.EMBO J. 2013 Nov 27;32(23):3041-54. doi: 10.1038/emboj.2013.228. Epub 2013 Oct 15.
• [660] Genetic and phenotypic characterization of complex hereditary spastic paraplegia.Brain. 2016 Jul;139(Pt 7):1904-18. doi: 10.1093/brain/aww111. Epub 2016 May 23.
• [661] FADD: A link between TNF family receptors and caspases in Parkinson's disease.Neurology. 2002 Jan 22;58(2):308-10. doi: 10.1212/wnl.58.2.308.
• [662] Genetic analysis of the FBXO42 gene in Chinese Han patients with Parkinson's disease.BMC Neurol. 2013 Sep 25;13:125. doi: 10.1186/1471-2377-13-125.
• [663] Altered expression of CG5961, a putative Drosophila melanogaster homologue of FBXO9, provides a new model of Parkinson disease.Genet Mol Res. 2016 May 9;15(2). doi: 10.4238/gmr.15028579.
• [664] Neurotrophic support of midbrain dopaminergic neurons.Adv Exp Med Biol. 2009;651:73-80. doi: 10.1007/978-1-4419-0322-8_7.
• [665] Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients.J Neuroimmunol. 2008 Sep 15;201-202:227-36. doi: 10.1016/j.jneuroim.2008.06.019. Epub 2008 Aug 8.
• [666] The role of the GABA(B) receptor and calcium channels in a Drosophila model of Parkinson's Disease.Neurosci Lett. 2012 May 16;516(2):167-70. doi: 10.1016/j.neulet.2012.03.034. Epub 2012 Mar 21.
• [667] A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson's disease.Hum Mol Genet. 2015 Dec 1;24(23):6711-20. doi: 10.1093/hmg/ddv376. Epub 2015 Sep 11.
• [668] The human GLUD2 glutamate dehydrogenase and its regulation in health and disease.Neurochem Int. 2011 Sep;59(4):495-509. doi: 10.1016/j.neuint.2011.03.015. Epub 2011 Mar 21.
• [669] Mutations in GNAL: a novel cause of craniocervical dystonia.JAMA Neurol. 2014 Apr;71(4):490-4. doi: 10.1001/jamaneurol.2013.4677.
• [670] GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients.Front Neurosci. 2019 Jul 5;13:697. doi: 10.3389/fnins.2019.00697. eCollection 2019.
• [671] Marginal association between SNP rs2046571 of the HAS2 gene and Parkinson's disease in the Chinese female population.Neurosci Lett. 2013 Sep 27;552:58-61. doi: 10.1016/j.neulet.2013.07.031. Epub 2013 Jul 31.
• [672] Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease.Free Radic Biol Med. 2010 Jan 15;48(2):332-41. doi: 10.1016/j.freeradbiomed.2009.11.004. Epub 2009 Nov 11.
• [673] Association between HLA rs3129882 polymorphism and Parkinson's disease: a meta-analysis.Eur Rev Med Pharmacol Sci. 2015;19(3):423-32.
• [674] Genetic variation associated with the occurrence and progression of neurological disorders.Neurotoxicology. 2017 Jul;61:243-264. doi: 10.1016/j.neuro.2016.09.018. Epub 2016 Oct 3.
• [675] Gene expression profiling combined with bioinformatics analysis identify biomarkers for Parkinson disease.PLoS One. 2012;7(12):e52319. doi: 10.1371/journal.pone.0052319. Epub 2012 Dec 28.
• [676] Analysis of heat-shock protein 70 gene polymorphisms and the risk of Parkinson's disease.Hum Genet. 2004 Feb;114(3):236-41. doi: 10.1007/s00439-003-1050-1. Epub 2003 Nov 6.
• [677] Association analyses of variants of SIPA1L2, MIR4697, GCH1, VPS13C, and DDRGK1 with Parkinson's disease in East Asians.Neurobiol Aging. 2018 Aug;68:159.e7-159.e14. doi: 10.1016/j.neurobiolaging.2018.03.005. Epub 2018 Mar 10.
• [678] Genome-wide variant by serum urate interaction in Parkinson's disease.Ann Neurol. 2015 Nov;78(5):731-41. doi: 10.1002/ana.24504. Epub 2015 Aug 29.
• [679] Multiple risk factors for Parkinson's disease.J Neurol Sci. 2004 Feb 15;217(2):169-74. doi: 10.1016/j.jns.2003.09.014.
• [680] Kinesin light chain 1 gene haplotypes in three conformational diseases.Neuromolecular Med. 2010 Sep;12(3):229-36. doi: 10.1007/s12017-009-8103-0. Epub 2009 Nov 13.
• [681] Identifying rare and common disease associated variants in genomic data using Parkinson's disease as a model.J Biomed Sci. 2014 Aug 30;21(1):88. doi: 10.1186/s12929-014-0088-9.
• [682] Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.Clin Neuropharmacol. 1996 Jun;19(3):213-21. doi: 10.1097/00002826-199619030-00003.
• [683] Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease.J Neural Transm (Vienna). 2010 Dec;117(12):1387-93. doi: 10.1007/s00702-010-0509-1. Epub 2010 Nov 11.
• [684] Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8.
• [685] Identification of genetic modifiers of age-at-onset for familial Parkinson's disease.Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11.
• [686] APOE and LRPAP1 gene polymorphism and risk of Parkinson's disease.Neurol Sci. 2014 Jul;35(7):1075-81. doi: 10.1007/s10072-014-1651-6. Epub 2014 Feb 7.
• [687] Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease.Hum Genet. 2005 Jun;117(1):27-33. doi: 10.1007/s00439-005-1259-2. Epub 2005 Apr 13.
• [688] Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease.Brain Res. 2011 Jun 7;1394:105-11. doi: 10.1016/j.brainres.2011.04.013. Epub 2011 Apr 13.
• [689] Microtubule-associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation.J Biol Chem. 2011 Mar 25;286(12):10367-77. doi: 10.1074/jbc.M110.206532. Epub 2011 Jan 24.
• [690] MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2.J Neurochem. 2010 Mar;112(6):1593-604. doi: 10.1111/j.1471-4159.2010.06568.x. Epub 2010 Jan 7.
• [691] A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690.
• [692] Association between MDR1 gene polymorphisms and Parkinson's disease in Asian and Caucasian populations: a meta-analysis.J Neurol Sci. 2016 Sep 15;368:255-62. doi: 10.1016/j.jns.2016.07.041. Epub 2016 Jul 18.
• [693] Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases.Int J Mol Sci. 2019 Jun 13;20(12):2876. doi: 10.3390/ijms20122876.
• [694] Targeted discovery and validation of plasma biomarkers of Parkinson's disease.J Proteome Res. 2014 Nov 7;13(11):4535-45. doi: 10.1021/pr500421v. Epub 2014 Jun 11.
• [695] The GBA, DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients.Neurosci Lett. 2016 May 16;621:133-136. doi: 10.1016/j.neulet.2016.04.014. Epub 2016 Apr 13.
• [696] Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.Hum Gene Ther. 2009 Aug;20(8):897-907. doi: 10.1089/hum.2009.023.
• [697] Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases.Acta Neurobiol Exp (Wars). 2007;67(2):113-29. doi: 10.55782/ane-2007-1639.
• [698] Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease.Neurogenetics. 2011 Nov;12(4):325-32. doi: 10.1007/s10048-011-0293-6. Epub 2011 Aug 12.
• [699] Genes associated with the progression of neurofibrillary tangles in Alzheimer's disease.Transl Psychiatry. 2014 Jun 10;4(6):e396. doi: 10.1038/tp.2014.35.
• [700] Myocilin variants in Indian patients with open-angle glaucoma.Arch Ophthalmol. 2007 Jun;125(6):823-9. doi: 10.1001/archopht.125.6.823.
• [701] Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases.J Neurol Sci. 1999 Jan 15;162(2):133-51. doi: 10.1016/s0022-510x(98)00297-4.
• [702] Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase.Hum Gene Ther. 2000 May 1;11(7):995-1004. doi: 10.1089/10430340050015301.
• [703] Differential -synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity.Acta Neuropathol. 2018 Jun;135(6):855-875. doi: 10.1007/s00401-018-1829-8. Epub 2018 Mar 3.
• [704] Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells.Oncol Rep. 2014 Jan;31(1):73-8. doi: 10.3892/or.2013.2801. Epub 2013 Oct 22.
• [705] Phosphorylated NUB1 distinguishes -synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.Brain Pathol. 2019 Nov;29(6):803-812. doi: 10.1111/bpa.12728. Epub 2019 May 17.
• [706] Association Analysis of Proteasome Subunits and Transporter Associated with Antigen Processing on Chinese Patients with Parkinson's Disease.Chin Med J (Engl). 2016 May 5;129(9):1053-8. doi: 10.4103/0366-6999.180513.
• [707] The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease.Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):216-22. doi: 10.1002/ajmg.b.30593.
• [708] Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.J Neurochem. 2015 Dec;135(6):1242-56. doi: 10.1111/jnc.13369. Epub 2015 Oct 19.
• [709] Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients.Genet Test Mol Biomarkers. 2010 Dec;14(6):793-6. doi: 10.1089/gtmb.2010.0076. Epub 2010 Oct 12.
• [710] Aggresome-related biogenesis of Lewy bodies.Eur J Neurosci. 2002 Dec;16(11):2136-48. doi: 10.1046/j.1460-9568.2002.02301.x.
• [711] Alteration of mitochondrial protein PDHA1 in Lewy body disease and PARK14.Biochem Biophys Res Commun. 2017 Aug 5;489(4):439-444. doi: 10.1016/j.bbrc.2017.05.162. Epub 2017 May 28.
• [712] Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.Brain Res. 2004 Oct 1;1022(1-2):164-72. doi: 10.1016/j.brainres.2004.07.026.
• [713] PEP-1-PEA-15 protects against toxin-induced neuronal damage in a mouse model of Parkinson's disease.Biochim Biophys Acta. 2014 Jun;1840(6):1686-700. doi: 10.1016/j.bbagen.2014.01.004. Epub 2014 Jan 8.
• [714] Peptidoglycan recognition protein genes and risk of Parkinson's disease.Mov Disord. 2014 Aug;29(9):1171-80. doi: 10.1002/mds.25895. Epub 2014 May 17.
• [715] Phactr2 and Parkinson's disease.Neurosci Lett. 2009 Mar 27;453(1):9-11. doi: 10.1016/j.neulet.2009.02.009. Epub 2009 Feb 10.
• [716] Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism.FASEB J. 2006 Nov;20(13):2302-12. doi: 10.1096/fj.06-6092com.
• [717] Age and -synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling.Neurobiol Dis. 2011 Nov;44(2):215-22. doi: 10.1016/j.nbd.2011.07.003. Epub 2011 Jul 18.
• [718] Rare variants in PLXNA4 and Parkinson's disease.PLoS One. 2013 Nov 11;8(11):e79145. doi: 10.1371/journal.pone.0079145. eCollection 2013.
• [719] An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.J Neurosci. 2007 Aug 1;27(31):8314-23. doi: 10.1523/JNEUROSCI.1972-07.2007.
• [720] Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease.J Mol Neurosci. 2013 Nov;51(3):863-70. doi: 10.1007/s12031-013-0075-8. Epub 2013 Jul 31.
• [721] A ratiometric two-photon fluorescent probe reveals reduction in mitochondrial H2S production in Parkinson's disease gene knockout astrocytes.J Am Chem Soc. 2013 Jul 3;135(26):9915-23. doi: 10.1021/ja404004v. Epub 2013 Jun 18.
• [722] Variants in estrogen-related genes and risk of Parkinson's disease.Mov Disord. 2011 Jun;26(7):1234-42. doi: 10.1002/mds.23604. Epub 2011 Apr 5.
• [723] Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia.Neurology. 2014 Sep 23;83(13):1155-62. doi: 10.1212/WNL.0000000000000821. Epub 2014 Aug 22.
• [724] Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration.Nat Commun. 2016 Oct 5;7:12932. doi: 10.1038/ncomms12932.
• [725] PSMC1 Gene in Parkinson's Disease.Eur Neurol. 2012;68(4):193-8. doi: 10.1159/000339003. Epub 2012 Aug 29.
• [726] n-butylidenephthalide protects against dopaminergic neuron degeneration and -synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.PLoS One. 2014 Jan 8;9(1):e85305. doi: 10.1371/journal.pone.0085305. eCollection 2014.
• [727] STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1202-7. doi: 10.1073/pnas.1417423112. Epub 2015 Jan 12.
• [728] Low-density lipoprotein receptor-related protein (LRP) gene 766T polymorphism and Parkinson's disease.Mov Disord. 1999 Sep;14(5):839-41. doi: 10.1002/1531-8257(199909)14:5<839::aid-mds1019>3.0.co;2-v.
• [729] GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10907-12. doi: 10.1073/pnas.0802437105. Epub 2008 Jul 31.
• [730] Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22474-9. doi: 10.1073/pnas.0912193106. Epub 2009 Dec 10.
• [731] Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1.EMBO J. 2015 Nov 12;34(22):2840-61. doi: 10.15252/embj.201591593. Epub 2015 Oct 15.
• [732] Genome-wide assessment of Parkinson's disease in a Southern Spanish population.Neurobiol Aging. 2016 Sep;45:213.e3-213.e9. doi: 10.1016/j.neurobiolaging.2016.06.001. Epub 2016 Jun 11.
• [733] An association analysis of the rs1572931 polymorphism of the RAB7L1 gene in Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in China.Eur J Neurol. 2014 Oct;21(10):1337-43. doi: 10.1111/ene.12490. Epub 2014 Jul 12.
• [734] Regulator of G-protein signaling-10 negatively regulates NF-B in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats.J Neurosci. 2011 Aug 17;31(33):11879-88. doi: 10.1523/JNEUROSCI.1002-11.2011.
• [735] SNPs in axon guidance pathway genes and susceptibility for Parkinson's disease in the Korean population.J Hum Genet. 2011 Feb;56(2):125-9. doi: 10.1038/jhg.2010.130. Epub 2010 Nov 18.
• [736] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [737] GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.PLoS One. 2016 Mar 3;11(3):e0149349. doi: 10.1371/journal.pone.0149349. eCollection 2016.
• [738] Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells.Autophagy. 2020 Jan;16(1):28-37. doi: 10.1080/15548627.2019.1630223. Epub 2019 Jun 18.
• [739] Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons.Cell Stem Cell. 2019 Oct 3;25(4):514-530.e8. doi: 10.1016/j.stem.2019.08.013. Epub 2019 Sep 19.
• [740] Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra.Mov Disord. 2005 Oct;20(10):1299-309. doi: 10.1002/mds.20573.
• [741] A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity.J Cell Sci. 2013 Feb 1;126(Pt 3):789-802. doi: 10.1242/jcs.114439. Epub 2012 Dec 13.
• [742] Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.EMBO J. 2014 Oct 16;33(20):2314-31. doi: 10.15252/embj.201487807. Epub 2014 Sep 8.
• [743] SEPT14 Is Associated with a Reduced Risk for Parkinson's Disease and Expressed in Human Brain.J Mol Neurosci. 2016 Jul;59(3):343-50. doi: 10.1007/s12031-016-0738-3. Epub 2016 Apr 26.
• [744] Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.Trends Neurosci. 2019 Feb;42(2):140-149. doi: 10.1016/j.tins.2018.11.001. Epub 2018 Nov 30.
• [745] Proapoptotic Nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model.J Biol Chem. 2007 Jan 12;282(2):1288-95. doi: 10.1074/jbc.M607038200. Epub 2006 Nov 9.
• [746] Lentiviral Vector-Mediated SHC3 Silencing Exacerbates Oxidative Stress Injury in Nigral Dopamine Neurons by Regulating the PI3K-AKT-FoxO Signaling Pathway in Rats with Parkinson's Disease.Cell Physiol Biochem. 2018;49(3):971-984. doi: 10.1159/000493228. Epub 2018 Sep 5.
• [747] SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.PLoS One. 2013 Oct 30;8(10):e77711. doi: 10.1371/journal.pone.0077711. eCollection 2013.
• [748] Molecular markers of early Parkinson's disease based on gene expression in blood.Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. doi: 10.1073/pnas.0610204104. Epub 2007 Jan 10.
• [749] CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.Mol Cell. 2002 Jul;10(1):55-67. doi: 10.1016/s1097-2765(02)00583-x.
• [750] PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease.Neurology. 2015 Mar 10;84(10):972-80. doi: 10.1212/WNL.0000000000001332. Epub 2015 Feb 6.
• [751] Genomic determinants of motor and cognitive outcomes in Parkinson's disease.Parkinsonism Relat Disord. 2012 Aug;18(7):881-6. doi: 10.1016/j.parkreldis.2012.04.025. Epub 2012 May 30.
• [752] Tef polymorphism is associated with sleep disturbances in patients with Parkinson's disease.Sleep Med. 2012 Mar;13(3):297-300. doi: 10.1016/j.sleep.2011.06.023. Epub 2012 Jan 17.
• [753] Novel THAP1 sequence variants in primary dystonia.Neurology. 2010 Jan 19;74(3):229-38. doi: 10.1212/WNL.0b013e3181ca00ca.
• [754] NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease.PLoS One. 2011;6(7):e21907. doi: 10.1371/journal.pone.0021907. Epub 2011 Jul 1.
• [755] Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinsons disease.Mov Disord. 2014 Apr;29(4):518-26. doi: 10.1002/mds.25729.
• [756] Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis.PLoS One. 2010 Jun 22;5(6):e11252. doi: 10.1371/journal.pone.0011252.
• [757] The role of the mitochondrial NCX in the mechanism of neurodegeneration in Parkinson's disease.Adv Exp Med Biol. 2013;961:241-9. doi: 10.1007/978-1-4614-4756-6_20.
• [758] Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression.PLoS One. 2016 Sep 9;11(9):e0161567. doi: 10.1371/journal.pone.0161567. eCollection 2016.
• [759] TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.Neurobiol Dis. 2010 May;38(2):210-8. doi: 10.1016/j.nbd.2010.01.007. Epub 2010 Jan 18.
• [760] Expression changes of genes associated with apoptosis and survival processes in Parkinson's disease.Neurosci Lett. 2016 Feb 26;615:72-7. doi: 10.1016/j.neulet.2016.01.029. Epub 2016 Jan 22.
• [761] Altered N100-potential associates with working memory impairment in Parkinson's disease.J Neural Transm (Vienna). 2017 Oct;124(10):1197-1203. doi: 10.1007/s00702-017-1758-z. Epub 2017 Jul 14.
• [762] Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without GBA mutations.Mol Genet Metab. 2016 Feb;117(2):179-85. doi: 10.1016/j.ymgme.2015.09.005. Epub 2015 Sep 14.
• [763] The analysis of association between SNCA, HUSEYO and CSMD1 gene variants and Parkinson's disease in Iranian population.Neurol Sci. 2016 May;37(5):731-6. doi: 10.1007/s10072-015-2420-x. Epub 2016 Jan 5.
• [764] Gene expression profiling predicts pathways and genes associated with Parkinson's disease.Neurol Sci. 2016 Jan;37(1):73-79. doi: 10.1007/s10072-015-2360-5. Epub 2015 Aug 13.
• [765] Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.JAMA Neurol. 2017 Aug 1;74(8):933-940. doi: 10.1001/jamaneurol.2017.0985.
• [766] Increase in proapoptotic activity of inhibitory PAS domain protein via phosphorylation by MK2.FEBS J. 2017 Dec;284(23):4115-4127. doi: 10.1111/febs.14300. Epub 2017 Nov 13.
• [767] Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.J Neurosci. 2017 Jun 14;37(24):5870-5884. doi: 10.1523/JNEUROSCI.2705-16.2017. Epub 2017 May 18.
• [768] Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults.Nat Commun. 2016 Mar 14;7:10943. doi: 10.1038/ncomms10943.
• [769] CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.J Neurosci. 2017 Dec 6;37(49):11930-11946. doi: 10.1523/JNEUROSCI.0443-17.2017. Epub 2017 Nov 2.
• [770] Altered praxis network underlying limb kinetic apraxia in Parkinson's disease - an fMRI study.Neuroimage Clin. 2017 Jul 18;16:88-97. doi: 10.1016/j.nicl.2017.07.007. eCollection 2017.
• [771] SUMOylation and ubiquitination reciprocally regulate -synuclein degradation and pathological aggregation.Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13176-13181. doi: 10.1073/pnas.1704351114. Epub 2017 Nov 27.
• [772] Ropinirole alters gene expression profiles in SH-SY5Y cells: a whole genome microarray study.Braz J Med Biol Res. 2016 Feb;49(2):e4857. doi: 10.1590/1414-431X20154857. Epub 2016 Jan 19.
• [773] Mitochondrial division inhibitor-1 is neuroprotective in the A53T--synuclein rat model of Parkinson's disease.Sci Rep. 2017 Aug 8;7(1):7495. doi: 10.1038/s41598-017-07181-0.
• [774] Interaction between RING1 (R1) and the Ubiquitin-like (UBL) Domains Is Critical for the Regulation of Parkin Activity.J Biol Chem. 2016 Jan 22;291(4):1803-1816. doi: 10.1074/jbc.M115.687319. Epub 2015 Dec 2.
• [775] Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases.JAMA Neurol. 2017 Jul 1;74(7):780-792. doi: 10.1001/jamaneurol.2017.0469.
• [776] Mild Inflammatory Profile without Gliosis in the c-Rel Deficient Mouse Modeling a Late-Onset Parkinsonism.Front Aging Neurosci. 2017 Jul 19;9:229. doi: 10.3389/fnagi.2017.00229. eCollection 2017.
• [777] BAG5 Interacts with DJ-1 and Inhibits the Neuroprotective Effects of DJ-1 to Combat Mitochondrial Oxidative Damage.Oxid Med Cell Longev. 2017;2017:5094934. doi: 10.1155/2017/5094934. Epub 2017 Mar 2.
• [778] Dynamin-related protein 1: A protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson's disease.Pharmacol Res. 2020 Jan;151:104553. doi: 10.1016/j.phrs.2019.104553. Epub 2019 Nov 21.
• [779] ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population.Neurol Sci. 2019 Jun;40(6):1237-1244. doi: 10.1007/s10072-019-03825-3. Epub 2019 Mar 16.
• [780] Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. doi: 10.1073/pnas.1006083107. Epub 2010 Sep 7.
• [781] Deregulation of glutamate dehydrogenase in human neurologic disorders.J Neurosci Res. 2013 Aug;91(8):1007-17. doi: 10.1002/jnr.23176. Epub 2013 Mar 6.
• [782] Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.Mol Ther. 2005 Jan;11(1):80-8. doi: 10.1016/j.ymthe.2004.09.007.
• [783] Association of Parkinson's Disease GWAS-Linked Loci with Alzheimer's Disease in Han Chinese.Mol Neurobiol. 2017 Jan;54(1):308-318. doi: 10.1007/s12035-015-9649-5. Epub 2016 Jan 6.
• [784] Rab1 in cell signaling, cancer and other diseases.Oncogene. 2016 Nov 3;35(44):5699-5704. doi: 10.1038/onc.2016.81. Epub 2016 Apr 4.
• [785] Structural insights into human angiogenin variants implicated in Parkinson's disease and Amyotrophic Lateral Sclerosis.Sci Rep. 2017 Feb 8;7:41996. doi: 10.1038/srep41996.
• [786] Association of rs62063857 variant of the saitohin gene with Parkinson's disease.Cell Mol Neurobiol. 2015 Jan;35(1):115-21. doi: 10.1007/s10571-014-0102-5. Epub 2014 Aug 29.
• [787] Cerebrospinal Fluid Proteomics For Identification Of 2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson's Disease And Schizophrenia.Neuropsychiatr Dis Treat. 2019 Oct 2;15:2853-2867. doi: 10.2147/NDT.S214217. eCollection 2019.
• [788] Postural sway in patients with early Parkinson's disease performing cognitive tasks while standing.Neurol Res. 2018 Jun;40(6):491-498. doi: 10.1080/01616412.2018.1451017. Epub 2018 Jun 5.
• [789] Polymorphisms of ACMSD-TMEM163, MCCC1, and BCKDK-STX1B Are Not Associated with Parkinson's Disease in Taiwan.Parkinsons Dis. 2019 Jan 2;2019:3489638. doi: 10.1155/2019/3489638. eCollection 2019.
• [790] Clinical characteristics and quality of life in Chinese patients with Parkinson's disease beyond 20years.Neurol Res. 2018 Apr;40(4):312-317. doi: 10.1080/01616412.2018.1438227. Epub 2018 Feb 15.
• [791] Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data.Lancet Neurol. 2006 Nov;5(11):911-6. doi: 10.1016/S1474-4422(06)70578-6.
• [792] Phosphorylation of Ser111 in Rab8a Modulates Rabin8-Dependent Activation by Perturbation of Side Chain Interaction Networks.Biochemistry. 2019 Aug 20;58(33):3546-3554. doi: 10.1021/acs.biochem.9b00516. Epub 2019 Aug 8.
• [793] CDK5-Mediated Phosphorylation-Dependent Ubiquitination and Degradation of E3 Ubiquitin Ligases GP78 Accelerates Neuronal Death in Parkinson's Disease.Mol Neurobiol. 2018 May;55(5):3709-3717. doi: 10.1007/s12035-017-0579-2. Epub 2017 May 20.
• [794] Alivin 1, a novel neuronal activity-dependent gene, inhibits apoptosis and promotes survival of cerebellar granule neurons.J Neurosci. 2003 Jul 2;23(13):5887-96. doi: 10.1523/JNEUROSCI.23-13-05887.2003.
• [795] SerThr-PhosphoProteome of Brain from Aged PINK1-KO+A53T-SNCA Mice Reveals pT1928-MAP1B and pS3781-ANK2 Deficits, as Hub between Autophagy and Synapse Changes.Int J Mol Sci. 2019 Jul 4;20(13):3284. doi: 10.3390/ijms20133284.
• [796] The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.J Pharm Pharmacol. 2019 Feb;71(2):206-212. doi: 10.1111/jphp.13031. Epub 2018 Oct 23.
• [797] Role of ANO3 mutations in dystonia: A large-scale mutational screening study.Parkinsonism Relat Disord. 2019 May;62:196-200. doi: 10.1016/j.parkreldis.2018.12.030. Epub 2019 Jan 2.
• [798] Gene therapy for Parkinson's disease.J Neural Transm Suppl. 2003;(65):205-13. doi: 10.1007/978-3-7091-0643-3_13.
• [799] Apolipoprotein D Concentration in Human Plasma during Aging and in Parkinson's Disease: A Cross-Sectional Study.Parkinsons Dis. 2018 Mar 26;2018:3751516. doi: 10.1155/2018/3751516. eCollection 2018.
• [800] Aquaporin-4 deficiency reduces TGF-1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease.J Cell Mol Med. 2019 Apr;23(4):2568-2582. doi: 10.1111/jcmm.14147. Epub 2019 Jan 25.
• [801] The Impact of Short and Long-Term Exercise on the Expression of Arc and AMPARs During Evolution of the 6-Hydroxy-Dopamine Animal Model of Parkinson's Disease.J Mol Neurosci. 2017 Apr;61(4):542-552. doi: 10.1007/s12031-017-0896-y. Epub 2017 Feb 28.
• [802] Astrocytic JWA deletion exacerbates dopaminergic neurodegeneration by decreasing glutamate transporters in mice.Cell Death Dis. 2018 Mar 2;9(3):352. doi: 10.1038/s41419-018-0381-8.
• [803] Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor 1 is enhanced after co-infusion in rats.Exp Neurol. 2010 Nov;226(1):136-47. doi: 10.1016/j.expneurol.2010.08.016. Epub 2010 Aug 14.
• [804] Examination of the MASH1 gene in patients with Parkinson's disease.Biochem Biophys Res Commun. 2010 Feb 19;392(4):548-50. doi: 10.1016/j.bbrc.2010.01.061. Epub 2010 Jan 25.
• [805] Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease.Neurosci Lett. 2004 Jan 30;355(3):193-6. doi: 10.1016/j.neulet.2003.11.006.
• [806] Activation of the ATF2/CREB-PGC-1 pathway by metformin leads to dopaminergic neuroprotection.Oncotarget. 2017 Jul 25;8(30):48603-48618. doi: 10.18632/oncotarget.18122.
• [807] Chinese Herbal Complex 'Bu Shen Jie Du Fang' (BSJDF) Modulated Autophagy in an MPP(+)-Induced Cell Model of Parkinson's Disease.Evid Based Complement Alternat Med. 2019 Mar 13;2019:8920813. doi: 10.1155/2019/8920813. eCollection 2019.
• [808] Neuroprotective effects of Tat-ATOX1 protein against MPP(+)-induced SH-SY5Y cell deaths and in MPTP-induced mouse model of Parkinson's disease.Biochimie. 2019 Jan;156:158-168. doi: 10.1016/j.biochi.2018.10.010. Epub 2018 Oct 21.
• [809] Parkinson disease related ATP13A2 evolved early in animal evolution.PLoS One. 2018 Mar 5;13(3):e0193228. doi: 10.1371/journal.pone.0193228. eCollection 2018.
• [810] Renin-angiotensin system gene expression and neurodegenerative diseases.J Renin Angiotensin Aldosterone Syst. 2016 Sep 9;17(3):1470320316666750. doi: 10.1177/1470320316666750. Print 2016 Jul.
• [811] Olfactory Function in SCA10.Cerebellum. 2019 Feb;18(1):85-90. doi: 10.1007/s12311-018-0954-1.
• [812] siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration.Mol Cell Neurosci. 2019 Mar;95:25-30. doi: 10.1016/j.mcn.2019.01.001. Epub 2019 Jan 3.
• [813] BAG1 is neuroprotective in in vivo and in vitro models of Parkinson's disease.J Mol Neurosci. 2015 Mar;55(3):587-95. doi: 10.1007/s12031-014-0396-2. Epub 2014 Aug 9.
• [814] A search for cortical correlates of trait impulsivity in Parkinsons disease.Behav Brain Res. 2019 Sep 2;369:111911. doi: 10.1016/j.bbr.2019.111911. Epub 2019 Apr 13.
• [815] Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson's disease.Sci Rep. 2017 Mar 10;7:44373. doi: 10.1038/srep44373.
• [816] Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.Ann Hum Genet. 2010 Mar;74(2):97-109. doi: 10.1111/j.1469-1809.2009.00560.x. Epub 2010 Jan 8.
• [817] Mutations in C19orf12 and intronic repeat expansions in C9orf72 not observed in Iranian Parkinson's disease patients.Neurobiol Aging. 2017 Jun;54:214.e11-214.e12. doi: 10.1016/j.neurobiolaging.2017.03.020. Epub 2017 Mar 18.
• [818] CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein.Biochem Biophys Res Commun. 2017 Aug 26;490(3):876-881. doi: 10.1016/j.bbrc.2017.06.134. Epub 2017 Jun 21.
• [819] Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease.EBioMedicine. 2019 Jul;45:351-361. doi: 10.1016/j.ebiom.2019.06.021. Epub 2019 Jun 20.
• [820] Postural control deficit during sit-to-walk in patients with Parkinson's disease and freezing of gait.Gait Posture. 2018 Mar;61:325-330. doi: 10.1016/j.gaitpost.2018.01.032. Epub 2018 Feb 2.
• [821] Gene co-expression network analysis for identifying genetic markers in Parkinson's disease - a three-way comparative approach.Genomics. 2019 Jul;111(4):819-830. doi: 10.1016/j.ygeno.2018.05.005. Epub 2018 May 28.
• [822] Dysautonomia is associated with structural and functional alterations in Parkinson disease.Neurology. 2019 Mar 26;92(13):e1456-e1467. doi: 10.1212/WNL.0000000000007181. Epub 2019 Feb 22.
• [823] Rhododendrin-Induced RNF146 Expression via Estrogen Receptor Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.Int J Mol Sci. 2019 Apr 10;20(7):1772. doi: 10.3390/ijms20071772.
• [824] Proteomics and bioinformatics approaches for the identification of plasma biomarkers to detect Parkinson's disease.Exp Ther Med. 2019 Oct;18(4):2833-2842. doi: 10.3892/etm.2019.7888. Epub 2019 Aug 14.
• [825] Parkinson disease loci in the mid-western Amish.Hum Genet. 2013 Nov;132(11):1213-21. doi: 10.1007/s00439-013-1316-1. Epub 2013 Jun 21.
• [826] Alzheimer's disease susceptibility genes modify the risk of Parkinson disease and Parkinson's disease-associated cognitive impairment.Neurosci Lett. 2018 Jun 11;677:55-59. doi: 10.1016/j.neulet.2018.04.042. Epub 2018 Apr 24.
• [827] Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population.BMC Med Genet. 2011 Aug 3;12:104. doi: 10.1186/1471-2350-12-104.
• [828] Downregulated expression of microRNA-329 inhibits apoptosis of nigral dopaminergic neurons by regulating CDKN2D expression via the FoxO3a signaling pathway in rats with Parkinson's disease.J Cell Physiol. 2018 Nov;233(11):8617-8629. doi: 10.1002/jcp.26608. Epub 2018 May 15.
• [829] Cerebral dopamine neurotrophic factor-deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice.Neurobiol Dis. 2020 Feb;134:104696. doi: 10.1016/j.nbd.2019.104696. Epub 2019 Nov 26.
• [830] CHCHD10 is involved in the development of Parkinson's disease caused by CHCHD2 loss-of-function mutation p.T61I.Neurobiol Aging. 2019 Mar;75:38-41. doi: 10.1016/j.neurobiolaging.2018.10.020. Epub 2018 Oct 23.
• [831] Is the 1254T>C polymorphism in the DMT1 gene associated with Parkinson's disease?.Neurosci Lett. 2015 May 6;594:51-4. doi: 10.1016/j.neulet.2015.03.054. Epub 2015 Mar 26.
• [832] 4-Hydroxynonenal and 4-Oxononenal Differentially Bind to the Redox Sensor MitoNEET.Chem Res Toxicol. 2019 Jun 17;32(6):977-981. doi: 10.1021/acs.chemrestox.9b00166. Epub 2019 May 29.
• [833] Parkin Mutation Affects Clock Gene-Dependent Energy Metabolism.Int J Mol Sci. 2019 Jun 5;20(11):2772. doi: 10.3390/ijms20112772.
• [834] Neurological and psychiatric associations in bullous pemphigoid-more than skin deep?.Exp Dermatol. 2017 Dec;26(12):1228-1234. doi: 10.1111/exd.13401. Epub 2017 Sep 24.
• [835] A Pooling Genome-Wide Association Study Combining a Pathway Analysis for Typical Sporadic Parkinson's Disease in the Han Population of Chinese Mainland.Mol Neurobiol. 2016 Sep;53(7):4302-18. doi: 10.1007/s12035-015-9331-y. Epub 2015 Jul 31.
• [836] Optimism, Pessimism, Coping, and Depression: A Study on Individuals With Parkinson's Disease.Int J Aging Hum Dev. 2019 Apr;88(3):231-249. doi: 10.1177/0091415018763401. Epub 2018 Mar 20.
• [837] Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.Neuropsychopharmacology. 2019 Apr;44(5):837-849. doi: 10.1038/s41386-018-0090-0. Epub 2018 May 16.
• [838] Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease.Ann Neurol. 1996 Sep;40(3):463-5. doi: 10.1002/ana.410400319.
• [839] Golden mean to longevity: rareness of mitochondrial cytochrome b variants in centenarians but not in patients with Parkinson's disease.J Neurosci Res. 2002 Nov 1;70(3):347-55. doi: 10.1002/jnr.10444.
• [840] Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.Neuropathology. 2013 Aug;33(4):391-6. doi: 10.1111/neup.12009. Epub 2012 Dec 13.
• [841] The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways.J Tissue Eng Regen Med. 2017 Nov;11(11):3236-3240. doi: 10.1002/term.2222. Epub 2016 Dec 12.
• [842] Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease.PLoS Genet. 2011 Jun;7(6):e1002141. doi: 10.1371/journal.pgen.1002141. Epub 2011 Jun 23.
• [843] Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson's disease model.Redox Biol. 2019 Apr;22:101134. doi: 10.1016/j.redox.2019.101134. Epub 2019 Feb 8.
• [844] Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.FASEB J. 2005 Apr;19(6):583-5. doi: 10.1096/fj.04-1854fje. Epub 2005 Feb 9.
• [845] The Short Isoform of DNAJB6 Protects against 1-Methyl-4-phenylpridinium Ion-Induced Apoptosis in LN18 Cells via Inhibiting Both ROS Formation and Mitochondrial Membrane Potential Loss.Oxid Med Cell Longev. 2017;2017:7982389. doi: 10.1155/2017/7982389. Epub 2017 Feb 9.
• [846] Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):768-773. doi: 10.1136/jnnp-2018-320151. Epub 2019 Mar 13.
• [847] Investigation of the roles of dysbindin-1 and SATB2 in the progression of Parkinson's disease.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7510-7516. doi: 10.26355/eurrev_201909_18865.
• [848] Lesion of the Locus Coeruleus Damages Learning and Memory Performance in Paraquat and Maneb-induced Mouse Parkinson's Disease Model.Neuroscience. 2019 Nov 1;419:129-140. doi: 10.1016/j.neuroscience.2019.09.006. Epub 2019 Oct 18.
• [849] Aberrantly expressed long noncoding RNAs and genes in Parkinson's disease.Neuropsychiatr Dis Treat. 2018 Nov 22;14:3219-3229. doi: 10.2147/NDT.S178435. eCollection 2018.
• [850] Association mapping of the PARK10 region for Parkinson's disease susceptibility genes.Parkinsonism Relat Disord. 2014 Jan;20(1):93-8. doi: 10.1016/j.parkreldis.2013.10.001. Epub 2013 Oct 11.
• [851] Cerebrospinal fluid levels of alpha-synuclein, amyloid , tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.Neurosci Lett. 2020 Jan 10;715:134564. doi: 10.1016/j.neulet.2019.134564. Epub 2019 Nov 13.
• [852] Combination of Multifocal Electroretinogram and Spectral-Domain OCT Can Increase Diagnostic Efficacy of Parkinson's Disease.Parkinsons Dis. 2018 Mar 1;2018:4163239. doi: 10.1155/2018/4163239. eCollection 2018.
• [853] Fasciculation and elongation protein zeta-1 (FEZ1) expression in reactive astrocytes in a rat model of Parkinson's disease.Neuropathol Appl Neurobiol. 2014 Feb;40(2):164-76. doi: 10.1111/nan.12077.
• [854] Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease.Sci Rep. 2012;2:953. doi: 10.1038/srep00953. Epub 2012 Dec 11.
• [855] Fibroblast Growth Factor 9 Suppresses Striatal Cell Death Dominantly Through ERK Signaling in Huntington's Disease.Cell Physiol Biochem. 2018;48(2):605-617. doi: 10.1159/000491889. Epub 2018 Jul 18.
• [856] MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients.Neurobiol Aging. 2018 Sep;69:283-291. doi: 10.1016/j.neurobiolaging.2018.05.032. Epub 2018 May 31.
• [857] Creating a graft-friendly environment for stem cells in diseased brains.J Clin Invest. 2018 Jan 2;128(1):116-119. doi: 10.1172/JCI98490. Epub 2017 Dec 11.
• [858] Overexpression of 17-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death.BMC Cancer. 2015 Mar 22;15:166. doi: 10.1186/s12885-015-1173-5.
• [859] Mitochondrial ferritin protects SH-SY5Y cells against H(2)O(2)-induced oxidative stress and modulates -synuclein expression.Exp Neurol. 2017 May;291:51-61. doi: 10.1016/j.expneurol.2017.02.001. Epub 2017 Feb 3.
• [860] Asymmetry of Periodic Leg Movements in Sleep (PLMS) in Parkinson's Disease.J Parkinsons Dis. 2020;10(1):255-266. doi: 10.3233/JPD-191667.
• [861] A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease.Neurosci Lett. 2018 Apr 23;673:12-18. doi: 10.1016/j.neulet.2018.02.055. Epub 2018 Feb 26.
• [862] GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features.Neuromolecular Med. 2017 Mar;19(1):24-40. doi: 10.1007/s12017-016-8415-9. Epub 2016 Jun 9.
• [863] GLIS1 rs797906: an increased risk factor for late-onset Parkinson's disease in the Han Chinese population.Eur Neurol. 2012;68(2):89-92. doi: 10.1159/000337955. Epub 2012 Jul 3.
• [864] Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease.Neurology. 2019 Aug 13;93(7):e665-e674. doi: 10.1212/WNL.0000000000007939. Epub 2019 Jul 9.
• [865] Reducing glypican-4 in ES cells improves recovery in a rat model of Parkinson's disease by increasing the production of dopaminergic neurons and decreasing teratoma formation.J Neurosci. 2014 Jun 11;34(24):8318-23. doi: 10.1523/JNEUROSCI.2501-13.2014.
• [866] Immunoreactivity of a G protein-coupled l-DOPA receptor GPR143, in Lewy bodies.Neurosci Res. 2019 Nov;148:49-53. doi: 10.1016/j.neures.2018.12.004. Epub 2018 Dec 24.
• [867] GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells.Neuropharmacology. 2019 Jul 1;152:51-57. doi: 10.1016/j.neuropharm.2018.11.009. Epub 2018 Nov 10.
• [868] Prioritized brain selenium retention and selenoprotein expression: Nutritional insights into Parkinson's disease.Mech Ageing Dev. 2019 Jun;180:89-96. doi: 10.1016/j.mad.2019.04.004. Epub 2019 Apr 15.
• [869] Identification of Shared Genes Between Ischemic Stroke and Parkinson's Disease Using Genome-Wide Association Studies.Front Neurol. 2019 Mar 28;10:297. doi: 10.3389/fneur.2019.00297. eCollection 2019.
• [870] Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.Sci Transl Med. 2010 Apr 21;2(28):28ra28. doi: 10.1126/scitranslmed.3000664.
• [871] Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.Sci Rep. 2016 Oct 20;6:35203. doi: 10.1038/srep35203.
• [872] Glutathione S-transferase M1 polymorphisms and Parkinson's disease risk: a meta-analysis.Neurol Res. 2016 Feb;38(2):144-50. doi: 10.1080/01616412.2015.1126996. Epub 2016 Mar 16.
• [873] Simultaneous Relative Quantification of Various Polyglycerophospholipids with Isotope-Labeled Methylation by Nanoflow Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry.Anal Chem. 2019 May 21;91(10):6716-6723. doi: 10.1021/acs.analchem.9b00800. Epub 2019 Apr 30.
• [874] Hapln2 in Neurological Diseases and Its Potential as Therapeutic Target.Front Aging Neurosci. 2019 Mar 21;11:60. doi: 10.3389/fnagi.2019.00060. eCollection 2019.
• [875] Dopamine depletion induced up-regulation of HCN3 enhances rebound excitability of basal ganglia output neurons.Neurobiol Dis. 2009 Apr;34(1):178-88. doi: 10.1016/j.nbd.2009.01.007.
• [876] Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies.Clin Neuropathol. 2009 Sep-Oct;28(5):333-43.
• [877] The single nucleotide polymorphism Rs12817488 is associated with Parkinson's disease in the Chinese population.J Clin Neurosci. 2015 Jun;22(6):1002-4. doi: 10.1016/j.jocn.2014.11.024. Epub 2015 Mar 26.
• [878] The metal transporter SMF-3/DMT-1 mediates aluminum-induced dopamine neuron degeneration. J Neurochem. 2013 Jan;124(1):147-57. doi: 10.1111/jnc.12072. Epub 2012 Nov 21.
• [879] Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 2014 Jun;14(3):289-94. doi: 10.1038/tpj.2013.37. Epub 2013 Oct 15.
• [880] Study of metabolic disorders associated with BDE-47 exposure in Drosophila model by MS-based metabolomics.Ecotoxicol Environ Saf. 2019 Nov 30;184:109606. doi: 10.1016/j.ecoenv.2019.109606. Epub 2019 Aug 28.
• [881] Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease.CNS Neurol Disord Drug Targets. 2019;18(2):156-169. doi: 10.2174/1871527317666180816095707.
• [882] Neuronal specific and non-specific responses to cadmium possibly involved in neurodegeneration: A toxicogenomics study in a human neuronal cell model.Neurotoxicology. 2020 Jan;76:162-173. doi: 10.1016/j.neuro.2019.11.002. Epub 2019 Nov 16.
• [883] Possible involvement of iron-induced oxidative insults in neurodegeneration.Neurosci Lett. 2015 Feb 19;588:29-35. doi: 10.1016/j.neulet.2014.12.052. Epub 2014 Dec 27.
• [884] Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson's disease.Brain Behav Immun. 2018 Jul;71:93-107. doi: 10.1016/j.bbi.2018.04.006. Epub 2018 Apr 9.
• [885] Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson's diseases.Aging Cell. 2019 Jun;18(3):e12941. doi: 10.1111/acel.12941. Epub 2019 Mar 5.
• [886] LDOC1 gene expression in two patients with head and neck squamous cell carcinomas and Parkinson's disease.Tumori. 2012 May-Jun;98(3):86e-88e. doi: 10.1700/1125.12418.
• [887] Modeling Parkinson's disease in adult Drosophila.J Neurosci Methods. 2019 Jan 1;311:89-94. doi: 10.1016/j.jneumeth.2018.10.018. Epub 2018 Oct 15.
• [888] Analysis and meta-analysis of five polymorphisms of the LINGO1 and LINGO2 genes in Parkinson's disease and multiple system atrophy in a Chinese population.J Neurol. 2015 Nov;262(11):2478-83. doi: 10.1007/s00415-015-7870-9. Epub 2015 Aug 8.
• [889] Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons.Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4387-96. doi: 10.1073/pnas.1520387113. Epub 2016 Jul 12.
• [890] Genetic Analysis of LRRK1 and LRRK2 Variants in Essential Tremor Patients.Genet Test Mol Biomarkers. 2018 Jun;22(6):398-402. doi: 10.1089/gtmb.2017.0277. Epub 2018 May 29.
• [891] U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease.Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16562-7. doi: 10.1073/pnas.1310249110. Epub 2013 Sep 10.
• [892] Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease.Mol Neurobiol. 2017 May;54(4):2878-2888. doi: 10.1007/s12035-016-9861-y. Epub 2016 Mar 28.
• [893] Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes.J Alzheimers Dis. 2017;56(4):1525-1539. doi: 10.3233/JAD-161032.
• [894] Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14280-14289. doi: 10.1073/pnas.1900576116. Epub 2019 Jun 24.
• [895] The PPARGC1A locus and CNS-specific PGC-1 isoforms are associated with Parkinson's Disease.Neurobiol Dis. 2019 Jan;121:34-46. doi: 10.1016/j.nbd.2018.09.016. Epub 2018 Sep 17.
• [896] Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease. Chem Res Toxicol. 2011 Oct 17;24(10):1644-52. doi: 10.1021/tx200082h. Epub 2011 Aug 22.
• [897] Role of microtubule-associated protein 6 glycosylated with Gal-(-1,3)-GalNAc in Parkinson's disease.Aging (Albany NY). 2019 Jul 9;11(13):4597-4610. doi: 10.18632/aging.102072.
• [898] Impaired set shifting is associated with previous falls in individuals with and without Parkinson's disease.Gait Posture. 2018 May;62:220-226. doi: 10.1016/j.gaitpost.2018.02.027. Epub 2018 Mar 6.
• [899] Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study.Front Aging Neurosci. 2019 Feb 8;11:21. doi: 10.3389/fnagi.2019.00021. eCollection 2019.
• [900] Restriction of mitochondrial calcium overload by mcu inactivation renders a neuroprotective effect in zebrafish models of Parkinson's disease.Biol Open. 2019 Oct 15;8(10):bio044347. doi: 10.1242/bio.044347.
• [901] Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1 transcription. Cell. 2013 Dec 5;155(6):1351-64. doi: 10.1016/j.cell.2013.11.009. Epub 2013 Nov 27.
• [902] Salidroside protects dopaminergic neurons by regulating the mitochondrial MEF2D-ND6 pathway in the MPTP/MPP(+) -induced model of Parkinson's disease.J Neurochem. 2020 Apr;153(2):276-289. doi: 10.1111/jnc.14868. Epub 2019 Oct 27.
• [903] AMP Kinase Activation is Selectively Disrupted in the Ventral Midbrain of Mice Deficient in Parkin or PINK1 Expression.Neuromolecular Med. 2019 Mar;21(1):25-32. doi: 10.1007/s12017-018-8517-7. Epub 2018 Nov 8.
• [904] Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).Hum Mutat. 2014 Apr;35(4):395-412. doi: 10.1002/humu.22515. Epub 2014 Feb 24.
• [905] Ferulic acid reinstates mitochondrial dynamics through PGC1 expression modulation in 6-hydroxydopamine lesioned rats.Phytother Res. 2020 Jan;34(1):214-226. doi: 10.1002/ptr.6523. Epub 2019 Oct 27.
• [906] Midnolin is a confirmed genetic risk factor for Parkinson's disease.Ann Clin Transl Neurol. 2019 Nov;6(11):2205-2211. doi: 10.1002/acn3.50914. Epub 2019 Oct 6.
• [907] Expression of Aquaporin 1 and Aquaporin 4 in the Temporal Neocortex of Patients with Parkinson's Disease.Brain Pathol. 2017 Mar;27(2):160-168. doi: 10.1111/bpa.12369. Epub 2016 Apr 6.
• [908] Integrated analysis of exosomal lncRNA and mRNA expression profiles reveals the involvement of lnc-MKRN2-42:1 in the pathogenesis of Parkinson's disease.CNS Neurosci Ther. 2020 May;26(5):527-537. doi: 10.1111/cns.13277. Epub 2019 Dec 8.
• [909] SH-SY5Y and LUHMES cells display differential sensitivity to MPP+, tunicamycin, and epoxomicin in 2D and 3D cell culture.Biotechnol Prog. 2020 Mar;36(2):e2942. doi: 10.1002/btpr.2942. Epub 2019 Dec 12.
• [910] Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells.Mol Med Rep. 2019 Jan;19(1):165-176. doi: 10.3892/mmr.2018.9670. Epub 2018 Nov 19.
• [911] Novel Oxindole-Curcumin Hybrid Compound for Antioxidative Stress and Neuroprotection.ACS Chem Neurosci. 2020 Jan 2;11(1):76-85. doi: 10.1021/acschemneuro.9b00619. Epub 2019 Dec 18.
• [912] Mitochondrial translation initiation factor 3 polymorphism and Parkinson's disease.Neurosci Lett. 2010 Dec 17;486(3):228-30. doi: 10.1016/j.neulet.2010.09.059. Epub 2010 Sep 29.
• [913] MUL1 gene polymorphisms and Parkinson's disease risk.Acta Neurol Scand. 2019 May;139(5):483-487. doi: 10.1111/ane.13081. Epub 2019 Mar 14.
• [914] Non-SMC condensin I complex, subunit D2 gene polymorphisms are associated with Parkinson's disease: a Han Chinese study.Genome. 2014 May;57(5):253-7. doi: 10.1139/gen-2014-0032. Epub 2014 Aug 11.
• [915] Acanthopanax senticosus Protects Structure and Function of Mesencephalic Mitochondria in A Mouse Model of Parkinson's Disease.Chin J Integr Med. 2018 Nov;24(11):835-843. doi: 10.1007/s11655-018-2935-5. Epub 2018 Aug 8.
• [916] Association of the mt-ND2 5178A/C polymorphism with Parkinson's disease.Neurosci Lett. 2015 Feb 5;587:98-101. doi: 10.1016/j.neulet.2014.12.005. Epub 2014 Dec 12.
• [917] Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease.Neurochem Res. 2011 Aug;36(8):1435-43. doi: 10.1007/s11064-011-0469-3. Epub 2011 Apr 12.
• [918] A missense MT-ND5 mutation in differentiated Parkinson Disease cytoplasmic hybrid induces ROS-dependent DNA Damage Response amplified by DROSHA.Sci Rep. 2017 Aug 25;7(1):9528. doi: 10.1038/s41598-017-09910-x.
• [919] Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases.Parkinsonism Relat Disord. 2019 Apr;61:82-87. doi: 10.1016/j.parkreldis.2018.11.021. Epub 2018 Nov 20.
• [920] Ndfip1 attenuated 6-OHDA-induced iron accumulation via regulating the degradation of DMT1.Neurobiol Aging. 2015 Feb;36(2):1183-93. doi: 10.1016/j.neurobiolaging.2014.10.021. Epub 2014 Oct 18.
• [921] Astrocyte-specific NDRG2 gene: functions in the brain and neurological diseases.Cell Mol Life Sci. 2020 Jul;77(13):2461-2472. doi: 10.1007/s00018-019-03406-9. Epub 2019 Dec 13.
• [922] Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease.Neurochem Res. 2004 Mar;29(3):569-77. doi: 10.1023/b:nere.0000014827.94562.4b.
• [923] Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness?.Exp Neurol. 2012 Dec;238(2):89-99. doi: 10.1016/j.expneurol.2012.08.008. Epub 2012 Aug 19.
• [924] CSF and blood biomarkers for Parkinson's disease.Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10.
• [925] Mechanisms and Consequences of Dopamine Depletion-Induced Attenuation of the Spinophilin/Neurofilament Medium Interaction.Neural Plast. 2017;2017:4153076. doi: 10.1155/2017/4153076. Epub 2017 May 28.
• [926] Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.Biochem Biophys Res Commun. 2020 Jan 1;521(1):245-251. doi: 10.1016/j.bbrc.2019.10.118. Epub 2019 Oct 22.
• [927] The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-kB/Nuclear Transcription Factor Related to NF-E2. Antioxid Redox Signal. 2017 Sep 10;27(8):453-471.
• [928] Understanding the Care Needs and Profile of People Living at Home With Moderate to Advanced Stage Parkinson Disease.J Geriatr Psychiatry Neurol. 2018 Sep;31(5):237-247. doi: 10.1177/0891988718788680. Epub 2018 Jul 16.
• [929] Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
• [930] Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.Neuroimage Clin. 2019;22:101748. doi: 10.1016/j.nicl.2019.101748. Epub 2019 Mar 6.
• [931] Dysregulation of serum NADPH oxidase1 and ferritin levels provides insights into diagnosis of Parkinson's disease.Clin Biochem. 2017 Dec;50(18):1087-1092. doi: 10.1016/j.clinbiochem.2017.09.014. Epub 2017 Sep 20.
• [932] Pyrosequencing analysis of methylation levels of clock genes in leukocytes from Parkinson's disease patients.Neurosci Lett. 2018 Mar 6;668:115-119. doi: 10.1016/j.neulet.2018.01.027. Epub 2018 Jan 17.
• [933] Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders.PLoS One. 2013 Dec 30;8(12):e82879. doi: 10.1371/journal.pone.0082879. eCollection 2013.
• [934] Development of a Parenteral Formulation of NTS-Polyplex Nanoparticles for Clinical Purpose.Pharmaceutics. 2018 Jan 3;10(1):5. doi: 10.3390/pharmaceutics10010005.
• [935] The association of low levels of nesfatin-1 and glucagon-like peptide-1 with oxidative stress in Parkinson's disease.Neurol Sci. 2019 Dec;40(12):2529-2535. doi: 10.1007/s10072-019-03975-4. Epub 2019 Jul 6.
• [936] Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.Acta Neuropathol. 2020 Feb;139(2):319-345. doi: 10.1007/s00401-019-02099-5. Epub 2019 Nov 25.
• [937] Odor Identification Performance in Idiopathic Parkinson's Disease Is Associated With Gender and the Genetic Variability of the Olfactory Binding Protein.Chem Senses. 2019 May 29;44(5):311-318. doi: 10.1093/chemse/bjz020.
• [938] Abundant fish protein inhibits -synuclein amyloid formation.Sci Rep. 2018 Apr 3;8(1):5465. doi: 10.1038/s41598-018-23850-0.
• [939] Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker?.Parkinsonism Relat Disord. 2019 Apr;61:132-137. doi: 10.1016/j.parkreldis.2018.10.032. Epub 2018 Nov 2.
• [940] Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study.Parkinsonism Relat Disord. 2019 Nov;68:40-45. doi: 10.1016/j.parkreldis.2019.09.032. Epub 2019 Oct 1.
• [941] Evidence for encephalopsin immunoreactivity in interneurones and striosomes of the monkey striatum.Exp Brain Res. 2018 Apr;236(4):955-961. doi: 10.1007/s00221-018-5191-9. Epub 2018 Jan 29.
• [942] Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease.Acta Neuropathol Commun. 2018 Sep 10;6(1):90. doi: 10.1186/s40478-018-0596-z.
• [943] Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson's disease.Brain Res. 2019 Nov 1;1722:146331. doi: 10.1016/j.brainres.2019.146331. Epub 2019 Jul 10.
• [944] Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.Neurobiol Dis. 2007 Aug;27(2):238-47. doi: 10.1016/j.nbd.2007.04.014. Epub 2007 May 18.
• [945] Exploring white matter microstructure and olfaction dysfunction in early parkinson disease: diffusion MRI reveals new insight.Brain Imaging Behav. 2019 Feb;13(1):210-219. doi: 10.1007/s11682-017-9781-0.
• [946] Mutation analyses and association studies to assess the role of the presenilin-associated rhomboid-like gene in Parkinson's disease.Neurobiol Aging. 2016 Mar;39:217.e13-5. doi: 10.1016/j.neurobiolaging.2015.11.025. Epub 2015 Dec 8.
• [947] Dopamine down-regulation of protein L-isoaspartyl methyltransferase is dependent on reactive oxygen species in SH-SY5Y cells. Neuroscience. 2014 May 16;267:263-76. doi: 10.1016/j.neuroscience.2014.03.001. Epub 2014 Mar 12.
• [948] Neuropeptidomics: expanding proteomics downwards.Biochem Soc Trans. 2007 Jun;35(Pt 3):588-93. doi: 10.1042/BST0350588.
• [949] L-dopa co-drugs in nanostructured lipid carriers: A comparative study.Mater Sci Eng C Mater Biol Appl. 2017 Mar 1;72:168-176. doi: 10.1016/j.msec.2016.11.060. Epub 2016 Nov 18.
• [950] Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.Parkinsonism Relat Disord. 2019 Dec;69:94-98. doi: 10.1016/j.parkreldis.2019.11.002. Epub 2019 Nov 5.
• [951] Functional Role of the Disulfide Isomerase ERp57 in Axonal Regeneration.PLoS One. 2015 Sep 11;10(9):e0136620. doi: 10.1371/journal.pone.0136620. eCollection 2015.
• [952] Rapid eye movement behavior disorder in drug-nave patients with Parkinson's disease.J Clin Neurosci. 2019 Jan;59:254-258. doi: 10.1016/j.jocn.2018.07.007. Epub 2018 Oct 9.
• [953] Peli1 controls the survival of dopaminergic neurons through modulating microglia-mediated neuroinflammation.Sci Rep. 2019 May 29;9(1):8034. doi: 10.1038/s41598-019-44573-w.
• [954] Alterations in prodynorphin, proenkephalin, and GAD67 mRNA levels in the aged human putamen: correlation with Parkinson's disease.J Neurosci Res. 2007 Mar;85(4):798-804. doi: 10.1002/jnr.21164.
• [955] Pluronic gel-based burrowing assay for rapid assessment of neuromuscular health in C. elegans.Sci Rep. 2019 Oct 23;9(1):15246. doi: 10.1038/s41598-019-51608-9.
• [956] Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.J Clin Invest. 2019 Oct 1;129(10):4539-4549. doi: 10.1172/JCI129987.
• [957] Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.Acta Neuropathol Commun. 2017 Jan 5;5(1):1. doi: 10.1186/s40478-016-0408-2.
• [958] Respiratory disturbances in a mouse model of Parkinson's disease.Exp Physiol. 2019 May;104(5):729-739. doi: 10.1113/EP087507. Epub 2019 Mar 7.
• [959] Overlapping genetic architecture between Parkinson disease and melanoma.Acta Neuropathol. 2020 Feb;139(2):347-364. doi: 10.1007/s00401-019-02110-z. Epub 2019 Dec 16.
• [960] Reprogramming of a human induced pluripotent stem cell (iPSC) line (IBMSi012-A) from an early-onset Parkinson's disease patient harboring a homozygous p.D331Y mutation in the PLA2G6 gene.Stem Cell Res. 2019 May;37:101432. doi: 10.1016/j.scr.2019.101432. Epub 2019 Apr 5.
• [961] Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.Neurol Genet. 2018 Oct 5;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct.
• [962] Retinal Microvascular Impairment in the Early Stages of Parkinson's Disease.Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4115-4122. doi: 10.1167/iovs.17-23230.
• [963] Genetic analysis of PODXL gene in patients with familial and young-onset Parkinson's disease in a Taiwanese population.Neurobiol Aging. 2019 Dec;84:235.e9-235.e10. doi: 10.1016/j.neurobiolaging.2019.08.027. Epub 2019 Sep 8.
• [964] Identification of potential diagnostic biomarkers for Parkinson's disease.FEBS Open Bio. 2019 Aug;9(8):1460-1468. doi: 10.1002/2211-5463.12687. Epub 2019 Jul 3.
• [965] PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins.Elife. 2019 Oct 30;8:e50416. doi: 10.7554/eLife.50416.
• [966] Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.Exp Neurol. 2018 May;303:95-107. doi: 10.1016/j.expneurol.2018.01.015. Epub 2018 Feb 9.
• [967] Age affects reinforcement learning through dopamine-based learning imbalance and high decision noise-not through Parkinsonian mechanisms.Neurobiol Aging. 2018 Aug;68:102-113. doi: 10.1016/j.neurobiolaging.2018.04.006. Epub 2018 Apr 19.
• [968] Mechanisms Regulating the Association of Protein Phosphatase 1 with Spinophilin and Neurabin.ACS Chem Neurosci. 2018 Nov 21;9(11):2701-2712. doi: 10.1021/acschemneuro.8b00144. Epub 2018 Jun 1.
• [969] PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications.Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):124-9. doi: 10.1002/ajmg.b.30785.
• [970] Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.Neurosci Lett. 2017 Sep 29;658:114-120. doi: 10.1016/j.neulet.2017.08.029. Epub 2017 Aug 18.
• [971] Cypermethrin Activates Autophagosome Formation Albeit Inhibits Autophagy Owing to Poor Lysosome Quality: Relevance to Parkinson's Disease.Neurotox Res. 2018 Feb;33(2):377-387. doi: 10.1007/s12640-017-9800-3. Epub 2017 Aug 24.
• [972] PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain. 2014 May;137(Pt 5):1361-73. doi: 10.1093/brain/awu067. Epub 2014 Apr 9.
• [973] A Novel Small Molecule Supports the Survival of Cultured Dopamine Neurons and May Restore the Dopaminergic Innervation of the Brain in the MPTP Mouse Model of Parkinson's Disease.ACS Chem Neurosci. 2019 Oct 16;10(10):4337-4349. doi: 10.1021/acschemneuro.9b00396. Epub 2019 Sep 11.
• [974] Use of Overlapping Group LASSO Sparse Deep Belief Network to Discriminate Parkinson's Disease and Normal Control.Front Neurosci. 2019 Apr 29;13:396. doi: 10.3389/fnins.2019.00396. eCollection 2019.
• [975] Sequencing of the GBA coactivator, Saposin C, in Parkinson disease.Neurobiol Aging. 2018 Dec;72:187.e1-187.e3. doi: 10.1016/j.neurobiolaging.2018.06.034. Epub 2018 Jul 2.
• [976] PINK1 suppresses alpha-synuclein-induced neuronal injury: a novel mechanism in protein phosphatase 2A activation.Oncotarget. 2017 Oct 6;9(1):37-53. doi: 10.18632/oncotarget.21554. eCollection 2018 Jan 2.
• [977] Novel application of the gray-level co-occurrence matrix analysis in the parvalbumin stained hippocampal gyrus dentatus in distinct rat models of Parkinson's disease.Comput Biol Med. 2019 Dec;115:103482. doi: 10.1016/j.compbiomed.2019.103482. Epub 2019 Oct 4.
• [978] Microarray Analysis of the Molecular Mechanism Involved in Parkinson's Disease.Parkinsons Dis. 2018 Mar 1;2018:1590465. doi: 10.1155/2018/1590465. eCollection 2018.
• [979] Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease.J Alzheimers Dis. 2018;63(1):157-165. doi: 10.3233/JAD-180023.
• [980] Rab32 interacts with SNX6 and affects retromer-dependent Golgi trafficking.PLoS One. 2019 Jan 14;14(1):e0208889. doi: 10.1371/journal.pone.0208889. eCollection 2019.
• [981] Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease.J Clin Neurol. 2019 Oct;15(4):488-495. doi: 10.3988/jcn.2019.15.4.488.
• [982] LncRNA HOTAIR targets miR-126-5p to promote the progression of Parkinson's disease through RAB3IP.Biol Chem. 2019 Aug 27;400(9):1217-1228. doi: 10.1515/hsz-2018-0431.
• [983] Cold-inducible protein RBM3 mediates hypothermic neuroprotection against neurotoxin rotenone via inhibition on MAPK signalling.J Cell Mol Med. 2019 Oct;23(10):7010-7020. doi: 10.1111/jcmm.14588. Epub 2019 Aug 22.
• [984] Comparison of Quantitative Electroencephalogram During Sleep in Depressed and Non-Depressed Patients with Parkinson's Disease.Med Sci Monit. 2019 Feb 7;25:1046-1052. doi: 10.12659/MSM.913931.
• [985] The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.PLoS One. 2017 Sep 6;12(9):e0184262. doi: 10.1371/journal.pone.0184262. eCollection 2017.
• [986] The deficiency of NRSF/REST enhances the pro-inflammatory function of astrocytes in a model of Parkinson's disease.Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165590. doi: 10.1016/j.bbadis.2019.165590. Epub 2019 Nov 7.
• [987] D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.J Neurosci. 2005 Feb 23;25(8):2157-65. doi: 10.1523/JNEUROSCI.2840-04.2005.
• [988] Protection of nigral dopaminergic neurons by AAV1 transduction with Rheb(S16H) against neurotoxic inflammation in vivo.Exp Mol Med. 2018 Feb 9;50(2):e440. doi: 10.1038/emm.2017.261.
• [989] Miro1 Marks Parkinson's Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson's Models.Cell Metab. 2019 Dec 3;30(6):1131-1140.e7. doi: 10.1016/j.cmet.2019.08.023. Epub 2019 Sep 26.
• [990] Effect of moxibustion on mTOR-mediated autophagy in rotenone-induced Parkinson's disease model rats.Neural Regen Res. 2018 Jan;13(1):112-118. doi: 10.4103/1673-5374.224380.
• [991] c-Jun/Bim Upregulation in Dopaminergic Neurons Promotes Neurodegeneration in the MPTP Mouse Model of Parkinson's Disease.Neuroscience. 2019 Feb 10;399:117-124. doi: 10.1016/j.neuroscience.2018.12.026. Epub 2018 Dec 25.
• [992] Downregulation of RTN1-C attenuates MPP(+)-induced neuronal injury through inhibition of mGluR5 pathway in SN4741 cells.Brain Res Bull. 2019 Mar;146:1-6. doi: 10.1016/j.brainresbull.2018.11.026. Epub 2018 Dec 3.
• [993] c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD(+) cleavage activity to inhibit mitochondrial respiration.J Biol Chem. 2018 Dec 7;293(49):18933-18943. doi: 10.1074/jbc.RA118.004578. Epub 2018 Oct 17.
• [994] The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease.Antioxid Redox Signal. 2016 Oct 10;25(11):609-622. doi: 10.1089/ars.2016.6634. Epub 2016 Aug 8.
• [995] No association of FAM47E rs6812193, SCARB2 rs6825004 and STX1B rs4889603 polymorphisms with Parkinson's disease in a Chinese Han population.J Neural Transm (Vienna). 2015 Nov;122(11):1547-52. doi: 10.1007/s00702-015-1430-4. Epub 2015 Jul 30.
• [996] Aegeline, a natural product from the plant Aegle marmelos, mimics the yeast SNARE protein Sec22p in suppressing -synuclein and Bax toxicity in yeast.Bioorg Med Chem Lett. 2019 Feb 1;29(3):454-460. doi: 10.1016/j.bmcl.2018.12.028. Epub 2018 Dec 13.
• [997] The Thioredoxin-Like Family of Selenoproteins: Implications in Aging and Age-Related Degeneration.Biol Trace Elem Res. 2019 Mar;188(1):189-195. doi: 10.1007/s12011-018-1521-9. Epub 2018 Sep 18.
• [998] Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinson's disease.J Trace Elem Med Biol. 2020 Jan;57:126412. doi: 10.1016/j.jtemb.2019.126412. Epub 2019 Sep 24.
• [999] Meta analysis of the association of rs7702187 SNP in SEMA5A gene with risk of Parkinson's disease.Eur Rev Med Pharmacol Sci. 2014;18(6):900-4.
• [1000] Modulation of ARTS and XIAP by Parkin Is Associated with Carnosic Acid Protects SH-SY5Y Cells against 6-Hydroxydopamine-Induced Apoptosis.Mol Neurobiol. 2018 Feb;55(2):1786-1794. doi: 10.1007/s12035-017-0443-4. Epub 2017 Feb 21.
• [1001] miR-185 and SEPT5 Genes May Contribute to Parkinson's Disease Pathophysiology.Oxid Med Cell Longev. 2019 Nov 14;2019:5019815. doi: 10.1155/2019/5019815. eCollection 2019.
• [1002] The homozygote AA genotype of the alpha1-antichymotrypsin gene may confer protection against early-onset Parkinson's disease in women.Parkinsonism Relat Disord. 2004 Dec;10(8):469-73. doi: 10.1016/j.parkreldis.2004.06.001.
• [1003] Phase lag index and spectral power as QEEG features for identification of patients with mild cognitive impairment in Parkinson's disease.Clin Neurophysiol. 2019 Oct;130(10):1937-1944. doi: 10.1016/j.clinph.2019.07.017. Epub 2019 Jul 25.
• [1004] Sestrin2 as Serum Protein Marker and Potential Therapeutic Target for Parkinson's Disease.J Gerontol A Biol Sci Med Sci. 2020 Mar 9;75(4):690-695. doi: 10.1093/gerona/glz234.
• [1005] Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.Sci Rep. 2019 Jun 19;9(1):8795. doi: 10.1038/s41598-019-45129-8.
• [1006] ERK/MAP Kinase Activation is Evident in Activated Microglia of the Striatum and Substantia Nigra in an Acute and Chronically-Induced Mouse Model of Parkinson's Disease.Curr Neurovasc Res. 2018;15(4):336-344. doi: 10.2174/1567202616666181123152601.
• [1007] Phosphoregulation on mitochondria: Integration of cell and organelle responses.CNS Neurosci Ther. 2019 Jul;25(7):837-858. doi: 10.1111/cns.13141. Epub 2019 Apr 25.
• [1008] Comparative analysis of four disease prediction models of Parkinson's disease.Mol Cell Biochem. 2016 Jan;411(1-2):127-34. doi: 10.1007/s11010-015-2574-0. Epub 2015 Oct 5.
• [1009] Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation.Cell Death Differ. 2017 Jan;24(1):120-131. doi: 10.1038/cdd.2016.104. Epub 2016 Sep 30.
• [1010] Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism.Curr Med Sci. 2019 Oct;39(5):831-835. doi: 10.1007/s11596-019-2113-4. Epub 2019 Oct 14.
• [1011] Inhibition of nSMase2 Reduces the Transfer of Oligomeric -Synuclein Irrespective of Hypoxia.Front Mol Neurosci. 2019 Aug 28;12:200. doi: 10.3389/fnmol.2019.00200. eCollection 2019.
• [1012] Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts.Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):437-450. doi: 10.1007/s00259-019-04570-7. Epub 2019 Nov 25.
• [1013] Synphilin-1 has neuroprotective effects on MPP(+)-induced Parkinson's disease model cells by inhibiting ROS production and apoptosis.Neurosci Lett. 2019 Jan 18;690:145-150. doi: 10.1016/j.neulet.2018.10.020. Epub 2018 Oct 11.
• [1014] Transcription factor PITX3 gene in Parkinson's disease.Neurobiol Aging. 2011 Apr;32(4):750-3. doi: 10.1016/j.neurobiolaging.2009.03.015. Epub 2009 Apr 24.
• [1015] Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson's disease.Hum Mol Genet. 2018 May 1;27(9):1514-1532. doi: 10.1093/hmg/ddy059.
• [1016] Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease.Neurosci Lett. 2018 May 1;674:123-126. doi: 10.1016/j.neulet.2018.03.036. Epub 2018 Mar 19.
• [1017] The Neuroprotective Effect of Steroid Receptor Coactivator-Interacting Protein (SIP) in Astrocyte Model of 1-Methyl-4-Phenylpyridinium (MPP?-Induced Parkinson's Disease.Med Sci Monit. 2019 Aug 3;25:5776-5784. doi: 10.12659/MSM.912106.
• [1018] SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.PLoS One. 2010 Feb 8;5(2):e9104. doi: 10.1371/journal.pone.0009104.
• [1019] Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders.Brain Sci. 2018 Aug 13;8(8):154. doi: 10.3390/brainsci8080154.
• [1020] Serine/Threonine Kinase 35, a Target Gene of STAT3, Regulates the Proliferation and Apoptosis of Osteosarcoma Cells.Cell Physiol Biochem. 2018;45(2):808-818. doi: 10.1159/000487172. Epub 2018 Jan 31.
• [1021] The landscape of multiscale transcriptomic networks and key regulators in Parkinson's disease.Nat Commun. 2019 Nov 20;10(1):5234. doi: 10.1038/s41467-019-13144-y.
• [1022] STXBP1 encephalopathy: Connecting neurodevelopmental disorders with -synucleinopathies?.Neurology. 2019 Jul 16;93(3):114-123. doi: 10.1212/WNL.0000000000007786. Epub 2019 Jun 20.
• [1023] The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance.ACS Chem Neurosci. 2019 Sep 18;10(9):3927-3938. doi: 10.1021/acschemneuro.9b00351. Epub 2019 Aug 23.
• [1024] Autophagy Activation Is Involved in Acidic Fibroblast Growth Factor Ameliorating Parkinson's Disease via Regulating Tribbles Homologue 3.Front Pharmacol. 2019 Dec 2;10:1428. doi: 10.3389/fphar.2019.01428. eCollection 2019.
• [1025] 6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease.Mov Disord. 2018 Aug;33(8):1331-1339. doi: 10.1002/mds.27391. Epub 2018 Mar 24.
• [1026] A baseline study for detection of Parkinson's disease with 3D-transcranial sonography and uni-lateral reconstruction.J Neurol Sci. 2019 Feb 15;397:16-21. doi: 10.1016/j.jns.2018.12.001. Epub 2018 Dec 3.
• [1027] Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies.JCI Insight. 2019 Aug 22;4(16):e129719. doi: 10.1172/jci.insight.129719.
• [1028] Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.Neurobiol Dis. 2014 Feb;62:172-8. doi: 10.1016/j.nbd.2013.09.019. Epub 2013 Oct 8.
• [1029] Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human -Synuclein Over-Expressing Mouse Model.Front Neurosci. 2019 Aug 7;13:839. doi: 10.3389/fnins.2019.00839. eCollection 2019.
• [1030] Down-regulated TMED10 in Alzheimer disease induces autophagy via ATG4B activation.Autophagy. 2019 Sep;15(9):1495-1505. doi: 10.1080/15548627.2019.1586249. Epub 2019 Mar 19.
• [1031] Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.Front Aging Neurosci. 2018 Jun 1;10:162. doi: 10.3389/fnagi.2018.00162. eCollection 2018.
• [1032] TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia.Ann Neurol. 2019 Jun;85(6):801-811. doi: 10.1002/ana.25486.
• [1033] A replication study of GWAS-genetic risk variants associated with Parkinson's disease in a Spanish population.Neurosci Lett. 2019 Nov 1;712:134425. doi: 10.1016/j.neulet.2019.134425. Epub 2019 Aug 17.
• [1034] Degradation of alpha-synuclein by dendritic cell factor 1 delays neurodegeneration and extends lifespan in Drosophila.Neurobiol Aging. 2018 Jul;67:67-74. doi: 10.1016/j.neurobiolaging.2018.03.010. Epub 2018 Mar 13.
• [1035] Defective mitochondrial protein import contributes to complex I-induced mitochondrial dysfunction and neurodegeneration in Parkinson's disease.Cell Death Dis. 2018 Nov 7;9(11):1122. doi: 10.1038/s41419-018-1154-0.
• [1036] Wild-type and mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2) associate with subunits of the translocase of outer mitochondrial membrane (TOM) complex.Exp Cell Res. 2019 Feb 15;375(2):72-79. doi: 10.1016/j.yexcr.2018.12.022. Epub 2018 Dec 28.
• [1037] TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson's Disease with Opposite Effects.J Mol Neurosci. 2018 Mar;64(3):341-345. doi: 10.1007/s12031-018-1031-4. Epub 2018 Feb 5.
• [1038] Novel biomolecular information in rotenone-induced cellular model of Parkinson's disease.Gene. 2018 Mar 20;647:244-260. doi: 10.1016/j.gene.2018.01.023. Epub 2018 Jan 10.
• [1039] Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.Brain. 2017 Sep 1;140(9):2444-2459. doi: 10.1093/brain/awx202.
• [1040] Silencing of TRIM10 alleviates apoptosis in cellular model of Parkinson's disease.Biochem Biophys Res Commun. 2019 Oct 20;518(3):451-458. doi: 10.1016/j.bbrc.2019.08.041. Epub 2019 Aug 28.
• [1041] Parkinson's Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32.Mol Neurobiol. 2018 Apr;55(4):3490-3498. doi: 10.1007/s12035-017-0570-y. Epub 2017 May 15.
• [1042] Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014.Gut. 2019 Jan;68(1):18-24. doi: 10.1136/gutjnl-2017-315666. Epub 2018 May 21.
• [1043] New Targets for Parkinson's Disease: Adhesion G Protein-Coupled Receptor B1 is Downregulated by AMP-Activated Protein Kinase Activation.OMICS. 2018 Jul;22(7):493-501. doi: 10.1089/omi.2018.0047.
• [1044] AF-6 Protects Against Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease.Front Cell Neurosci. 2017 Aug 10;11:241. doi: 10.3389/fncel.2017.00241. eCollection 2017.
• [1045] AMBRA1-Mediated Mitophagy Counteracts Oxidative Stress and Apoptosis Induced by Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells.Front Cell Neurosci. 2018 Apr 18;12:92. doi: 10.3389/fncel.2018.00092. eCollection 2018.
• [1046] Acid ceramidase inhibition ameliorates -synuclein accumulation upon loss of GBA1 function.Hum Mol Genet. 2018 Jun 1;27(11):1972-1988. doi: 10.1093/hmg/ddy105.
• [1047] Extended "Timed Up and Go" assessment as a clinical indicator of cognitive state in Parkinson's disease.J Neurol Sci. 2017 Apr 15;375:86-91. doi: 10.1016/j.jns.2017.01.050. Epub 2017 Jan 17.
• [1048] Abnormalities of age-related T cell senescence in Parkinson's disease.J Neuroinflammation. 2018 May 28;15(1):166. doi: 10.1186/s12974-018-1206-5.
• [1049] Gangliosides, -Synuclein, and Parkinson's Disease.Prog Mol Biol Transl Sci. 2018;156:435-454. doi: 10.1016/bs.pmbts.2017.12.009. Epub 2018 Feb 24.
• [1050] Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson's disease.Mol Med. 2018 Nov 28;24(1):61. doi: 10.1186/s10020-018-0059-9.
• [1051] Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate.JCI Insight. 2018 Jul 26;3(14):e98202. doi: 10.1172/jci.insight.98202. eCollection 2018 Jul 26.
• [1052] U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells.Synapse. 2017 Sep;71(9). doi: 10.1002/syn.21980. Epub 2017 Jun 20.
• [1053] Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.Dis Model Mech. 2017 May 1;10(5):619-631. doi: 10.1242/dmm.028035. Epub 2017 Jan 20.
• [1054] Impairment of mitochondria dynamics by human A53T -synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.Exp Brain Res. 2017 Mar;235(3):731-742. doi: 10.1007/s00221-016-4836-9. Epub 2016 Nov 19.
• [1055] Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson's Disease.Front Mol Neurosci. 2018 Nov 2;11:412. doi: 10.3389/fnmol.2018.00412. eCollection 2018.
• [1056] A cullin-RING ubiquitin ligase targets exogenous -synuclein and inhibits Lewy body-like pathology.Sci Transl Med. 2019 Jun 5;11(495):eaau6722. doi: 10.1126/scitranslmed.aau6722.
• [1057] Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.Cell Mol Life Sci. 2018 Jun;75(11):2075-2091. doi: 10.1007/s00018-017-2727-2. Epub 2017 Dec 20.
• [1058] Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease.J Parkinsons Dis. 2017;7(2):279-287. doi: 10.3233/JPD-160937.
• [1059] Assessing the sensitivity and specificity of cognitive screening measures for people with Parkinson's disease.NeuroRehabilitation. 2018;43(4):491-500. doi: 10.3233/NRE-182433.
• [1060] Identification of Critical Genes and miRNAs Associated with the Development of Parkinson's Disease.J Mol Neurosci. 2018 Aug;65(4):527-535. doi: 10.1007/s12031-018-1129-8. Epub 2018 Aug 6.
• [1061] N400 and emotional word processing in Parkinson's disease.Neuropsychology. 2017 Sep;31(6):585-595. doi: 10.1037/neu0000333. Epub 2017 Mar 13.
• [1062] Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson's disease.Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2735-2740. doi: 10.1073/pnas.1621218114. Epub 2017 Jan 30.
• [1063] Faim2 contributes to neuroprotection by erythropoietin in transient brain ischemia.J Neurochem. 2018 May;145(3):258-270. doi: 10.1111/jnc.14296. Epub 2018 Feb 20.
• [1064] Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinson's Disease.Neurosci Bull. 2017 Oct;33(5):510-514. doi: 10.1007/s12264-017-0122-5. Epub 2017 Mar 24.
• [1065] Glucosylsphingosine Promotes -Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.J Neurosci. 2017 Oct 4;37(40):9617-9631. doi: 10.1523/JNEUROSCI.1525-17.2017. Epub 2017 Aug 28.
• [1066] Comparison Between Automatic and Visual Scorings of REM Sleep Without Atonia for the Diagnosis of REM Sleep Behavior Disorder in Parkinson Disease.Sleep. 2017 Feb 1;40(2). doi: 10.1093/sleep/zsw060.
• [1067] Functional lesional neurosurgery for tremor: a systematic review and meta-analysis.J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):717-726. doi: 10.1136/jnnp-2017-316302. Epub 2018 Jan 11.
• [1068] Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1.J Neurol Sci. 2017 Oct 15;381:176-181. doi: 10.1016/j.jns.2017.08.3235. Epub 2017 Aug 24.
• [1069] Potential Role of Mic60/Mitofilin in Parkinson's Disease.Front Neurosci. 2019 Jan 25;12:898. doi: 10.3389/fnins.2018.00898. eCollection 2018.
• [1070] Angiotensin II induces oxidative stress and upregulates neuroprotective signaling from the NRF2 and KLF9 pathway in dopaminergic cells.Free Radic Biol Med. 2018 Dec;129:394-406. doi: 10.1016/j.freeradbiomed.2018.10.409. Epub 2018 Oct 11.
• [1071] First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire.Eur J Neurol. 2018 Oct;25(10):1255-1261. doi: 10.1111/ene.13691. Epub 2018 Jun 22.
• [1072] LRP10 in autosomal-dominant Parkinson's disease.Mov Disord. 2019 Jun;34(6):912-916. doi: 10.1002/mds.27693. Epub 2019 Apr 9.
• [1073] Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.
• [1074] Comparative assessment of 6-[(18) F]fluoro-L-m-tyrosine and 6-[(18) F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson's disease rat model.J Neurochem. 2017 May;141(4):626-635. doi: 10.1111/jnc.14016. Epub 2017 Apr 12.
• [1075] Progression Rate Associated Peripheral Blood Biomarkers of Parkinson's Disease.J Mol Neurosci. 2018 Jul;65(3):312-318. doi: 10.1007/s12031-018-1102-6. Epub 2018 Jun 23.
• [1076] NCEH-1 modulates cholesterol metabolism and protects against -synuclein toxicity in a C. elegans model of Parkinson's disease.Hum Mol Genet. 2017 Oct 1;26(19):3823-3836. doi: 10.1093/hmg/ddx269.
• [1077] Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model.Cell Death Dis. 2017 Feb 2;8(2):e2574. doi: 10.1038/cddis.2016.454.
• [1078] Inhibition of microRNA-505 suppressed MPP+?induced cytotoxicity of SHSY5Y cells in an in vitro Parkinson's disease model.Eur J Pharmacol. 2018 Sep 15;835:11-18. doi: 10.1016/j.ejphar.2018.07.023. Epub 2018 Jul 17.
• [1079] Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.Curr HIV/AIDS Rep. 2019 Feb;16(1):76-81. doi: 10.1007/s11904-019-00420-1.
• [1080] Drug-induced Parkinson's disease modulates protein kinase A and Olfactory Marker Protein in the mouse olfactory bulb.Behav Brain Funct. 2017 Jan 26;13(1):1. doi: 10.1186/s12993-017-0119-2.
• [1081] The crystal structure of pseudokinase PEAK1 (Sugen kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization.J Biol Chem. 2018 Feb 2;293(5):1642-1650. doi: 10.1074/jbc.RA117.000751. Epub 2017 Dec 6.
• [1082] Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease.J Pharmacol Sci. 2018 Sep;138(1):31-37. doi: 10.1016/j.jphs.2018.08.008. Epub 2018 Aug 26.
• [1083] Clinical variations in Parkinson's disease patients with or without REM sleep behaviour disorder: a meta-analysis.Sci Rep. 2017 Jan 16;7:40779. doi: 10.1038/srep40779.
• [1084] The Parkinson's disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking.Hum Mol Genet. 2017 Feb 15;26(4):729-741. doi: 10.1093/hmg/ddw413.
• [1085] The Matricellular Protein R-Spondin 2 Promotes Midbrain Dopaminergic Neurogenesis and Differentiation.Stem Cell Reports. 2018 Sep 11;11(3):651-664. doi: 10.1016/j.stemcr.2018.07.014. Epub 2018 Aug 23.
• [1086] Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.Brain Res. 2019 Jan 1;1702:85-95. doi: 10.1016/j.brainres.2017.12.029. Epub 2017 Dec 21.
• [1087] Synapsin III deficiency hampers -synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.Acta Neuropathol. 2018 Oct;136(4):621-639. doi: 10.1007/s00401-018-1892-1. Epub 2018 Jul 25.
• [1088] Correlation of serum levels and gene expression of tumor necrosis factor--induced protein-8 like-2 with Parkinson disease severity.Metab Brain Dis. 2018 Dec;33(6):1955-1959. doi: 10.1007/s11011-018-0302-7. Epub 2018 Aug 13.
• [1089] Salusin- mediate neuroprotective effects for Parkinson's disease.Biochem Biophys Res Commun. 2018 Sep 10;503(3):1428-1433. doi: 10.1016/j.bbrc.2018.07.059. Epub 2018 Jul 13.
• [1090] Effects of Transcranial Direct Current Stimulation (tDCS) Over the Frontal Polar Area on Motor and Executive Functions in Parkinson's Disease; A Pilot Study.Front Aging Neurosci. 2018 Jul 30;10:231. doi: 10.3389/fnagi.2018.00231. eCollection 2018.
• [1091] The E3Ubiquitin Ligases TRIM17 and TRIM41 Modulate -Synuclein Expression by Regulating ZSCAN21.Cell Rep. 2018 Nov 27;25(9):2484-2496.e9. doi: 10.1016/j.celrep.2018.11.002.